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PREFACE 
In 1962, Nobel Price virologist Mac Burnet wrote the following: “One can think of the middle 
of the twentieth century as the end of one of the most important social revolutions in history, 
the virtual elimination of the infectious diseases as a significant factor in social life” (Burnet, 
1962). Unfortunately, the last decades have proven he was wrong; as described by Jones et al. 
(2008), the number of human emerging infectious diseases (EID) has continued to increase 
after 1960, reaching a peak in the 1980s, and still representing a significant burden on global 
economies and public health.  
The concept of EID started to be used in the late 1980s, when major epidemics occurred 
around the globe which surprised many scientists who considered such diseases to be of the 
past or limited to the less developed parts of the world (Chomel, 1998). It has primarily been 
applied to diseases affecting humans (Cleaveland et al., 2001). The basic definition of an EID 
is an infection that has appeared in a population for the first time, or that may have existed 
previously but is rapidly increasing in incidence or geographic range (Morse, 1995; WHO, 
2013). If the disease was present in the region in the past and at one point considered 
controlled and eradicated, the disease is considered to be re-emerging.  
Recent EIDs have predominantly originated from animal reservoirs. More than 60% of the 
roughly 400 human EIDs that have been identified since 1940 are zoonotic (Jones et al., 
2008).  
The emergence of an infection can be seen as a two-step process, with: 1. the introduction of 
the pathogen into a new host population and 2. the establishment and spread within the new 
host population (Morse, 1995). Most EIDs appear to be caused by pathogens already present 
in the environment given an opportunity to infect new host populations. Introduction and 
spread of infectious diseases are known to be driven by a wide range of factors. The 
emergence can result from the modification of the pathogen characteristics (e.g., by mutation 
or recombination) and/or the host(s) characteristics, which themselves are thought to be 
driven largely by socio-economic, environmental and ecological factors. The increase of 
world-wide exchanges and consumerism, among others, are factors known to be precipitating 
disease emergence, by placing naïve hosts at increased contact with a previously unfamiliar 
pathogen or its natural host (Cleaveland et al., 2001; Dufour et al., 2008; Morse, 1995). The 
obvious increase of those factors suggests that EIDs will continue to occur in the future. 
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Indeed, even when adjusting for the improvement of global surveillance, it is observed that 
the frequency with which new pathogens emerge is clearly increasing in time (Morse et al., 
2012).  
Influenza, Malaria and West Nile virus are only a few examples among many others of recent 
emerging or re-emerging threats. The potential pandemic spread of such diseases, as it was 
observed for instance during the H1N1 Influenza epidemic in 2009 (Mexican Flue), and the 
negative economic and social consequences this will bring, clearly emphasizes the paramount 
need for improvement of the anticipation, surveillance and control of EIDs (Morse et al., 
2012). 
 
 
I.I. Emerging arboviral infections 
One fourth of the EID events which occurred between 1940 and 2004 in the global human 
population (25.4%) were caused by viral and prion pathogens. Indeed, because of their poor 
mutation error-correction capacity and often high rates of nucleotides substitution, viruses are 
prone to adapt easily to new hosts. In addition, viral diseases are less easily controlled 
compared to other types of infectious diseases because of their difficulty to be treated, and are 
thus more likely to spread within the host populations (Morse, 1995; Jones et al., 2008).  
Arthropod-borne viruses or arboviruses (ABV) are viral pathogens transmitted among 
vertebrate hosts by hematophagous arthropod vectors including mosquitoes, sandflies, biting 
midges and ticks. The last International Catalogue of ABV listed more than 550 ABV and 
related viruses. They are found in diverse viral families, including Togaviridae (genus 
Alphavirus); Bunyaviridae (genera Nairovirus, Orthobunyavirus, Phlebovirus, and 
Tospovirus); Flaviviridae (genus Flavivirus); Rhabdoviridae (genus Vesiculovirus); 
Orthomyxoviridae (genus Thogotovirus); Reoviridae (genus Orbivirus); and Asfarviridae 
(genus Asfarvirus). ABV are all RNA viruses except for African swine fever virus which is 
the only known DNA virus in this category (Weaver and Reisen, 2010). RNA viruses in 
general are characterised by higher mutation rates compared to DNA viruses (Cleaveland, 
2001). Consequently, ABV are especially prone to emerge in new host populations. More 
than 150 of the ABV are known to cause human and/or animal diseases. Table 1 summarizes 
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information on important ABV which infect domestic and wild ruminants. Almost half of 
these ruminant viruses also have a zoonotic potential.  
During the last decade, several human and animal pathogenic ABV, including West Nile virus 
(Monaco et al., 2010), Japanese encephalitis (Mackenzie et al., 2004) and Bluetongue virus 
(BTV) (Toussaint et al., 2006), have emerged and caused epidemics in countries where they 
had never before. Because of the requirement for certain vectors, ABV infections mostly 
occur in tropical and subtropical regions. Indeed, the cooler climate experienced in Northern 
latitudes means that there are fewer species of arthropod compared to tropical regions. 
Because ABV are totally dependent on their vectors, a good knowledge of the distribution of 
the latter is absolutely necessary in order to ensure a comprehensive understanding of the risk 
for introduction of a given virus. For example, after the emergence of the Chikungunya virus 
in the Indian Ocean islands in 2005 (Flahaut, 2007), and in Italy in 2007, the European Center 
for Disease Prevention and Control (ECDC) worked together with entomologists to develop 
Aedes albopictus distribution maps for Europe (ECDC, 2009).  
Nevertheless, ABV infections often persist at very low levels in a population until some 
changes in viral/vector genetics, host/vector population composition/dynamics, or 
environmental features occurs and make them amplify to epidemics levels (Weaver and 
Reisen, 2010). Human behavior seems to play a non-negligible role in the abovementioned 
factors. Vectors may be introduced to new geographic areas inter alia by human travel, 
international trade and animal/plant movement (Mintiens et al., 2008a; EFSA, 2012a). The 
increased level of international flux has greatly facilitated the spread of viruses and vectors, 
which means that the geographical barriers faced by infectious diseases in the past have 
largely been removed. Also, environmental factors, including urban expansion and population 
growth have facilitated contacts between hosts and vectors. In addition, climate change is 
thought to play a significant role in the emergence of ABV (Hollidge, 2010). Receptivity of a 
given population to viral establishment seems to be closely related to climatic conditions (e.g, 
seasonal duration) conducive to viral replication. Global warming will create altered 
environmental conditions leading to changes in vector range, vertebrate host and dynamics 
(Maclachlan and Guthrie, 2010; Weaver and Reisen, 2010). BTV started to spread in Europe 
because climate warming allowed the main vector (Culicoides imicola) to expand its 
geographical distribution northward to include parts of Southern Europe (Purse et al., 2005). 
Following the heat wave in 2003, a French group of experts identified six priority diseases 
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that were likely to evolve in response to global warming. Five out of the six diseases were 
vector-borne and four out of five were ABV (ANSES, 2005). 
 
Table 1:  List of important arboviruses affecting domestic and wild ruminants; Viruses in italic are 
zoonotic (sources: Karabatsos, 1985; Johnson et al., 2012, and Powers, 2009) 
 
 
Name Genus Vector Affected hosts Established OIE listed disease 
Akabane virus Orthobunyavirus
Culicoides, 
Aedes, Culex 
and Anopheles
Cattle, sheep, 
goat 
Japan, Sout-East Asia, 
Australia, Turkey, South 
Africa
no
Aino virus Orthobunyavirus
Culicoides, 
Aedes, Culex 
and Anopheles
Cattle, sheep Japan, Australia
Bluetongue virus Orbivirus Culicoides
Several domestic 
and wild 
ruminant species
America, Africa, Asia, 
Australia, Middle East yes
Bovine ephemeral fever 
virus Ephemerovirus
Culicoides, 
Anopheles
Cattle and water 
buffalo
Africa, Asia, Australia, 
Middle East no
Dugbe virus Nairovirus Tick Human, cattle Africa no
Epizootic haemorrhagic 
disease virus
Orbivirus Culicoides Deer, cattle Americas, Africa, Asia, Australia yes
Inkoo virus Orthobunyavirus Aedes Cattle Finland no
Louping ill virus Flavivirus Ixodes ricinus Sheep, cattle British Isles no
Murray Valley encephalitis 
virus Flavivirus
Culex 
annulirostris
Human, horse, 
cattle Australia, Indonesia no
Nairobi sheep disease 
virus
Nairovirus Ripicephalus 
appendiculatus Sheep, goat East Africa yes
Palyam virus Orbivirus
Culicoides, 
Culicine 
moquitoe
Cattle, sheep Africa, Asia, Australia no
Rift Valley fever virus Phlebovirus Aedes Human, sheep, goat, camel Africa yes
Russian spring-summer 
encephalitis virus Flavivirus
Ixodes 
persulcatus
Human, cattle, 
goat
Eurasia no
Thogoto virus Thogotovirus Tick Sheep Africa no
Vesicular stomatitis virus Vesiculovirus
Phlebotomine 
sandfly, 
Culicoides, 
Simulium 
blackfly
Cattle, horse, 
pig, (human) America yes
Wesselsbron virus Flavivirus Aedes Human, sheep, 
cattle Africa, Asia no
West Nile virus Flavivirus Culex Human, cattle, horse, avian Africa, Eurasia, America yes
Western equine 
encephalitis virus Alphavirus Culex
Human, cattle, 
horse America yes
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I.II. Surveillance of emerging arboviral infections 
I.II.1. Objectives of surveillance 
Surveillance of animal infectious diseases is essential to improve animal health, protect public 
health, support economic growth, and enhance access to international markets for trade in 
animals. The Food and Agricultural Organization (FAO) wrote that ‘In an increasingly 
globalized world, veterinary surveillance systems and services are vital to detect these 
diseases early enough and to prepare contingency plans to contain those outbreaks’ (FAO, 
2000; Mariner et al., 2011). Surveillance aims at producing health data designed to guide 
decision-making. 
The two terms ‘monitoring’ and ‘surveillance’ are often used interchangeably in animal health 
programs. Stricto sensu, disease monitoring is defined as the ongoing efforts directed at 
assessing the disease status of a given population; The efforts consisting in the routine 
recording, analyses and distribution of information related to the disease. The term disease 
surveillance on the other hand is used to describe a more active system and implies that some 
form of directed action will be taken if the data indicate a disease level above a certain 
threshold (Christensen, 2001; Salman et al., 2003; Dufour and Hendrickx, 2009). In order to 
facilitate the reading of the text, we will from here on simplify the term ‘monitoring and 
surveillance’ by using instead the word ‘surveillance’.  
When designing an appropriate surveillance system for an EID, the initial step will be 
identifying and evaluating the risk of introduction and establishment of specific diseases in 
free host-populations. At the European level, the European Food Safety Authority (EFSA) is 
responsible for assessing and communicating on all risks associated with the food chain. 
Under the framework of Council Regulation (EC) No 178/2002 and as a consequence of the 
emergence of BTV in North-Western Europe in 2006 (Toussaint et al., 2006), a call for 
proposals was published on the EFSA website in August 2007 (CFP/EFSA/AHAW/2007/02) 
to provide an evaluation of the distribution of arthropod vectors and their potential for 
transmitting emerging vector-borne animal diseases and zoonoses. In this context, potential 
tick and mosquito vectors and associated ABV were listed for risk anticipation (EFSA, 
2009a,b). Repeated assessments of the risk of emergence of specific pathogens present in the 
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animal population of neighboring regions and trading partners need to be performed at a 
regular basis (Doherr and Audigé, 2001). 
Figure 1 displays the example of an emerging ABV epidemic curve with its different phases. 
The objectives of the surveillance process applied to an EID usually follow the evolution of 
the epidemic curve and are adapted to the epidemiological stage (Thulke et al., 2009; 
Randolph and Rogers, 2010; EFSA, 2011a). 
The objective of surveillance during the initial phase of the epidemic, at t0 (figure 1), will be 
to detect the introduction of the infection. At this stage, the host population which is being 
closely watched over is still naïve (i.e., without any history of the exotic/unknown infection) 
and is therefore fully susceptible to the infection. Should the introduction occur, the objective 
will be to detect it as soon as possible (early detection).  
In the progress of any epidemic, following an exponential rise, the number of new cases 
eventually reaches a maximum and then starts to decrease. In the context of an ABV, in our 
latitudes, the transmission process fades out naturally as the vector activity decreases when 
the winter season begins. At this point of the epidemic (at t1a and t1b), it is usually time to take 
stock of the situation. Thus, the main surveillance objective will now be to assess the extent of 
the infection. The result of this assessment will also constitute the basis for future sampling, 
for predicting future spread, and will also be one of the aspects to consider before deciding on 
possible intervention measures such as vaccination.  
Control measures such as mass vaccination or slaughter are implemented in the infected area 
to contain the epidemic.  At t2, the surveillance process will consist in evaluating the impact 
of the control measure. To do so, an option can be to monitor the targeted decrease of the 
prevalence indicator, thus, by assessing the extent of the infection as it is done at t1. 
At t3, the epidemic has ceased following a natural fade-out of transmission or effective control 
actions. No more outbreaks are reported in the country. At this stage, it is important to provide 
sufficient proof that the animals are not infected anymore, especially for lifting trade 
restrictions for OIE-listed diseases (World Organization for Animal Health). The objective of 
surveillance at this point will be to investigate if a given population is truly free from the 
disease. Once this has been successfully accomplished, the focus will move again to the first 
Chapter I : General Introduction 
 
 
9 | P a g e  
 
stage of surveillance, but, at this point, taking into account the fact that the population is not 
naïve anymore. 
 
Figure 1: Example of emerging arboviral infection epidemic curve (t0: before epidemic starts, 
t1a and t1b: plateau after epidemic episode, t2: after control measures and t3: when epidemic has 
stopped) 
 
 
Next to general recommendations for animal health surveillance, the OIE Terrestrial Animal 
Health Code sets out specific guidelines for improving surveillance of arthropod-vectors of 
animal diseases (OIE, 2013a). Even though the objectives of the programs as described in 
figure 1 will be similar to that of any other EID, arthropod-borne diseases pose an additional 
challenge to animal health surveillance systems due the complexity of their transmission 
cycle. A sound surveillance program will require a thorough understanding of the biology, 
ecology and interactions of the vertebrate and arthropod hosts and a multidisciplinary 
approach involving both animal health specialists and entomologists will always be needed. 
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The main objectives of the vector surveillance will be determining the areas and seasons of 
risk for emergence/re-emergence of the disease and implementing an early-detection system 
for vectors and/or vector-borne pathogens in those risk units during the vector season. 
Therefore, it is necessary to establish: 1. whether the vector(s) is (are) present in a region or 
not, and in the case it is, 2. the distribution of the vector(s) in the region, 3. the abundance of 
the vector(s) and its (their) spatial and temporal variability (OIE, 2013a; OIE, 2013b).  In case 
the vector is not (yet) present in an area, a risk assessment will be useful for identifying 
potential pathways for introduction and subsequently watch them closely. Next to this, the 
detection of the pathogen itself in arthropod populations is a key element of the entomological 
surveillance. 
 
I.II.2. Strategies for surveillance 
 
There are various ways of classifying surveillance strategies available to meet the objectives 
described in previous section. Dufour and Audigé (1997) and Doherr and Audigé (2001) 
propose several classification criteria including the type/source and the method of data 
collection. As shown in figure 2, most surveillance programs of ABV are based on two 
methods of data collection: 1. the reporting of clinical suspicions (so–called ‘passive 
surveillance’) and 2. the sample-based surveys (so-called ‘active surveillance’).  
Passive surveillance is a pivotal source of information for detecting EID, since it theoretically 
covers the whole susceptible animal population which is under farmer and/or veterinarian 
surveillance, continuously in time. The population is expected to express the clinical form of 
the disease, when infected (Doherr and Audigé, 2001). The veterinarians decide to submit 
samples for further diagnosis to the veterinary laboratories. Notification of suspect cases of 
OIE listed ABVs (Table 1) to the competent authorities is usually mandatory within national 
disease surveillance legislation. The detection and subsequent investigation of disease 
suspicions obviously relies on a chain of events including the capacity of animal-health 
professionals to recognize the clinical signs. Passive surveillance is not only important in the 
initial stage of the epidemic (at t0), but remains also very useful during the outbreaks. Indeed, 
the early detection of new cases helps controlling the impact of the epidemic.  
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Active surveillance is defined as the periodic collection of samples or case reports from 
veterinary authorities (Doherr and Audigé, 2001; Hadorn and Stark, 2008). The main 
difference between active and passive surveillance is that the former follows a prescribed 
sampling protocol. A very common example of active surveillance is the cross-sectional 
survey which will give a snapshot in time and space and will allow estimating the prevalence 
of the infection, the clinical disease, or the immune status of a population. In most cases, this 
type of surveys will provide a more valid picture of the impact of the EID than when relying 
on passive surveillance only. Many data sources are usually available, such as samples 
collected at the farm or animal health data records. The main drawback of active surveillance 
will be its cost, especially when a large sample is required.  
Sentinel animals are a form of targeted surveillance with a prospective study design. They 
consist in cohorts of unexposed animals (initially seronegative) managed at fixed locations 
and monitored regularly to detect new infections (seroconversions) (OIE, 2013b).  Risk-based 
approaches can help improve sentinel systems and give the possibility to concentrate 
resources on specific areas and periods which have been identified to be at-risk for the 
emergence. Hadorn et al. (2002) illustrated how taking account of risk assessments regarding 
disease introduction when designing surveys reduce considerably the sample size needed. In 
the context of an ABV, high-risk patterns can be identified based on several risk criteria (or a 
combination of criteria): 1.presence of the vector 2.vector ecological requirements (climatic 
and geographic factors) and 3.exposure of the hosts. Some ABV are transmitted by different 
species of arthropods and thus different risk criteria have to be dealt with simultaneously 
when building the sampling design. The elaboration of risk-based sentinel networks totally 
relies on the sufficient epidemiological knowledge of the disease which often requires among 
other things a preliminary entomological surveillance system to be in place. This kind of 
approach thus obviously supposes that the risk of emergence is well known by the veterinary 
authorities. 
In the context of an emerging ABV, a substantial part of the active surveillance system 
concerns the surveillance of the vector itself (figure 3). Many scientific sampling techniques 
have been developed for capturing vector arthropods. Depending on the targeted ABV and on 
the purpose of the surveillance linked to the stage of the epidemic (figure 2), the vector 
surveillance protocol will vary in terms of: 1. the type of traps used, 2. the number/density of 
traps, 3. the location sites of traps and 4. the frequency of sampling. Once the objective of the 
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surveillance program has been clearly defined, historical data on the vector and the ABV 
should be collected. The choice of the type and the number of traps as well as their frequency 
of use should be based on this data, taking the following into account: 1.biology of the 
arthropod, 2.ecological criteria relevant to the arthropod, and 3.host population characteristics. 
Still depending on the objective of the entomological surveillance, the collection protocols 
should be able to obtain information about different life stages of the vector. For instance, if 
an arthropod is absent from an area, the trapping should target the developmental stages that 
are most likely to be introduced (OIE, 2013a). The detection of the ABV itself in the vector 
will usually be by performing identification at species level and analyzing pools of 
arthropods. 
As pointed out by figure 2, the role of diagnostic tests is central as they will contribute to both 
passive and active surveillance. The diagnosis usually consists in identifying the presence of 
the virus, viral genetic material or of antibodies in potential samples, but can also take the 
form of a vector’s morphological identification. The selection of the method to use will 
depend again on the purpose of the surveillance. The effectiveness of the surveillance 
programs will rely largely on the performance of the diagnostic tests that is used (sensitivity 
(DSe) and specificity (DSp) of the tests), which is closely linked to the status of the targeted 
population and to the dynamics of the infection (EFSA, 2011a). 
Syndromic surveillance is a method for early identification of the impact of potential health 
threats which can complement the traditional surveillance systems. It consists in the real-time 
screening of non-specific health indicators for atypical syndromes. There are many sources of 
information which can be suitable for that purpose, such as data from veterinary practitioners, 
milk recording, fertility/abortion recording, rendering plant, etc. The data are usually initially 
collected for other reasons than surveillance; therefore, this approach is economically 
interesting since it would only rely on data routinely collected in many countries. The 
principal advantage of syndromic over clinical surveillance is that the former reduces under-
reporting as well as the time lag linked to passive surveillance by monitoring continuously 
animal populations before laboratory confirmation. This is a relatively emerging field which 
has already encountered limitations principally regarding the availability of animal-health 
data, but the costs of overcoming these barriers are justified by their utility (Shephard, 2006; 
Dorea et al., 2011). 
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Figure 2: The different components of the monitoring and surveillance program of an arbovirus 
 
 
I.III. Bluetongue virus  
I.III.1. General 
                        As shown in table 1, Bluetongue (BT) is an ABV holds a very important place in the history 
of EIDs, as it was added in the sixties to the former List A of the OIE International 
Zoosanitary Code as one of the 15 diseases that “are highly contagious and pose particularly 
serious threats to national and regional economies” (Gibbs and Greiner, 1994). Indeed, BT 
can cause mild to spectacular outbreaks in ruminant populations and has in addition an 
adverse impact on worldwide trade due to restrictions on the source of animals (MacLachlan 
and Osburn, 2006).  
                        BT is caused by BTV, the type species of the genus Orbivirus. There are several antigenic 
strains of BTV. Recently, it was suggested to add a 25th and 26th member to the 24 
serologically distinct serotypes of the virus already internationally recognized (Hofmann et 
al., 2008; Maan et al., 2011).  Furthermore, there are variations in the virulence characteristics 
of individual strains of the same serotype (MacLachlan, 1994). 
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                        Adult females of haematophagous midges of the genus Culicoides (Diptera: 
Ceratopogonidae) currently are the only known vectors for transmitting BTV between 
animals (Du Toit, 1944; Osburn, 1994). The geographical distribution of Bluetongue around 
the world is a reflection of the Culicoides’ distribution and the climatic conditions favorable 
to the transmission cycle of the virus. Therefore, BT was traditionally understood as 
occurring around the world between latitudes of approximately 40°N and 35°S (figure 3), 
although in certain areas (i.e. western North America, China and Kazakhstan) it may extend 
up to around 50°N (Dulac et al., 1989; Zhang et al., 1999, 2004; Lundervold et al., 2003; 
Mellor et al., 2008; Wilson and Mellor., 2009). The Culicoides species that serve as the 
principal vectors of the virus differ between regions. Historically, C. imicola is believed to be 
the main vector in Africa and around the Mediterranean Basin, C.variipennis in North 
America, C. insignis in Central and South America and C.fulvus and C.wadai in Australasia 
(MacLachlan, 1994). So far, six proven or potential Culicoides vectors have been recognized 
in Western Europe: C.imicola and five potential vectors of the Obsoletus and Pulicaris 
species complexes (EFSA, 2011b). Several episystems have been recognized around the 
world as relatively stable relationships between the different species of Culicoides, distinct 
strains of BTV and susceptible host species, despite extensive and ongoing trade and 
movement of ruminants between individual episystems (Caporale et al., 2004). 
In Europe, the only areas known to have experienced the disease before the 1990s were parts 
of Portugal, Spain and Greek islands (Manso-Ribeiro and Noronha, 1958; Sellers, 1975; 
Vassalos, 1980). These epidemics however have never persisted. From 1998 onwards, the 
situation changed for BT emerged in several areas from Southern and Eastern Europe that had 
so far never recorded the virus (Anon, 1999a,b; 2000a,b,c, d; 2001a,b,c; Di Ventura et al., 
2004; Boinas et al., 2005). At least five serotypes (BTV-1, -2, -4, -9, and -16) of BTV were 
involved in the BTV incursions between 1998 and 2005 (Mellor et al., 2008). It was shown 
that BTV was probably spread to those countries by the introduction of infected Culicoides by 
the wind or by moving infected animals from the Eastern and Southern boundaries of Europe 
(Gomez-Tejedor, 2004; Wilson and Mellor, 2009).  
As described in figure 4, both Culicoides and ruminants are essential for the life cycle of 
BTV. Following the introduction of BTV through the skin of the host via the bite of an 
infected vector, the virus reaches the regional lymph nodes where initial replication occurs. 
BTV is then transported via the efferent lymphatic vessels throughout the body to secondary 
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sites of replication, mainly the lymph nodes, the lungs and the spleen. The virus replicates 
principally in the vascular endothelium and mononuclear phagocytes and is then released 
massively into the blood stream (Whetter et al., 1989; MacLachlan, 1994). The viraemic 
ruminant host becomes a source of virus for the Culicoides and act as a transient reservoir for 
maintenance of BTV. The maximal duration of viraemia is known to be around 8 and 9 weeks 
for sheep and cattle, respectively (Richards et al., 1988; Singer et al., 2001). The probability 
of a susceptible biting midge to become infected is dependent on the level of viremia of the 
host and the competence of the vector. When infected, the vector becomes persistently 
infectious for its entire lifespan which lasts more or less a few weeks (Gibbs and Greiner, 
1994).  
In addition, it was shown that BTV excretion in semen might occur sporadically (Howard et 
al., 1985). More recent findings have demonstrated that the transmission of BTV from 
ruminant to ruminant was possible via the transplacentary and presumably oral routes (De 
Clercq et al., 2008; Menzies et al., 2008; Backx et al., 2009; Mayo et al., 2010).  Cases of 
contamination of a canine vaccine with BTV showed that dogs are also susceptible to BTV 
infection (Akita et al., 1994). 
Common clinical signs of BT are pyrexia, inflammation of the oral mucosa, tongue and 
coronary band, excessive salivation, oedema of the head, anorexia, muscle degeneration and 
lameness (Breard et al., 2004; OIE, 2013c). Death may occur in 8-10 days, but the main 
impact of BTV infection comes from the indirect losses due to abortion and delayed 
convalescence (McKercher et al., 1953). BTV can infect most species of domesticated and 
wild ruminants although the clinical form of the infection is mostly seen in sheep and some 
species of deer (Erasmus, 1975; Osburn, 1994). The incidence of clinical disease is influenced 
by several other factors such as the breed and age of the host and the virus strain involved 
(Gibbs and Greiner, 1994). In cattle, BT is usually described as sub-clinical, but during the 
early stages of an epidemic in a naïve population, clinical cases are often reported 
(MacLachlan, 1994).  
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Figure 3: Map of the estimated global range of bluetongue virus prior to 1998 (from Wilson and 
Mellor, 2009) 
 
 
 
Figure 4: Bluetongue virus transmission cycle 
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I.III.2. Emergence of Bluetongue virus in North-Western Europe 
 
BTV is considered an ‘emerging virus’ since it has recently expanded its range towards 
North-Western Europe, outside its previous environment. Starting August 2006, a first 
epidemic of BTV was diagnosed in The Netherlands, Belgium and Germany.  As early as 
June that year, Belgian veterinarians started to observe unusual clinical signs in cattle which 
were primarily attributed to photosensitization or exposure to mycotoxins. In August 2006, 
several different practitioners in different sheep flocks in the Netherlands reported similar 
clinical signs and, for this reason, a contagious disease was suspected. The first outbreak was 
confirmed in the southern part of the Netherlands (van Schaik et al., 2007). At the end of the 
year, outbreaks were also reported in Luxemburg and France (OIE Animal Health 
Department, 2006; Toussaint et al., 2006). The virus was first isolated at the Veterinary and 
Agrochemical Research Centre (CODA-CERVA, Belgium) and identified as BTV-serotype 8 
(BTV-8) by scientists of the European Commission (EC) Reference Laboratory for BTV 
(Pirbright, United Kingdom) (CRL, 2006; Toussaint et al., 2007). The introduction of this 
serotype came as a surprise, since it was not circulating in Europe at that time. Prior to this 
epidemic, BTV-8 had only occurred in Africa, Central America, Malaysia, and India/Pakistan 
(Herniman et al., 1980; Hassan, 1992; Mo et al., 1994; Daniels et al., 2004; Gerdes, 2004). 
Even though several possibilities have been hypothesized, the route of introduction of BTV-8 
still remains undiscovered (Mintiens et al., 2008a). Serotype 8 was shown to differ from other 
serotypes in: 1.its ability for transplacental transmission and contamination of semen, 2.its 
extensive spread in North-Western Europe, and 3.its capacity to induce important clinical 
signs in cattle (EFSA, 2007b; De Clercq et al., 2010; Vercauteren et al., 2008; Vanbinst et al., 
2010; EFSA, 2011b). 
In May 2007, a sentinel cow seroconverted in Germany and it became evident that BTV-8 
somehow overwintered from 2006 and re-emerged within the original affected countries. In 
addition, the virus emerged in the United Kingdom, Denmark, Switzerland and the Czech 
Republic (OIE, 2007). It is still not clear how BTV-8 managed to survive winter 2006-2007. 
Some hypotheses refer to the vector and others to the host (Garigliany et al., 2011). During 
the second wave of the BTV-8 epidemic in the Netherlands, Elbers et al. (2009) found a 
median morbidity rate of 5.6% and 4.1% in sheep and cattle, respectively. The scale of the 
epidemic at that time became so important that the European Union (EU) decided to launch a 
massive vaccination campaign in 2008. In Belgium, mandatory vaccination of cattle and 
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sheep and voluntary vaccination of veal calves, goats and cervids with inactivated vaccine 
against BTV-8 took place between May 2008 and December 2010. From January 2011 
onwards, vaccination of ruminants against BTV-8 was still possible but no more compulsory. 
Ever since the start of the vaccination campaign, no more clinical cases of BT occurred. 
Subsequently, active surveillance demonstrated that BTV-8 was no longer present and, in 
consequence, Belgium regained its free status in 2012. In countries adjacent to Belgium and 
in most European member states (MS), BTV-8 has now been eradicated after almost six years 
of struggle. In total, between 1st July 2006 and 30 April 2008, 58156 outbreaks of BTV-8 
were confirmed throughout Europe (Figure 5). 
Furthermore, two more BTV serotypes were detected in 2008 in North-Western Europe: 
serotype 11 in Belgium and serotype 6 in Germany and the Netherlands but the epidemics 
were rapidly jugulated (De Clercq et al., 2009).  Data on the genetic sequence available 
indicates a high similarity with the BTV strains that were used to produce the South African 
modified live vaccines for the two serotypes (EC, 2009). 
 
 
 
Figure 5: Temporal distribution of the number of outbreaks due to BTV-8 (source: Surveillance 
Network for Bluetongue, 2013) 
 
 
Chapter I : General Introduction 
 
 
19 | P a g e  
 
I.III.3. Control of Bluetongue virus 
 
Culicoides control using chemical (insecticides, larvicides and/or repellents) or physical 
methods (removal of larval breeding sites on farm holdings) can be used to limit the 
transmission and spread of BTV. There are currently no chemical products authorized in the 
EU specifically for use against Culicoides, but some compounds used to control other types of 
parasites have also the potential to impact upon Culicoides. The treatment of breeding sites 
remains difficult as habitats are poorly defined for most species. (EFSA, 2008).  Globally, the 
use of control measures against Culicoides will only have temporary effects (Bréard et al., 
2004) and in any case can surely not be considered by itself to control an epidemic of BTV. 
Slaughter of BTV infected ruminants (stamping-out) may, in some specific situations, be 
considered as a control measure. In general, this type of policy is applied in the context of a 
disease for which no vaccine is available (or is not wanted to be used for specific reasons) or 
when the epidemic has reached very low incidence (Horst et al., 1999). A stamping-out 
strategy may be used as control measure against BTV, for instance, in the context of single 
infected imported animal where no further disease is detected (DEFRA, 2008). 
Traditional control measures include the restriction of animal movements from infected areas. 
Most European countries require testing ruminants and animal products in provenance of a 
country which is not free of BTV. Since the year 2000 through Council Directive 
2000/75/EC, European legislation provides directives on control measures implemented on 
animals, live animal products, or vectors, aiming at preventing the dispersion or eliminating 
BTV (CEC, 2000, 2005; Mintiens et al., 2008b). MS are to integrate these directives in their 
national BTV control programs. These measures include the establishment of three levels of 
zones in which movement restrictions should be applied in case of outbreak (Restricted zones: 
20 km-radius, the protection and the surveillance zones) and a ban on susceptible animal 
species and on their biological products (semen, ova and embryos) leaving those zones. 
Nevertheless, even though these types of measures are essential in controlling BTV, they will 
never be totally efficient in preventing the virus from spreading. The reason for this is that no 
movement restriction can possibly be applied to the main actor of BTV’s transmission, 
namely the Culicoides vector.  
Vaccination of susceptible hosts is known to be the most efficient way of controlling BT and 
is also used to allow safe trade in live animals in accordance to the OIE standards and 
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European legislation. Live attenuated vaccines have been used for ages and are cheap to 
produce and effective in controlling clinical BT in areas where the disease is endemic like in 
South Africa (Hammoumi et al., 2003). However, those vaccines are known to encounter 
safety issues. Indeed, cases of reversions to virulence, reassortments and teratogen effects 
have been reported in the past (Dungu et al., 2004; Saegerman et al., 2007; Savini et al., 
2008). Inactivated vaccines have been developed in the recent years principally to avoid these 
issues, but, are more expensive to produce and the induced immune response is generally 
short and requires repeated doses. However, they are effective when administrated in two 
doses and protect fully against both the clinical signs and the viraemia (EFSA, 2007a).  
Vaccination programs for the control of BT in ruminants have limitations due to difficulties in 
differentiating infected from vaccinated animals based on serology (DIVA). Recombinant 
DNA vaccines together with a suitable diagnostic test would allow that distinction to be made 
(Barros et al., 2009; Anderson et al., 2013). 
In an emergency situation, such as the BTV-8 epidemic in 2007, MS are allowed to use 
vaccine without a marketing authorization, after consultation of the EC (Saegerman et al., 
2007). 
 
I.III.4. Surveillance of Bluetongue virus 
Guidelines for BT surveillance are proposed in Chapter 8.3 of the OIE Terrestrial Animal 
Health Code. Because the impact and epidemiology of BT may differ in different regions of 
the world, these guidelines should be adapted by each country to its local conditions (OIE, 
2013). Commission Regulation (EC) No 1266/2007, last amended on 30 May 2012 (CEC, 
2007), introduces the obligation for MS to implement bluetongue monitoring and surveillance 
programs, which outcomes will guide veterinary authorities in the decision-making process. 
The minimal requirements have been summarized in table 2 and should always include 
clinical, active laboratory-based and entomological components. The requirements have been 
classified according to the surveillance aim: 1.to detect any possible incursion of BTV and 
2.to demonstrate the absence of certain serotypes of BTV in a MS or epidemiological relevant 
geographical area (during a period of at least two years). 
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BT appears on the list of diseases ‘notifiable’ to the OIE, which means that an affected 
country has always to report a new outbreak to the OIE.  According to EC No 1266/2007, MS 
should always notify outbreaks (i.e. holdings where at least one case has been confirmed) of 
BTV through the Animal Disease Notification System (ADNS). In Belgium, next to the 
traditional clinical surveillance described previously as well as in table 2, a compulsory 
reporting system of cattle abortions is implemented in the framework of Brucellosis 
surveillance (Abortus Protocol). All dead foeti samples presenting typical lesions of BT are 
tested by Real time Reverse-transcription polymerase chain reaction (RT-qPCR) to exclude 
the diagnosis of BTV (DGZ, 2013). 
The ‘design prevalence’ (table 2) is a critical epidemiological notion in the active laboratory-
based surveillance component, which will influence sample size. Indeed, if the purpose of the 
survey is to demonstrate freedom from infection at a given confidence level, sample size will 
increase as the expected prevalence decreases. The value of design prevalence can be derived 
from past observations or from disease modeling and will depend on the epidemiological 
context. In a recent Scientific Opinion pertaining to BT monitoring and surveillance, EFSA 
recommended to decrease the prevalence level prescribed at that time in the EU Regulation 
for the purpose of demonstrating freedom from disease  (Cannon, 2002; EFSA, 2011a). In 
Regulation (EC) No 1266/2007, it is stated that in the absence of relevant information on the 
design prevalence for the target population, a prevalence of 20% should be used to detect an 
incursion of BTV in the susceptible population of a relevant geographical area and a design 
prevalence of 5% must be considered to demonstrate freedom of BTV. 
In contrast to surveillance programs for non-vector diseases in which the epidemiological 
reference unit is usually the holding, the unit of reference for BTV is a geographical area 
(‘geographical unit of reference’ in table 2). It should be taken into consideration in the 
sampling protocol of the BTV sentinel system. This is due to the central role of Culicoides in 
the BTV transmission cycle and to the fact that midges are never confined to a specific 
holding. This unit of reference was defined based on past experience with BT surveillance as 
a grid of around 45 x 45 km (EFSA, 2011a). 
The objective of the entomological component as described in table 2, is to determine the 
‘vector‐free period’ which is an important concept in the surveillance of BTV. Linked to 
climatic parameter conditions, vector densities and activity fluctuates greatly seasonally. For 
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instance, BTV replication is not possible in Culicoides under a certain temperature threshold 
(11-13°C) (Carpenter et al., 2011). In Belgium, the main activity of Culicoides was shown to 
occur between August and November (De Deken et al., 2008). In accordance to the European 
Regulation, the following criteria based on the surveillance activities should be taken into 
account to establish the vector-free period (VFP): 1.no evidence of BTV circulation, 
2.cessation of vector activity, 3.captures below a maximum threshold and, 4.maximum 
temperature threshold. This concept is important in terms of legislation as it is a period during 
which restrictions of animal movements are loosened (EPIZONE, 2011).  
In addition, EC No 1266/2007 states that an integrated approach at European level is required 
in order to be able to analyze seamlessly the epidemiological data provided by the 
surveillance programs of the different MS. In this context, a web-based application has been 
developed by the Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise G. Caporale 
to gather BTV surveillance data at the EU level (BT-Net system). The system collects, stores, 
analyses and disseminates relevant epidemiological data on BTV between the different MS 
(EC, 2013). 
Several virological assays are available to detect BTV, antigen or viral RNA. RT-qPCR is a 
very sensitive and fast technique which is able to detect low concentrations of viral RNA. It is 
a valid method for the purpose of surveillance. However, viral RNA can be detected by RT-
qPCR in the blood of the host longer than the infectious virus itself (MacLachlan, et al., 
1994). The only method able to detect the presence of infectious BTV in a sample is viral 
isolation from eggs/mammal or insect cells (EFSA, 2011a). The most commonly used 
techniques for revealing the presence of BTV-antibodies in animal samples are the 
competitive enzyme-linked immunosorbent assay (c-ELISA), the indirect ELISA for bulk 
milk samples, the agar gel immunodiffusion and the serum neutralization method. The c-
ELISA is able to detect the presence of antibodies against all BTV serotypes. Because of its 
high DSe and DSp and low cost, the c-ELISA is often the method of choice to monitor BTV 
circulation. However, this test cannot be used for identifying BTV infections in a vaccinated 
population since it can’t make any distinction between infected and vaccinated animals. 
Furthermore, ELISA tests are not able to discriminate BTV serotypes from one and another. 
The seroneutralisation is the only serotype-specific serological assay existing up to now 
(EFSA, 2011a). 
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Table 2: Summary of Commission Regulation (EC) No 1266/2007 (last amended 30 May 2012) 
minimum requirements for BT monitoring and surveillance programs 
Surveillance component Activities 
Passive clinical -ongoing system of early detection and reporting of 
suspicions. 
 
Active laboratory-based -annual program consisting of at least one of the 
following: serological/virological monitoring with 
sentinel animals, surveys or risk-based surveillance.  
-at least once a year. 
-sampled animals should be non-vaccinated, exposed 
to the vector and representative of susceptible 
population. 
-sample size for appropriate design prevalence 
prevalence with 95% confidence in each geographical 
unit of reference. 
-positive screening tests should be followed by 
specific serotype tests. 
 
Entomological 
 
-permanently sites traps to determine the population 
dynamics of the vector.  
-aspiration traps equipped with ultraviolet light  
operated at least 1 night/week at least during the 
month before the expected end of the VFP and 1 
night/month in each geographical unit of reference 
during the VFP. 
-a proportion of the collected midges sent to 
specialized laboratory for counting and identifying 
species. 
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I.IV. Schmallenberg virus  
I.IV.1. General 
During summer 2011, an unidentified disease appeared in adult cattle in several farms located 
in Germany and the Netherlands (19 November 2011, Promed). The animals showed non-
specific acute symptoms (milk drop, watery diarrhea and high hyperthermia (>40°C)) and 
recovered after a few days. In December that year, researchers from the Friedrich Loeffler 
Institute (FLI) (Greifswald, Germany) isolated and identified a new emerging virus which was 
shown to be responsible for the abovementioned symptoms and was provisionally named after 
the municipality in Germany where it was first identified: the Schmallenberg virus (SBV).  
Metagenomic analysis indicated that the virus was closely related to viruses from the Simbu 
serogroup, part of the family Bunyaviridae, genus Orthobunyavirus. (Hoffmann et al., 2012; 
Muskens et al., 2012).  
Several viruses from the Simbu serogroup such as Shamonda, Akabane (Table 1) and Aino 
viruses are known to be teratogenic for ruminants when infected during a vulnerable period 
during gestation and may lead to abortion or congenital malformation (Yanase et al., 2012; 
OIE, 2013). Starting from December 2011, domestic ruminants in Germany and the 
Netherlands suffered from abortions and stillborn malformed offspring with signs including 
the hydranencephaly-arthrogryposis syndrome (Garigliany et al., 2012a; Herder et al., 2012; 
Van den Brom et al., 2012).  
RT-qPCR made available by the FLI was used to confirm SBV suspected cases (Hoffmann et 
al., 2012). The presence of SBV was demonstrated in Germany, the Netherlands, Belgium, the 
United Kingdom and France and to a lesser extent in Italy, Luxembourg, Spain, Switzerland, 
Denmark, Austria, Ireland, Sweden, Norway, Finland, Poland and Estonia (EFSA, 2012b; 
OIE, 2013; Figure 6). In Belgium, the first reports of malformation in newborn lambs 
occurred mid-December 2011 and were confirmed by RT-qPCR in a farm in the North of the 
country located near the Dutch border (23 December 2011, Promed). At the end of August 
2012, SBV had been detected in 408 cattle holdings, 167 sheep holdings and 2 goat holdings 
in Belgium.  
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Figure 6: Schmallenberg virus confirmed herds by week of first report and country all species until 
April 2013 (source: EFSA, 2013) 
 
 
 
I.IV.2. Epidemiology of Schmallenberg virus   
 
Scientific research on the epidemiology of SBV is ongoing in the different affected countries 
with the financial support of the EC (EC, 2012). The OIE summarizes and updates regularly 
the scientific knowledge which has been accumulated on the virus in its SBV Technical 
Factsheet (OIE, 2013). 
SBV is now known to affect several species of ruminants. Thus far, the virus was detected by 
RT-qPCR or virus isolation in cattle, sheep, goat, bison and roe deer. In addition, SBV was 
confirmed by serology in various wildlife species: red deer, fallow deer, sika deer, alpaca and 
mouflon (Jack et al., 2012; Beer et al., 2013; OIE, 2013; 30 May 2012, ProMed).  
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The identification of SBV in biting midges (Culicoides spp.) collected during summer and 
autumn of 2011 suggests the central role of the vectors in transmitting the virus (De Regge et 
al., 2012; Rasmussen et al., 2012; Elbers et al., 2013). Further information is required to 
exclude other arthropod species from the range of putative SBV vectors. Direct transmission 
of the virus from animal to ruminant has so far not been detected and has never been reported 
in other Simbu serogroup viruses either (Beer et al., 2013). SBV-genome was detected in bull 
semen. However, virus transmission by insemination remains to be proven; further research is 
ongoing to determine the importance of semen and embryos in the transmission of SBV. As a 
precautionary measure, several countries have already applied restrictions on imports of 
bovine semen and embryos collected after 1 June 2011 from all EU countries (20 December 
2012, ProMed). 
SBV is able to cross the placenta and infect the foetus, which can result in viraemic offspring 
(Garigliany, 2012; Van den Brom et al., 2012). The temporal patterns of the epidemics differ 
depending on the host species and the production type. This is to put in relation with the 
different timings for calving and lambing and to the time interval in pregnancy during which 
infection can lead to disease in the foetus. Linked to the gestational stage of the animal at 
infection time, SBV causes more or less severe damage to the foetus (Conraths et al., 2013). 
The incubation period observed in an experimental challenge trial on cattle ranged between 2 
and 5 days post-inoculation and the viraemia was very short with duration of maximum 6 
days (Hoffmann et al., 2012). An antibody response to SBV can be detected in infected 
animals within 12 to 14 days. In analogy to infections with other viruses of the Simbu 
serogroup (Taylor and Mellor, 1994) and based on the results of a recent experimental study 
showing that neither oral exposure nor contact infection could induce SBV-infection in re-
infected cattle (Wernike et al., 2013), it seems likely that infection with SBV induces 
protective immunity. It is not yet known how long protection might last and be detectable 
(Conraths et al., 2013). 
 
I.IV.3. Control and surveillance of Schmallenberg virus 
Acting on the control of potential vectors or rescheduling breeding outside the vector season 
were during the 2011-2012 epidemic the only available preventive measures that could be 
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implemented at the farm level. Since summer 2013, a vaccine is available in the United 
Kingdom (Merck Animal Health, 2012). In addition, based on the current scientific 
knowledge, the OIE has proposed test procedures that may help countries free of SBV to 
protect themselves from a potential introduction (OIE, 2013). As described previously, the 
SBV-genome can be detected by RT-qPCR (Hoffmann et al., 2012) and antibodies against the 
virus can be demonstrated by virus neutralization test, indirect immunofluorescent antibody 
test and ELISA (Conraths et al., 2013). The latter is the best diagnostic procedure for large-
scale screening. 
Unlike BTV for which specific surveillance requirements are foreseen, nothing is compulsory 
for SBV, since the virus, as other Simbu serogroup viruses, is not classified as notifiable to 
the OIE. However, affected countries have notified the OIE of the presence of SBV under 
required reporting procedures for emerging diseases. In the Netherlands, immediately after the 
emergence of the virus was recognized, SBV has been declared officially a reportable disease 
to the Dutch veterinary authorities. Later on during the epidemic, other countries including 
Germany and France, made the reporting mandatory as well (Beer et al., 2013).  
Next to this, the Belgian compulsory Abortus protocol (as described in the BTV section) has 
now been extended to test also samples from foetuses with malformations typical of SBV 
with RT-qPCR.  
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     The introduction of BTV-8 into the North-Western European ruminant population in 2006 
was a major and unexpected animal health event. At that time, the virus was known to be an 
important pathogen of ruminants, but was still completely exotic to North-Western Europe. A 
few years later, history seemed to be repeating itself with the emergence of another ABV 
affecting also ruminants in the same geographical area. This time, the guilty party was a novel 
virus closely related to viruses from the Simbu serogroup, also totally unknown in Europe 
before summer 2011. The two viruses emerged in the exact same region at a five-year 
interval, meaning that this area probably includes an unidentified route of introduction.   
At the moment there are very few endemic ABV in ruminant populations in North-Western 
Europe. This means that there is room for many other emergences as these populations are 
still naïve to many viruses (Table 1) (Johnson et al., 2011). In light of the increased risk of 
ABV emergence in Europe linked to globalization and climate change, it has become 
imperative for animal-health professionals to proactively improve the surveillance process. 
The occurrence of BTV and SBV in Belgium are two recent and unprecedented illustrations 
of ABV emergences which can be used as models to identify key elements to enhance 
surveillance in the future.   
The main objective of this thesis is to analyze the surveillance activities which were 
implemented in Belgium in the context of the BTV-8 and SBV epidemics in order to be able 
to provide recommendations to anticipate and prepare adequately the potential next ABV 
emergence. This will be done by answering the following questions:   
• How well were we prepared in Belgium for the BTV-8 epidemic? 
• Did the BTV-8 epidemic experience helped to be better prepared for the SBV 
epidemic? 
• What is the reliability of the early case detection for BTV-8 based on clinical 
surveillance? 
• What are the other alternatives for the early detection of an ABV? 
• Why and how to evaluate the spread of an ABV epidemic? 
• How to plan and conduct the evaluation of a vaccination campaign against an ABV? 
• How to demonstrate freedom from disease in a population immunized against an 
ABV? 
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Abstract 
Bluetongue (BT) was notified for the first time in several Northern European countries in 
August 2006. The first reported outbreaks of BT were confirmed in herds located near the 
place where Belgium, The Netherlands and Germany share borders. The disease was rapidly 
and widely disseminated throughout Belgium in both sheep and cattle herds. During the 
epidemic, case-reporting by the Veterinary Authorities relied almost exclusively on the 
identification of herds with confirmed clinical infected ruminants. A cross-sectional 
serological survey targeting all Belgian ruminants was then undertaken during the vector-free 
season. The first objective of this study was to provide unbiased estimates of BT-
seroprevalence for different regions of Belgium. Since under-reporting was suspected during 
the epidemic, a second goal was to compare the final dispersion of the virus based on the 
seroprevalence estimates to the dispersion of the confirmed clinical cases which were notified 
in Belgium, in order to estimate the accuracy of the case-detection based on clinical suspicion. 
True within-herd seroprevalence was estimated based on a logistic-normal regression model 
with prior specification on the diagnostic test’s sensitivity and specificity. The model was 
fitted in a Bayesian framework. Herd seroprevalence was estimated using a logistic regression 
model. To study the linear correlation between the BT winter screening data and the case-
herds data, the linear predicted values for the herd prevalence were compared and the Pearson 
correlation coefficient was estimated. The overall herd and true within-herd seroprevalences 
were estimated at 83.3 (79.2-87.0) and 23.8 (20.1-28.1) per cent, respectively. BT 
seropositivity was shown to be widely but unevenly distributed throughout Belgium, with a 
gradient decreasing towards the south and the west of the country. The analysis has shown 
there was a strong correlation between the outbreak data and the data from the survey (r=0.73, 
p<0.0001). The case detection system based on clinical suspicion underestimated the real 
impact of the epidemic, but indicated an accurate spatial distribution of the virus at the end of 
the epidemic. 
 
Keywords 
Bluetongue; Survey; Seroprevalence; Correlation; Belgium; Epidemics 
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Introduction 
Bluetongue (BT), a vector-borne viral disease, is transmitted in ruminant populations almost 
exclusively by several species of biting midges of the genus Culicoides (Diptera: 
Ceratopogonidae) (Cêtre-Sossah et al., 2004; Pili et al., 2006). BT virus (BTV) is a species of 
the genus Orbivirus within the Reoviridae family. To date, 24 distinct BTV-serotypes have 
been identified (Gorman, 1990; Takamatsu et al., 2003). BT can cause spectacular outbreaks 
and has an adverse impact on worldwide trade due to restrictions on the source of animals 
(Green et al., 2005; FAO, 2006). It thus appears on the list of diseases notifiable to the World 
Organisation for Animal Health (OIE). Influenced by several factors such as geographical 
location, the incidence of clinical disease is highly variable. BT disease is uncommon in many 
areas where BTV is endemic (MacLachlan, 2004). The virus is traditionally known to be 
distributed around the world in countries lying in the tropics and subtropics, although it may 
extend further north like in parts of Western North America and Xinjiang, China (Dulac et al., 
1989; Gibbs et al., 1994; Qin et al., 1996). The virus has been documented as far as 45°N in 
Southern Europe (Caporale et al., 2004). 
In August 2006, very unexpectedly, BT was for the first time notified in The Netherlands, 
Belgium and Germany. (OIE Animal Health Department, 2006; Toussaint et al., 2006). Later 
on during the epidemic, related cases were also reported in France and Luxembourg. The 
virus incriminated was identified as BTV-serotype 8 (CRL, 2006; Toussaint et al., 2007a), 
which prior to this epidemic had only occurred in Africa, Central America, Malaysia, and 
India/Pakistan (Herniman et al., 1980; Hassan, 1992; Mo et al., 1994; Daniels et al., 2004; 
Gerdes, 2004). Although the possible routes of introduction were investigated, the exact 
origin remains unknown (Mintiens et al., 2008). Based on the data from the early stages of the 
epidemic, the rate of the local spread was estimated to be around 15 km/week, partially 
reflecting the rapid extension of BTV in Northern Europe (Gerbier et al., 2008). 
In Belgium, the first 11 ever reported BT outbreaks were confirmed in the near East-border 
part of the country on the 19th of August 2006, in both sheep and cattle herds (Toussaint et 
al., 2007b). Despite the measures implemented banning animal movement, the disease was 
rapidly and widely disseminated throughout the Belgian territory. By December 2006, a total 
of 695 herds or flocks were declared “case herds” of which 297 were cattle herds. During the 
epidemic, case-reporting by the Belgian Veterinary Authorities relied almost exclusively on 
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the identification of herds with confirmed clinical infected ruminants. Laboratory diagnoses 
were mostly used for confirmation of BTV infections in ruminants reported with BT-like 
clinical signs. Therefore under-reporting was suspected.  
During the winter of 2006/2007, it was assumed that climatic conditions were unfavourable 
for further propagation of BTV. The last cases of the epidemic in Belgium were reported by 
the Veterinary Authorities on 15 December 2006. A serological and virological cross-
sectional survey (BT winter screening) targeting all Belgian ruminants was undertaken in 
January-February 2007 in order to establish the true final dispersion of the virus across the 
country. The first objective of the study was to provide unbiased estimates of BT-
seroprevalence for different regions of Belgium. A second objective was to compare the final 
dispersion of the virus based on the seroprevalence estimates to the dispersion of the 
confirmed clinical cases which were notified in Belgium, in order to estimate the accuracy of 
the case-detection based on clinical surveillance. This paper presents the descriptive 
epidemiology of the BT winter screening 2007. 
 
 
Material and Methods 
Sampling design for the BT winter screening 
The study population of the winter screening consisted of dairy cattle of more than two years 
old which were housed in dairy farms with on-farm delivery of dairy products. Cattle were 
sampled because of expected higher prevalence in this species compared to sheep (Ward et 
al., 1994). Only dairy cattle were considered for sampling since serologically negative 
animals that were to be identified by the BT winter screening would participate afterwards in 
a longitudinal BT sentinel animals monitoring programme (logistically dairy animals are 
sampled more easily). The sampling frame was provided by the list of 1245 diary herds with 
on-farm delivery of dairy product previously identified for the official Belgian Leucois-
Brucellosis winter screening. In this programme, all animals of more than two years were 
sampled. 
Since no prior information on the herd prevalence was available, the number of herds to be 
sampled was based on an expected prevalence of 50 per cent (maximal variance), a desired 
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absolute precision of 5 per cent and 95 per cent confidence level. Since at the time of sample 
size’s selection, no information was available on the diagnostic test’s sensitivity and 
specificity, these were assumed to be perfect. A sample of 384 herds was set to be selected 
(Cannon and Roe, 1982). A one-stage cluster sampling design was performed with 
stratification of the herds by province and proportional allocation according to province 
surface.  
 
Diagnostic methods 
Samples were collected by the official farm veterinarians and conditioned to serum samples at 
the regional laboratories of ‘Dierengezondheidszorg Vlaanderen’ and the ‘Association 
Régionale de Santé et d'Identification Animales’. The serum samples were assayed using a 
commercially available competitive ELISA (c-ELISA) kit (ID Screen® Blue Tongue 
Competition for detection of anti-VP7 antibodies; ID.VET, Montpellier, France) which was 
carried out according to the OIE Manual of Standards (OIE, 2004) and to the procedure 
described by the manufacturer. Results were expressed as percentage negativity (PN) 
compared to the negative kit control and cut-off settings considered were those provided by 
the manufacturer. Samples which presented a PN less or equal to 35 per cent, between 35 and 
45 per cent, and greater than 45 per cent were considered as positive, doubtful and negative, 
respectively. Doubtful results were classified positive in the data analysis. Using RT-qPCR as 
reference test during the epidemic, the diagnostic sensitivity and specificity of the c-ELISA 
was estimated at 87.4 per cent (95%CI: 83.5-90.4) and 99.0 per cent (95%CI: 97.2-99.6), 
respectively (Vandenbussche et al., 2007). 
 
Case herds 
Case herds were mostly herds (cattle or ovine) for which the veterinary practitioner, who has 
been consulted by the animal owner, identified suspicious clinical cases and where at least 
one of those animals was subsequently confirmed positive using a laboratory test (c-ELISA 
and/or real-time PCR) and then notified to the veterinary authorities (EFSA, 2007). A 
maximum of three animals were sampled per herd. In addition, herds without clinical signs 
but with seropositive animals which were then confirmed positive with real-time PCR 
(Toussaint et al., 2007a) were also included. For example, animals could be detected when 
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tested serologically for certification prior to trade between zones with different BTV-8 status 
within the country or prior to export. EDTA blood and serum samples were tested at the 
Belgian National Reference Laboratory (VAR). 
 
Statistical methods 
The estimation of within-herd seroprevalence was based on a logistic-normal regression 
model. For the BT winter screening data, let iZ  be the number of positive tested animals out 
of iN  tested animals from herd i. It was assumed that the number of positive animals 
followed a binomial distribution:  
iZ ~ ),( aii pNBin ,      (1) 
with aip  the apparent prevalence. The true prevalence tip , reflecting the true serological status 
of the animals, was derived from the following equation (Rogan and Gladen, 1978) taking the 
sensitivity and specificity of the c-ELISA test into account: 
),1()1( titiai pSppSep −×−+×=    (2) 
or, 
1
1
−+
−+
=
SpSe
Spp
p
a
it
i ,    
where Se is the test sensitivity and Sp is the test specificity.  
To account for possible correlation among the animals from the same herd, the seroprevalence 
in herd i was modelled as 
logit iti up += β)( ,     (3) 
with iu ~Normal( 2,0 σ ) being the normally distributed random intercepts for each herd. This 
model is a special form of a generalized linear mixed model as described by Molenberghs and 
Verbeke (2005). The Intraclass Correlation Coefficient (ICC) given by 
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=ICC ,  
was estimated to establish the correlation between the infection status of two animals within a 
herd. Since the sensitivity and specificity were no fixed or known values, a prior distribution 
for the sensitivity and specificity was assumed. Thus, model specification was further 
extended by assuming a beta-distribution for the Se and Sp parameters:  
    Se ~ beta( 11 ,ba ),     (4) 
    Sp ~ beta( 22 ,ba ),     (5) 
where 2211 ,,, baba were chosen based on literature material (Vandenbussche et al., 2007). In 
summary, the within-herd seroprevalence estimation was based on a logistic-normal 
regression model, accounting for the test sensitivity and specificity of the test. The model is 
given by equations (1) to (5). Because of its hierarchical structure, it was fitted in a Bayesian 
framework, using WinBUGS software (http://www.winbugs-development.org.uk). Non-
informative priors were used for all model parameters. Posterior seroprevalence distributions 
and 95 per cent central credibility intervals were generated. A density plot of the predicted 
within-herd seroprevalence estimates, was produced based on the logistic-normal regression 
model (1)-(5). 
The herd seroprevalence (probability that a herd was infected) was estimated using a logistic 
regression model:  
iY ~ )( hpBernouilli ,      (6) 
Logit β=)( hp , 
where hp  is the apparent herd prevalence. This model was extended by allowing different β ’s 
for the different provinces, in order to estimate the province-specific herd seroprevalences. 
For the purpose of this study, a herd was considered as positive if at least one of the sampled 
animals had a positive ELISA test result, otherwise it was considered negative. 
In both models described above, the design-effect was taken into account by weighting each 
observation by the inverse of the sampling probability. Provinces which were under-
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represented in the sample were attributed a higher weight, whereas the over-represented 
received smaller weight. Herd density data was extracted from the Belgian animal 
identification and registration system (SANITEL) to provide estimates of the population at 
risk. A map showing herd density for cattle at municipality level was produced using 
ArcView GIS 3.2. (ESRI). 
A map showing the distribution of within-herd seroprevalence in the country was produced. 
The true within-herd prevalence estimates of the farms which were sampled were interpolated 
by Inverse Distance Weighting (IDW) (Shepard, 1968; ESRI, 1996). 
In order to estimate the accuracy of the case-detection based on clinical surveillance, the 
linear correlation between the BT winter screening data and the case data was estimated. For 
both data sets, herd prevalence per municipality was estimated based on logistic regression 
models, as in equation (6). In order to account for spatial differences, a flexible smoothing 
method was used to estimate the spatial trend. It is assumed that  
Logit ),()( yxfp h = , 
where ),( yxf  is some unspecified smooth function of the x- and y-coordinates. The method 
used penalized splines with radial basis function, fitted as a generalized linear mixed model 
(Eilers et al., 1996; Ruppert, Wand and Carroll, 2003). This method was implemented in the 
SAS procedure GLIMMIX (9.1.3. SAS, Inc.). 
To study the linear correlation between the two datasets, the linear predicted values ),( yxf  
for herd prevalence, resulting from the logistic regression models applied to the two datasets, 
were compared and the Pearson correlation coefficient was estimated. For the outbreak data to 
be comparable with the winter screening data, solely cattle results were used for this part of 
the analysis. Maps showing the distribution of herd prevalence estimates at municipality level 
were produced. 
Daily meteorological data on the mean temperature were collected at 247 weather stations in 
The Netherlands, Belgium, Germany and France. The raw temperature values were 
interpolated between the locations of the weather stations using IDW. A model of the German 
meteorological service for large scale maps was used to adjust the interpolated temperature 
values for the correlation between temperature and altitude (Müller-Westermeier, 1995; 
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Ahrens, 2006). In a first step, the raw temperature data were reduced to sea level and 
interpolated on a grid cell size of 250 m using the IDW algorithm. Finally, the interpolated 
values were adjusted for the height in the actual topography using altitude data with a 
resolution of 90 m (NASA SRTM data). Maps of the spatially interpolated mean daily 
temperature were produced for six dates at monthly intervals. 
 
 
Results 
Bluetongue winter screening  
A total of 25,846 cattle from 344 herds were sampled between the first and the 31st of January 
2007. An average of 75 animals (standard deviation, 51), ranging from 1 to 370, were 
sampled per herd. Among those samples, 5008 gave positive results. The overall herd 
seroprevalence was estimated at 83.3 per cent (95%CI 79.2-87.0). Province-specific herd 
seroprevalence estimates are shown in Figure 1. The highest estimates were found in 
provinces located in the north-east of Belgium, near the place where the epidemic started.  
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Figure 1: Bluetongue herd seroprevalence (%) and associated CI95% at the provincial level in 
Belgian dairy cattle based on the winter screening data, January 2007 
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The true overall within-herd prevalence was 23.8 per cent (95%CI 20.1-28.1). The spatial 
distribution of the within-herd prevalence is presented in Figure 2. The highest provincial 
within-herd prevalence estimates were found in Limburg and Liege provinces. There was a 
second focus around the city of Ghent in East Flanders province. On the other hand, the 
lowest within-herd seroprevalence was found in Hainaut province.  
 
 
Figure 2: Distribution of within-herd seroprevalence (%) in Belgian dairy cattle based on the winter 
screening data, January 2007 
  
 
Figure 3 shows the density plot of within-herd seroprevalence estimates. A large variability in 
within-herd seroprevalence was observed. However, in most herds, within-herd 
seroprevalence was between 0 and 20 per cent. The within herd ICC was estimated at 0.41 
(95%CI 0.36-0.47). This shows that correlation between the infectious statuses of two animals 
within a herd was high.  
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Figure 3: Density plot of the farm-specific within-herd seroprevalence estimates based on the winter 
screening data 
 
 
Figure 4 presents herd density at municipality level. High herd densities in 2006 were mainly 
observed in the western part of the country. Figure 5 shows maps of the spatially interpolated 
temperature for the 30 June, 30 July, 30 August, 30 September, 30 October and 30 November 
2006. Around the possible time of introduction (June-July), the temperature was high in 
Belgium. The global temperature trend during the BT epidemic consisted of two warm time 
periods (June-July and End-September) separated by a cooler period. Local differences in 
mean temperature were also suggested by the maps. 
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Figure 4:  Cattle herd density at the municipality level in Belgium, 2006 
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Figure 5:  Maps of the spatially interpolated temperature in Belgium on the (a.) 30 June (b.) 30 July 
(c.) 30 August (d.) 30 September (e.)  30 October and (f.) 30 November 2006 
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Case herds 
Between the 18th of August and the 31st of December 2006, a total of 1445 cattle and 893 
sheep samples were analysed. The overall BT herd prevalence was estimated at 0.7 per cent 
(95%CI 0.7-0.8) for cattle herds and 1.3 per cent (95%CI 1.2-1.4) for sheep flocks. Herd 
prevalence estimates at the provincial level for cattle and sheep are shown in Table 1. 
Estimates were found to be more or less twice higher for sheep than for cattle. However, the 
distributions of herd prevalence estimates at the provincial level were found to be similar in 
the two species. 
 
Table 1: Bluetongue herd prevalence (%) and associated 95%CI in Belgian cattle and sheep 
population based on the 2006 case herd data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Province   Herd-prevalence (%) (95%CI) 
  cattle sheep 
Antwerp  0.7 (0.5-1.0) 1.5 (1.1-2.0) 
East Flanders  1.5 (1.3-1.8) 2.2 (1.9-2.5) 
Flemish Brabant 0.8 (0.5-1.2) 1.2 (0.9-1.6) 
Hainaut  0.1 (0.0-0.3) 0.1 (0.0-0.3) 
Liege  1.6 (1.3-2.1) 1.5 (1.1-2.2) 
Limburg  1 (0.7-1.4) 3.2 (2.5-4.0) 
Luxembourg  0.2 (0.1-0.4) 0.1 (0.0-0.5) 
Namur 0.3 (0.2-0.7) 0.5 (0.3-0.9) 
Walloon Brabant 1 (0.5-2.1) 0.3 (0.1-1.2) 
West Flanders 0.1 (0.1-0.2) 0.4 (0.3-0.7) 
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Comparison of winter screening and cattle case herd results 
Based on the linear predicted values for herd prevalence of the winter screening and the cattle 
case herd data, the Pearson correlation coefficient was 0.73 and significant (p-value<0.0001). 
Figure 6 consists of two maps showing the distribution of BT herd prevalence estimates at 
municipality level based on cattle case-herd and winter screening data. The patterns indicated 
by the two maps seemed to be similar to each other. 
 
 
Figure 6: Bluetongue herd prevalence at the municipality level in Belgian dairy cattle based on (a.) 
the 2006 case herd data and on (b.) the winter screening data. 
 
 
 
Discussion 
Starting from the original focus in the area where Belgium, The Netherlands and Germany 
share borders, the epidemic gradually disseminated throughout the Northern European 
countries. The epidemic predominantly spread horizontally along an East-West axis (EFSA, 
2007). In Belgium, until October 2006, case herds were mainly limited to an area situated in 
the Eastern part of the country. Early September 2006, the area of chief concern appeared to 
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be the infectious status of the “still free” provinces; therefore, a serological screening was 
conducted and demonstrated freedom of BTV infection for all the provinces in which no case 
herd was notified at that time (Vandenbussche et al., 2007). The first case in East Flanders 
was notified on September 18 and the infection then further continued its spread to the west. 
At the end of the epidemic, BTV-seropositivity in dairy cattle herds was shown to be widely 
but unevenly distributed throughout Belgium. Seroprevalence was found to be the highest 
near the area of first infection with a gradient decreasing towards the south and the west of the 
country. In The Netherlands, the same distribution was observed, with, in this case, a gradient 
decreasing towards the Northern part of the country (Elbers et al., 2007). Based on case herd 
data, Gerbier et al. (2007) identified two spatial clusters of cases in Belgium which centered 
around the cities of Maastricht (the Netherlands) and Ghent. The authors stated that a gap 
between the two clusters remained by the end of the epidemic. The results of the present study 
on the other hand demonstrated a herd seroprevalence gradually decreasing towards the west 
with no higher level around the Ghent area. The within-herd seroprevalence map (Figure 2) 
revealed areas around Maastricht and Ghent where the within-herd seroprevalence was high. 
The highest within-herd seroprevalences were found on farms situated in Liege, Limburg, 
Flemish and Walloon Brabant provinces most certainly due to the fact that those regions were 
affected at the beginning of the epidemic. However, further study of specific risk factors such 
as local temperature, farm management system, and abundance of vector, is needed to better 
understand the spatial variation in the occurrence of BT and to allow a more efficient control 
of the infection in the future. The second focus around the city of Ghent could be explained 
for instance by the high cattle farm density in this area (Figure 4) which could be a risk factor 
for within-herd propagation of BT. Visual examination of the temperature maps (Figure 5) 
suggested that hilly areas were always cooler compared to areas of lower elevation. Those 
lower temperatures may have had an influence on the life cycle of Culicoides and the 
replication of BTV in the vectors. The high ICC reflected the important correlation between 
two animals within a herd with respect to the presence/absence of BTV. A study conducted in 
Kazakhstan demonstrated also significant clustering at farm level (Lundervold et al., 2003). 
The authors pinpointed the fact that this effect could be related to local variations in the 
vector’s distribution. 
Clinical signs of BT appear as soon as five days post-infection. Therefore, in the early stages 
of an epidemic, infected animals are more quickly detected by clinical examination than by 
serology. In Italy, during the 2000-2001 BT-outbreak, sero-surveillance only debuted in the 
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decreasing phase of the epidemic curve (Giovannini et al., 2004). In a reporting system such 
as the one implemented during the course of the outbreak in Belgium, a succession of events 
has to occur before a case is detected. Theoretically, the reporting of suspect cases allows for 
a view of the situation for the entire susceptible population which is under owner and 
veterinary observation. This first relies on the assumption that the infection will produce 
clinical signs; hence, subclinical cases will go unnoticed (Doherr et al., 2001). BTV has in the 
past been isolated in several countries without clinical disease being recognised (Gibbs et al., 
1994; Mulhern, 1985). Based on the sparse data from whole-herd-sampling during the 
Northern European epidemic, it has been shown that a high proportion of cattle within a herd 
could be PCR or seropositive, while not showing any BT-clinical signs. Moreover, owners 
and veterinarians in Belgium had never previously experienced this exotic disease; therefore 
clinical signs were unfamiliar to them (Elbers et al., 2008). Also, owners may have been 
reluctant to report cases for fear of consequent loss of trade. The winter screening revealed 
indeed a higher prevalence than demonstrated by the reporting of clinical cases. Results 
demonstrated a high level of exposure to BTV in the dairy herds. The results confirm the fact 
that BTV spreads very quickly in an immunologically naïve ruminant population. The first 
Italian epidemic of BT in 2000 in Sardinia has demonstrated a rate of spread of 30 km per 
week and 80% of the island had been infected. Both in Sardinia and Sicilia, serological 
surveillance detected virus circulation to be wider than shown by clinical surveillance 
(Calistri et al., 2004; Giovannini et al., 2004). Serological screening demonstrated a BT 
animal-prevalence levels ranging from 3.23 to 61.11% in Albania after recent first infection 
(Di Ventura , 2004). In the present study, the obtained Pearson correlation coefficient showed 
that the spatial distributions of the virus indicated by the two datasets (Figure 6) were very 
similar. However, there was a large scale-difference in estimated prevalences. The case 
detection system based on clinical suspicion underestimated the real impact of the epidemic, 
but indicated an accurate spatial distribution of the virus at the end of the epidemic. 
In theory, each individual within the target population, namely the Belgian ruminant 
population, should have had an equal chance of being selected for sampling. For accessibility 
matters, only dairy herds with on-farm delivery of dairy product were considered in the 
sampling frame. Moreover, solely animals older than 24 months were sampled. Sub sampling 
presents an opportunity for selection bias which must be accounted for when willing to 
extrapolate the results to the target population. From the outbreak data, BT herd prevalence 
level in sheep was higher than in cattle. Ovine BTV infection cases might have been easier to 
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detect since this species is commonly known to be more prone to develop the clinical form of 
the disease (Gibbs et al., 1994). However, the particularity of this BTV-8 epidemic was that 
the virus was able to induce severe clinical signs in cattle (Thiry et al., 2006). Moreover, the 
results of the confirmation analyses showed that clinical signs observed in cattle were more 
specific than those observed in sheep (Toussaint et al., 2007b). In general, seroprevalence is 
known to be higher in cattle than in small ruminant populations (Ward et al., 1994; Di 
Ventura et al., 2004). On the other hand, a study conducted on the Indian sub-continent, 
demonstrated a higher seroprevalence in sheep than in cattle, with 45.71% and 33.4%, 
respectively (Sreenivasulu et al., 2004). Those findings demonstrate differences which can 
occur when sampling a particular species instead of another. In the same way, many studies 
have concluded that older cattle were more likely to be positive to BTV antibodies than 
younger cattle, related to a greater opportunity for repeated exposure to the virus (Uhaa et al., 
1990; Ward et al., 1994; Lundervold et al., 2003). Factors such as breed specific genetics or 
management methods differ a lot between a beef and a dairy cattle herd; hence, the level of 
prevalence may not follow identical patterns. Moreover, the “on-farm delivery of diary 
products” characteristic of selected herds may be associated for instance to a more artisanal 
agriculture which may indirectly have consequences on disease control. An analysis 
performed by Green et al. in the United States (2005), has not proven herd type to be a 
significant risk factor. However, this conclusion may depend on local conditions and 
consequently differ for Belgian cattle. 
The only indication a positive serological result gives is that the tested animal was at one 
point infected with the virus. Due to resistance in host population, future outbreaks would 
probably occur more silently in herds which were already infected during the 2006 epidemic. 
In this case, the genuine dissemination of the virus would certainly be much more extensive 
than the distribution of suspected cases (Purse et al., 2006). 
 
 
Conclusion 
These findings currently provide the best information available on the unprecedented 
occurrence of BT in Belgium and emphasized the rapid and non-confined spread of the virus 
in a susceptible ruminant population. Local variations in estimated prevalence should be 
further investigated to help identify particular risk factors and be able to better control future 
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outbreaks. The results of the winter screening were also used to set up a sentinel program in 
the country. This study showed that the case detection system based on clinical suspicion 
underestimated the real impact of the epidemic, but provided an accurate indication of the 
spatial distribution of the virus at the end of the epidemic 
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Abstract 
Bluetongue (BT) is an arthropod-borne viral disease of ruminants. In August 2006, domestic 
ruminant populations in Northern Europe became infected with BT virus serotype 8 (BTV-8). 
The first BTV-8-case of the year 2007 in Belgium was notified in July. This case was the 
starting point of a second wave of BT outbreaks. The main objective of this study was to 
describe the evolution and the clinical impact of the second episode of BT in Belgium. In 
addition, the main differences with the previous episode (August-December 2006) are 
reported. Both outbreak and rendering plant data were analysed. Overall cumulative incidence 
at herd level was estimated at 11.5 (11.2-11.8) and 7.5 (7.3-7.8) % in cattle and sheep 
populations, respectively. The findings went in favour of a negative association between 
within-herd prevalence in 2006 and the risk of showing clinical signs of BT in 2007 (via 
protective immunity). A high level of correlation was demonstrated between BT incidence 
and small ruminant mortality data when shifting the latter of one week backwards. This result 
supports the hypothesis that the high increase in small ruminant mortality observed in 2007 
was the consequence of the presence of BT.  For cattle, the correlation was not as high. An 
increase in cattle foetal mortality was also observed during the year 2007 and a fair 
correlation was found between BT incidence and foetal mortality. 
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Introduction 
Bluetongue (BT) is an arthropod-borne viral disease of both wild and domestic ruminants. BT 
virus (BTV) is a species of the genus Orbivirus within the Reoviridae family which is 
transmitted in ruminant populations almost exclusively by several species of biting midges of 
the genus Culicoides (Diptera: Ceratopogonidae). Of more than 1400 Culicoides species 
worldwide, fewer than 20 are actual or possible vectors of BTV (Cêtre-Sossah et al., 2004). 
To date, 24 distinct BTV-serotypes have been identified. The virus is traditionally known to 
be distributed around the world in countries lying in the tropics and subtropics, although it 
may extend further north like in parts of western North America and Xinjiang, China (Dulac 
et al., 1989; Gibbs and Greiner, 1994; Qin et al., 1996). Until recently, the virus has been 
documented as far as 45°N in southern Europe. (Gibbs and Greiner., 1994; Caporale, 2004). 
The vast majority of BT infections are clinically unapparent. Cattle can act as a reservoir for 
disease to keep the infection circulating. Sheep are more prone to show clinical signs. When 
the disease does occur, common clinical signs are pyrexia, inflammation of the oral mucosa, 
excessive salivation, oedema of the head (OIE, 2008a). Reproductive disorders such as 
infertility, congenital abnormalities, and abortion are also reported in infected sheep and 
cattle. BTV has been shown to cross the placenta barrier and may be arbortigenic and 
teratogenic (Luedke, 1985). 
In August 2006, domestic ruminant populations in Northern Europe became infected with 
BTV. Very unexpectedly, BT was notified in the Netherlands, Belgium and Germany. (OIE, 
2006; Toussaint et al., 2006). The index cases were reported in the area where the three 
countries share borders. Later on during the epidemic, related cases were also declared in 
France and Luxembourg. The virus incriminated was identified as BTV-serotype 8 (CRL, 
2006; Toussaint et al., 2007). By the end of the first epidemic in December 2006, a total of 
695 outbreaks were notified in Belgium. One of the particularities of this BTV-8 epidemic 
was the virus’ capability of inducing severe clinical signs in cattle (Thiry et al., 2007; Elbers 
et al., 2008). At the end of January 2007, a cross-sectional serological study was performed 
(‘winter screening 2007’) in the Belgian cattle population in order to establish the spread of 
BTV after the 2006 episode (Méroc et al., 2008). The findings of the study emphasized the 
rapid and non-confined spread of the virus. Indeed, overall herd seroprevalence in January 
2007 attained 83% and all Belgian provinces were concerned. Overall within-herd 
seroprevalence was estimated at 24%. The question whether BTV would over-winter was of 
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major concern at that time. In June 2007, a sentinel cow was confirmed positive in North-
Rhein Westphalia (Germany). The first Belgian case of BT in 2007 was suspected in a flock 
located in Antwerp (Oelegem), subsequently confirmed at the National reference laboratory 
(CODA-CERVA) and notified on the 17 July 2007. This case was the starting point of a new 
wave of BT outbreaks in Belgium. In 2007, BTV-8 re-emerged in the Netherlands, Belgium, 
Germany, Luxembourg and northern France, and was also reported in the United Kingdom, 
Switzerland, Denmark and the Czech Republic (OIE, 2008b). Farmers suggested that BT 
induced more severe clinical signs in 2007 than it did the previous year. 
The main objective of this study was to describe the evolution and the clinical impact of the 
2007 BTV episode in Belgium. In addition, the main differences with the previous epidemic 
(19 August to 15 December 2006) are reported. 
 
 
Materials and Methods 
Temporal evolution of the incidence 
Outbreak data (case data at farm level) was obtained from the Belgian Federal Agency for the 
Safety of the Food Chain (FASFC) for the 2006 and 2007 episodes. Outbreaks are mostly 
herds for which the veterinary practitioner, who has been consulted by the animal owner, 
identified suspicious clinical cases and where at least one of those animals was subsequently 
confirmed positive using a laboratory test (c-ELISA and/or real-time RT-PCR) and then 
notified to the veterinary authorities (EFSA, 2007). A maximum of three animals were 
sampled per suspected herd. Weekly incidence counts of BT outbreak herds were calculated 
for each species separately based on the dates when cases were reported to the FASFC. 
Temperature data was obtained from the Royal Meteorological Institute of Belgium (KMI-
IRM), and Culicoides data from the Institute of Tropical Medicine (ITG) who was 
coordinating the entomological surveillance. The temporal distribution of the epidemic 
(incidence curve), the mean weekly temperature data, and the weekly numbers of Culicoides 
trapped during 2007 were analysed. 
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Spatial evolution of the incidence 
Livestock density data was extracted from the Belgian animal identification and registration 
system (SANITEL) to provide estimates of the population at risk at the start of the 2007 
episode. The cumulative incidence (probability that a herd at risk developed BT during the 
year 2007; based on outbreak data) and 95% confidence intervals were estimated.  
 
Outbreaks’ characteristics 
The characteristics of the outbreaks were defined by analysing the distributions of the species 
and the herd types involved. In order to establish the influence of the herd immune status at 
the start of the episode on the incidence of BT during the episode (i.e. risk of becoming an 
outbreak), 286 dairy cattle which had been sampled during the ‘winter screening 2007’ and 
were found to be BT-seropositive at that time (Méroc et al, 2008), were investigated. A 
multiple logistic regression model was used to model the probability of a herd to become an 
outbreak according to its seroprevalence level at the end of the first BT episode, controlling 
for two other independent variables (herd province and herd size) (Agresti, 2002).The level of 
significance used was fixed to 0.05.  
  
Rendering plant 
In order to obtain information on BT mortality in Belgium in 2007, rendering plant data 
(Rendac) from 2002 onwards were acquired. Homogeneity in numbers of carcasses for years 
2002 to 2005 (i.e. historical data, before emergence of BTV-8 in Northern Europe) was 
verified using a one-way Analysis of variance (ANOVA; Neter et al., 1996). The cumulative 
differences (starting from week 28, which is the date of onset of the 2007 episode) of number 
of carcasses collected by the rendering plant between 2007 and average (2002-2005) for cattle 
and for sheep and goat were calculated. The average number of carcasses that were collected 
per week from 2002 to 2005 was calculated and compared to the weekly numbers that were 
collected in 2006 and 2007, respectively. Multiple pair-wise comparisons between 2007 and 
average (2002-2005), 2006 and average (2002-2005), and between 2006 and 2007 were 
performed using t-tests with Bonferroni correction (Bonferroni, 1937). 
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To study the impact of BT on ruminant mortality, the BT weekly incidence curve for 2007 
was compared to rendering plant data for the same time period. The correlation between BT 
incidence curve and the curve of weekly differences (2007 minus average (2002-2005)) was 
evaluated using the Pearson correlation coefficient. Statistical significance of the test was 
based on a p-value equal or lower than 0.05. The date of sampling was chosen in the BT 
dataset as reference to mimic the true date of disease onset. The analyses were performed for 
small ruminants and cattle separately. In addition, per ruminant species, different age/weight 
categories available in the Rendac dataset were considered (for sheep/goats: lambs and adults; 
for cattle: ≤50 kg calves and adults). The same comparison process was followed for dead 
cattle foeti, but, in this case, on a wider time scale (i.e. over both 2006 and 2007 calendar 
years). 
All statistical analyses were computed using SAS software, Version 9.1.3. 
 
 
Results  
Temporal evolution of the incidence 
Weekly BT incidence counts for each species concerned are shown in figure 1. The first 
outbreak was reported during week 28 and a peak was reached at week 36-38. We notice that, 
after having steadily diminished following week 38, the number of new cattle outbreaks has 
increased again at week 45 and this tendency continued until week 51. Pertaining to sheep 
population, the incidence curve in 2007 indicated first an exponential trend which reached a 
peak of 452 new outbreaks notified during week 36. Following this week, the number of new 
outbreaks reported decreased continually. At the end of the year 2007, a total of 6870 
outbreaks were reported throughout the country. Temperature (figure 1) started to decrease 
slowly from week 35 until week 44 when it increased again a little and then decreased again. 
The weekly numbers of Culicoides (figure 2) which were trapped increased from week 16 
until week 40 when the numbers started to sharply diminish. 
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Figure 1: Weekly incidence counts of reported Bluetongue outbreaks and weekly mean temperatures 
in Belgium in 2007 (week 23-52). 
 
Figure 2: Weekly incidence counts of reported Bluetongue outbreaks and weekly total numbers of 
Culicoides trapped in Belgium in 2007 (week 14-52) 
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Spatial evolution of the incidence 
Cumulative spatial distribution of confirmed cases with monthly intervals are presented along 
with farm density data in figure 3a (cattle) and figure 3b (sheep). The first outbreaks reported 
in 2007 were mainly located in East Flanders, and, until September, the vast majority of cases 
were reported in this province (for location, see figures 4a and b). The epidemic progressively 
spread to all provinces and especially towards West Flanders and Hainaut. At the end of the 
epidemic, BT was widely but unevenly distributed across all Belgian provinces. The disease, 
in both species, was mainly notified in regions where farm density was high. The vast 
majority of the outbreaks were located in the western half of Belgium. Indeed, 26.1 and 
21.2% of the outbreaks were situated in East and West Flanders respectively, while only 
1.4%, 4.9 and 3.7% of the cases in 2007 were located in Walloon Brabant, Liege, and 
Limburg provinces, where many of the outbreaks were reported in 2006. 
 
 
Figure 3a: Distribution of Bluetongue 2007 cattle outbreaks and cattle farm density data in Belgium 
at date a. 1st September 2007, b. 1st October 2007, c. 1st November, d. 1st December 2007 
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Figure 3b: Distribution of Bluetongue 2007 sheep outbreaks and sheep farm density data in Belgium 
at date a. 1st September 2007, b. 1st October 2007, c. 1st November, d. 1st December 2007 
 
 
Overall cumulative incidence at herd level based on confirmed outbreaks was estimated at 
11.5 (11.2-11.8) and 7.5 (7.3-7.8) % in cattle and sheep populations, respectively. Province-
specific cumulative incidence estimates and their 95% confidence intervals are presented for 
cattle in figure 4a and for sheep in figure 4b. The incidence in cattle was the highest in the 
southern part of Belgium. It was found to be the highest in Luxembourg and the lowest in 
Liege, Limburg and Flemish Brabant. For sheep, the highest estimate was found for East 
Flanders.  
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Figure 4:  Province-specific BT cumulative incidence estimates (in %) and 95%CI for the year 2007. 
a. in Belgian cattle population. b. in Belgian sheep population. (based on confirmed cases) 
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Outbreaks’ characteristics 
In 2007, cattle outbreaks represented 64.4%, while sheep herds represented 34.9% of the total 
outbreaks (1% left: goat, bison, lama and deer). Leaving herds with non-identifiable herd-type 
aside, 55% of the cattle outbreaks were of dairy type. Two hundred and one of the dairy herds 
that were seropositive during the ‘winter screening 2007’ suffered clinical outbreaks during 
the 2007 episode. Controlling for herd size and province, the results of the logistic regression 
model indicated that a unit increase of within-herd seroprevalence is a significant protecting 
factor for BT in 2007 (OR=0.96; 95%CI 0.95-0.98; p<0.0001). 
 
Rendering plant 
The results of the one-way ANOVA showed no statistical significant difference between the 
mean numbers of carcasses across years 2002 to 2005 for the two categories of ruminants (p-
values >0.05). Thus, homogeneity was assumed in the historical data and the average numbers 
(2002-2005) were further considered in the analyses as reference number. At the end of the 
year 2007, cumulative differences in number of carcasses between 2007 and reference value 
had reached 30693 carcasses in small ruminant population and 17517 carcasses in cattle 
population. Table 1 shows the results of the analysis made in order to compare mean weekly 
differences in mortality. The most important difference was observed for adult sheep and 
goats when comparing 2007 to average (2002-2005), with 554 carcasses per week more in 
2007 (p<0.05). An important difference was also seen for adult cattle with 122 carcasses more 
in 2006 than on average (2002-2005) (p<0.05). Figure 5a and 5b show the differences of 
number of carcasses between 2007 and average (2002-2005) for different sub-categories for 
cattle and small ruminant, respectively. For cattle, differences in all sub-categories are 
positive from week 35 onwards. For small ruminants, the difference curve clearly increased 
between week 29 and 43. This difference seemed to be attributed almost totally to adult 
carcasses. However, a small increase for lamb carcasses was also noticed. 
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Table 1: Differences between mean weekly numbers of carcasses collected yearly by the rendering 
plant and 95% CI Bonferroni (* indicates statistical significance) 
 
 sheep and goats cattle 
 
Year comparison 
 
lambs 
 
adults 
 
dead foeti 
 
calves(≤50kg) 
 
adults 
2007- 
average(2002-2005) 
120 
(-1;241) 
554 
(260;840)* 
80 
(54;103)* 
99 
(-135;33) 
120 
(18;222)* 
2006- 
average(2002-2005) 
114 
(-6;235) 
142 
(-144;428) 
23 
(-3;47) 
96 
(-138;330) 
122 
(20;223)* 
2007-2006 6 
(-114;126) 
412 
(126;697)* 
57 
(31;81)* 
3 
(-232;238) 
-1.54 
(-104;101) 
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Figure 5: Weekly differences in number of carcasses collected by the rendering plant between 2007 
and average (2002-2005). a. cattle, b. sheep and goats 
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Figure 6a and 6b show the BT incidence curves along with the rendering plant data curve 
(differences between 2007 and average (2002-2005)) for both species. The visual analysis of 
the cattle curves (Figure 6a) shows mortality differences were positive from week 35 
onwards. This positive mortality pattern seemed to follow the increase of the BT incidence 
curve for cattle. For sheep (Figure 6b), the two curves clearly follow the same trend with a 
delay of more or less one week between them. Table 2 presents Pearson correlation 
coefficient estimates and associated p-values showing the correlation between BT incidence 
and rendering plant data for each species and sub-category within species. The Pearson 
correlation coefficient was shown to be the highest for adult sheep and goats when shifting 
back the rendering plant data of one week with r=0.98 (p<0.001). Correlation between BT and 
mortality was not as good for cattle as it was for sheep and goats. Figure 6c shows the cattle 
BT incidence curve along with the rendering plant data for dead foeti. For dead foeti, 
correlation was found to be the highest when shifting back the data of 3 weeks (r=0.57; 
p<0.0001).  
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Figure 6:  Bluetongue weekly incidence curve and difference in number of carcasses collected by the 
rendering plant per week between 2007 and average (2002-2005) for cattle in Belgium in 2007.a. 
cattle. b. sheep and goats 
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Table 2: Pearson correlation coefficient estimates and associated p-values showing correlation 
between Bluetongue incidence and number of carcasses collected by the rendering plant in 2007 
 
 
sheep and goats cattle 
time lag   
 (nb week) lambs adults calves (≤50kg) adults 
-1 0.50(<0.001) 0.57(<0.001) 0.56(<0.001)    0.47(<0.01) 
0 0.63(<0.001) 0.83(<0.001)        0.52(<0.001)    0.45(<0.001) 
1 0.73(<0.001) 0.98(<0.001) 0.62(<0.001)    0.54(<0.001) 
2 0.67(<0.001) 0.83(<0.001) 0.64(<0.001)    0.53(<0.001) 
 
 
 
Figure 6c: Bluetongue weekly incidence curve and difference in number of dead cattle foeti collected 
by the rendering plant per week between 2006/2007 and average (2002-2005) in Belgium, from week 
1 2006 to week 52 2007 
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Discussion 
The epidemic in 2007 expanded in such a way that within the two first months, four times 
more outbreaks were identified than during the entire 2006 episode. The higher overall 
cumulative incidence estimates in 2007 compared to 2006 may be due to many causes or to a 
combination of these causes:  
 
• a higher level of infection in the population (linked to the presence of a considerable 
virus reservoir at the onset of the epidemic and/or to a change in Culicoides abundance 
(Elbers et al., 2007)). 
• a more severe disease within individual animals infected (which could be a 
consequence of a variation in the virus strain and is still to be examined (Maan et al., 
2008)). 
• a better awareness of the clinical signs by the owners.  
 
The observed provincial differences in cumulative incidence (figure 4a and 4b) could be 
explained by various risk factors such as the within-herd prevalence level at the end of the 
2006-epidemic (via protective immunity). The cumulative incidence in the cattle population 
(figure 4a) was the highest in the province of Luxembourg where seroprevalence at the end of 
the 2006-epidemic was the lowest. The lowest estimates were found in Liege, Limburg and 
Flemish Brabant, where seroprevalence was the highest at the end of 2006 (Méroc, 2008). 
These results and those of the limited analysis using the results of the ‘winter screening 2007’ 
seem to go in favour of a negative association between within-herd prevalence in 2006 and 
the risk of showing clinical signs of BT in 2007. The preliminary results from a longitudinal 
study in the Netherlands indicated that animals infected during the 2006-epidemic did not 
become infected (no PCR positives) again during the 2007-epidemic (Elbers et al., 2007). 
Another risk factor could be for instance the average size of herds in the province. 
Luxembourg leads with a mean of 130 cattle /herd, followed by Namur with 105 cattle/herd. 
We notice that the highest BT incidences in cattle were observed in the provinces of 
Luxembourg and Namur (figure 4a). 
As it was already the case during the first epidemic, BTV-8 appears to cause clinical disease 
both in sheep and cattle, whereas the clinical form of the disease is commonly known to be 
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restricted to sheep. The ratio of large to small ruminant farms affected was larger in 2007 
compared to 2006, since at the end of the 2006-epidemic, the distribution was 57.3% of sheep 
outbreaks and 42.7% of cattle outbreaks. From figure 1, it can be observed that the sheep 
incidence started to diminish two weeks before that of the cattle (week 36 vs. week 38). This 
apparent delay between incidence curves could be the consequence of cattle not producing 
many clinical signs except for a loss in milk production, therefore owners often delayed the 
moment when they would call the veterinarian (De Deken, personal communication). This 
important impact of BT on milk production in cattle may explain the predominance of dairy 
type (55%) within reports of BT cattle herds. The latter may also be related to the fact that 
dairy cattle are more frequently and closely observed by the farmers compared to beef cattle. 
One notable difference between the two episodes of BT was also the confirmation of goat 
outbreaks in 2007, whereas no caprine case had been recorded in 2006. This particularity was 
also reported in the other countries concerned by BTV-8 in 2007 (Dercksen et al., 2007). 
Figure 1 shows that the BT incidence curves seem to have globally followed the same trend as 
the temperature curve, with a delay of 2-4 weeks. The results of a study pertaining to 
association between temperature and BT incidence during the 2006-BT-epidemic, found the 
strongest correlation between the 2 parameters when shifting back the BT incidence data of 4 
weeks (EFSA, 2007). Nevertheless, even if temperature was clearly demonstrated to influence 
Culicoides’ life cycle, BTV replication in the vector and the biting rate of the midges, it is 
difficult to consider these associations by themselves. Indeed other parameters such as 
humidity are known to have confounding effects on the association (Mellor, et al., 2000). 
During the 2006-epidemic, two peaks of notifications were observed end-August and mid-
October. However, BT epidemics are commonly known to follow a unimodal temporal 
distribution (Erasmus, 1985). Normally, as the cold weather intensifies towards the end of 
autumn, blood feeding of the midges declines. Baldet and Delécolle (2007) have partially 
explained the unusual pattern of last year’s epidemic by unfavourable climatic conditions 
prevailing in August which could have led to a decrease in the vector population. 
Many reproductive disorders in cattle have been reported during the year 2007 in Belgium. 
Those presumed consequences of BT included infertility, early embryonic deaths, abortions 
and stillbirths. It has well been demonstrated in the past that strains of BTV which have been 
modified by the passage in cell culture (e.g. modified live virus vaccine strains) are able to 
cross the ruminant placenta and consequently have various outcomes according to the timing 
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of foetal infection  (MacLachlan, 2000). Recent laboratory analyses on aborted foeti, newborn 
calves and dam-newborn pairs provided evidence of the capacity of BTV serotype 8 to pass 
the placental barrier (De Clercq et al., 2008). The present study indicated an increase in foetal 
mortality in 2007, as well as a fair correlation between the incidence curve of BT and that of 
abortions when shifting back the mortality data of 3 weeks (Figure 6c). The association 
between BT and abortion is however difficult to objectify using this type of study design, 
since various impacts on embryo/foetus may have occurred according to the gestation stage 
the dam was infected. 
Death may occur in 8-10 days in diseased animals. Infected ruminants either die from BT 
directly or from a secondary bacterial infection. Mortality usually ranges between 10 and 20 
percent, but can reach 70 percent in individual flocks (Breard et al., 2004). The analysis 
demonstrated a strong and significant correlation between the incidence of BT and adult sheep 
and goat mortality since the coefficient was close to 1 (table 2). However, this high 
correlation does not necessarily induce a relation of causality between the two events. Some 
factors such as the breeds of the infected animals or the presence of concomitant diseases may 
here interact. 
The objective of this paper was to describe the evolution and the clinical impact of the BT 
2007 episode. Even though further validation is needed, some conclusions can be drawn: 
• Incidence counts were related to the population density of the susceptible hosts. BT 
was mainly reported in regions where farm density was high. 
• The findings went in favour of a negative association between the within-herd 
seroprevalence level at the end of 2006 and the risk of showing clinical signs in 2007. 
• The impact of BTV-8 on mortality was more important in small ruminant than in 
cattle population. 
• A high level of correlation was demonstrated between small ruminant mortality and 
BT incidence data when shifting back the mortality data of one week. This finding 
supports the hypothesis that the high increase in small ruminant mortality in 2007 was 
the consequence of the presence of BT.  For cattle, the correlation was not as high. 
• An increase in cattle foetal mortality was observed during the year 2007 and a fair 
correlation was found between BT incidence and foetal mortality. 
Chapter IV: Second Episode of Bluetongue 
 
 
93 | P a g e  
 
Acknowledgements 
The authors gratefully acknowledge Dr. M. Madder, Dr. R. De Deken (ITG), Prof. B. Losson 
(Faculty of Veterinary Medicine, Liège), Ir. C. Fassotte, Prof. E. Haubruge (Gembloux 
Agricultural University) for providing entomological data, and the staff at the FASFC for the 
Bluetongue data. 
The authors thank the veterinarians and all the persons who have contributed to the collection 
of data for their cooperation in this study. 
 
 
References 
Agresti, A., 2002. Categorical Data Analysis. (Second edition.) New York. Wiley. 
Baldet, T. and J.C. Delecolle, 2007. Studies on Culicoides found in association with livestock 
in the Bluetongue virus affected region of northern France. Annex of Distribution and 
dynamics of vector species. European Food Safety Authority Epidemiological analysis of the 
2006 Bluetongue virus serotype 8 epidemic in north-western Europe. Available at 
http://www.efsa.europa.eu/fr/in_focus/bluetongue/bluetongue_report_s8.html (accessed on 15 
January 2008). 
Bonferroni, C.E., 1937. Teoria statistica delle classi e calcolo delle probabilita. In ‘Volume in 
Onore di Ricarrdo dalla Volta’, Universita di Firenza, 1-62. 
Breard, E., C. Hamblin, S. Hammoumi, C. Sailleau, G. Dauphin, and S. Zientara, 2004. The 
epidemiology and diagnosis of bluetongue with particular reference to Corsica. Res.  Vet. Sci. 
77, 1-8. 
Caporale, V., N.J. MacLachlan, J.E. Pearson, and A. Schudel, 2004 Introduction Third 
International Symposium on Bluetongue. Vet. Ital.. 40, 29-30. 
Cêtre-Sossah, C., T. Baldet, J.C. Delécolle, B. Mathieu, A. Perrin, C. Grillet, and E. Albina, 
2004. Molecular detection of Culicoides spp. and Culicoides imicola, the principal vector of 
bluetongue (BT) and African horse sickness (AHS) in Africa and Europe. Vet. Res. 35, 325-
337. 
Chapter IV: Second Episode of Bluetongue 
 
 
94 | P a g e  
 
CRL, European Community .Reference Laboratory, 2006. Bluetongue virus in the 
Netherlands identified as serotype 8 by Institute for Animal Health, Promed, August 28. 
Accessed at www.promedmail.org, archive no.: 20060828.2448.  
De Clercq, K., F. Vandenbussche, E. Vandemeulebroucke, T. Vanbinst, I. De Leeuw, B. 
Verheyden, N. Goris, K. Mintiens, E. Méroc, C. Herr, J.  Hooybergs, P. Houdart, B. 
Sustronck, R. De Deken, G. Maquet, J. Bughin, M. Saulmont, M. Lebrun, G Bertels, and C. 
Miry, 2008. Transplacental bluetongue infection in cattle. Vet. Rec. 162, 564. 
Dercksen, D., N. Groot Nibbelink, R. Paauwe, A. Backx, P. van Rijn, P. Vellema, 2007. First 
Bluetongue outbreak in goats in the Netherlands Tijdschrift Diergeneeskund 132, 786-790. 
Dulac, G.C., C. Dubuc, D.J. Myers, A. Afshar, and E.A. Taylor, 1989. Incursion of 
Bluetongue virus type 11 and Epizootic Haemorrhagic disease of deer type 2 for 2 
consecutive years in the Okanagan valley. Can. Vet. J. 30, 351. 
EFSA (European Food Safety Authority), 2007. Technical report on epidemiological analysis 
of the 2006 bluetongue virus serotype 8 epidemic in north-western Europe. EFSA Journal 5, 
42. 
Elbers, A.R.W., A. Backx, E. Méroc, G. Gerbier, C. Staubach, G. Hendrickx, A. van der 
Speck, and K. Mintiens, 2008. Field observations during the bluetongue epidemic in North-
West Europe.I. Detection of first outbreaks and clinical signs in sheep and cattle. Prev. Vet. 
Med. 87, 21-30. 
Elbers, A.R.W., K. Mintiens, A. Backx, E. Méroc, and R. Meiswinkel, 2007. Re-emergence 
of Bluetongue serotype 8 in Belgium and the Netherlands in 2007. Proceedings of the Dutch 
Society for Veterinary Epidemiology and Economics 2007 Symposium, Wageningen, The 
Netherlands.19-23. 
Erasmus, B.J., 1985. The history of Bluetongue. Bluetongue and related orbiviruses: 
Proceedings of an international symposium, Asilomar, California, New York Alan R. Liss. 
Gibbs, E.P.J. and E.C. Greiner, 1994.  The epidemiology of Bluetongue. Comp. Immun. 
Microbiol. Infect. Dis. 17, 207-220. 
Chapter IV: Second Episode of Bluetongue 
 
 
95 | P a g e  
 
Luedke, A.J., 1985. Effect of Bluetongue virus on reproduction in sheep and cattle. 
Bluetongue and Related Orbiviruses. Progress in Clinical Biological Research. 178. 71-78. 
Maan, S., N.S. Maan, N. Ross-smith, C. A. Batten, A. E. Shaw, S. J. Anthony, A. R. Samuel, 
K. E. Darpel, E. Veronesi, C. A. L. Oura, K. P. Singh, K. Nomikou, A. C. Potgieter, H. 
Attoui, E. van Rooij, P. van Rijn, K. De Clercq, F. Vandebussche, S. Zientara, E. Bréard, C. 
Sailleau, M. Beer, B. Hoffman, P.S. Mellor, P.P.C. Mertens, 2008. Sequence analysis of 
bluetongue virus serotype 8 from the Netherlands 2006 and comparison to other European 
strains. Virol.  377, 308-18. 
MacLachlan, N.J., A.J. Conley, and P.C.  Kennedy, 2000. Bluetongue and equine viral 
arteritis viruses as models of virus-induced fetal injury and abortion. Animal Reproductive 
Science 60-61, 643-651. 
Mellor, P.S., J. Boorman, and M.  Baylis, 2000. Culicoides biting midges: Their role as 
arbovirus vectors. Annual Review of entomology 45, 307-340. 
Méroc, E., C. Faes, C. Herr, C. Staubach, B. Verheyden , T. Vanbinst, F. Vandenbussche, J. 
Hooyberghs, M. Aerts, K. De Clercq, and K. Mintiens, 2008. Establishing the spread of 
Bluetongue virus at the end of the 2006 epidemic in Belgium. Vet. Microbiol. 131, 133-144. 
Neter, J., M. Kutner, C. Nachtsheim, 1996. Applied linear statistical models. 4th edition, 
Irwin: Chicago. 
OIE, Animal Health Department, 2006. Bluetongue—Netherlands, Belgium, Germany-OIE. 
ProMed. August 21, 2006. Accessed athttp://www.promedmail.org, archive no. 
20060821.2353. 
OIE, World Organization for Animal Health, 2008a: Animal diseases data-Bluetongue. [cited 
2008 7 May]. Available from: http://www.oie.int/eng/maladies/fiches/a_A090.html. Updated 
19 March 2008. 
OIE, World Organization for Animal Health, 2008b. World Animal Health Information 
Database Interface. Summary of Immediate notifications and Follow-ups-2007. [cited 2008 
20 March]. Available from  http://www.oie.int/wahid-
prod/public.php?page=disease_immediate_summary&disease_id=9.  Updated 9 May 2008. 
Chapter IV: Second Episode of Bluetongue 
 
 
96 | P a g e  
 
Qin, Q., Z. Tai, L. Wang, Z. Luo, J. Hu, and H. Lin, 1996. Bluetongue epidemiological survey 
and virus isolation in Xinjiang, China. In: St. George, T.D., Kegao, P. (Eds.), Bluetongue 
disease in Southeast Asia and Pacific, 1996, Proceedings of the First South-East Asia and 
Pacific. 
Thiry, E., S. Zientara, and K. De Clercq, 2007: Bluetongue in Belgium, 2006. Emerg. Infect. 
Dis. 13, Number 4, Available at: http://www.cdc.gov/eid/content/13/14/614.html (accessed on 
4 April 2007). 
Toussaint, J.F., F. Vandenbussche, J. Mast, L. De Meester, N. Goris, W. Van Dessel, E. 
Vanopdenbosche, P. Kerkhofs, S. Zientara, C. Sailleau, G. Czaplicki, G. Depoorter, J.M. 
Dochy, and K. De Clercq, 2006. Bluetongue in northern Europe. Vet. Rec. 159, 327. 
Toussaint, J.F., C. Sailleau, J. Mast, P. Houdart, G. Czaplicki, L. Demeestere, F. 
VandenBussche, W. van Dessel, N. Goris, E. Bréard, L. Bounaadja, E. Thiry, S. Zientara, and 
K. De Clercq, 2007. Bluetongue in Belgium, 2006. Emerg. Infect. Dis. 13, Number 4. 
Available at: http://www.cdc.gov/eid/content/13/14/614.html (accessed on 4 April 2007). 
 
Chapter V: Evaluation of the Bluetongue Vaccination Campaign 
 
 
97 | P a g e  
 
 
 
CHAPTER V 
 
EVALUATION OF THE BLUETONGUE 
VACCINATION CAMPAIGN 
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Abstract 
In order to control the devastating impact of Bluetongue in ruminant population, Belgium 
decided to start using an inactivated vaccine in 2008. The objective of the study was to 
evaluate the effect of this first vaccination campaign. Three cross-sectional screenings were 
undertaken in the cattle population during winters of 2007 and 2008 (before vaccination) and 
2009 (after vaccination). The results showed that the target of 80% of vaccination coverage 
was attained but late in the season. The effect of several vaccination factors on the serology 
and RT-PCR response were analysed using linear and generalized mixed models. The 
interaction between time since vaccination and the booster injection’s achievement was 
significantly associated to the change in serology after vaccination (β= -32.69; p=0.02). The 
study demonstrated the importance of respecting the vaccine’s protocol in its entirety and in 
due time, for the level of antibodies depends on it. 
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Bluetongue virus serotype 8; Cattle; c-ELISA; inactivated vaccine; real time RT-PCR 
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Introduction 
Bluetongue (BT) is a vector-borne viral disease of ruminants. BT virus (BTV) is the type 
species of the genus Orbivirus within the Reoviridae family. Thus far, 25 distinct BTV-
serotypes have been identified (Gorman, 1990; Hofman et al., 2008; Takamatsu et al., 2003).  
Midges of the genus Culicoides (Diptera: Ceratopogonidae) are, until now, the only proven 
vectors in the transmission of BTV from ruminant to ruminant (Cêtre-Sossah et al., 2004; Pili 
et al., 2006; Vanbinst, et al, 2009). BT can cause mild to spectacular outbreaks and therefore 
appears on the list of diseases notifiable to the World Organisation for Animal Health (OIE). 
It thus has an adverse impact on worldwide trade due to restrictions on the source of animals 
(Green et al., 2005). The vast majority of BT infections are clinically unapparent. Cattle act as 
a reservoir of BTV and keep the infection circulating. Cattle appear to be much more 
attractive to Culicoides spp. than sheep and this may enhance their importance as carriers 
(Ward et al., 1994).  Sheep on the other hand are more prone to show clinical signs (Gibbs et 
al., 1994). When the disease does occur, common clinical signs are pyrexia, inflammation of 
the oral mucosa, excessive salivation, oedema of the head (OIE, 2008). 
BTV is considered as an “emerging virus” since it has recently expanded its range towards 
Northern Europe, outside its previous environment (as far as 45°N). Starting in August 2006 
from the area where Belgium, the Netherlands and Germany share borders, an epidemic of 
BTV serotype 8 (BTV-8) gradually disseminated throughout the North-Western European 
countries (Toussaint et al., 2007), causing the most severe outbreak of this disease ever 
recorded.  In 2007, BTV-8 re-emerged in the same countries and extended also to the United 
Kingdom, Switzerland, Denmark and the Czech Republic (OIE, 2008). In order to control the 
devastating effect of BTV-8, several European Member States decided to start vaccination 
before the following summer season (Council Directive 2000/75/EC). In the past, BTV 
vaccination has been successfully used by a number of European countries which have been 
affected by the infection (Savini et al., 2008). The vaccination campaign intended to reach a 
target of at least 80% of coverage in order to stop the spread of the infection and ultimately to 
eradicate the disease. This target was fixed by the European Commission based on past mass 
vaccination experience for other diseases (P.Houdart, personal communication). In Belgium, 
compulsory vaccination of cattle and sheep with inactivated vaccine against BTV-8 began in 
May 2008, after a devastating epidemic starting during summer 2007 (Méroc, 2009). This 
means that livestock population was already highly immunized before the campaign took 
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place, making it impossible to distinguish infected from vaccinated animals based on 
serology. The objective of this study was to explore the effect of livestock vaccination against 
BTV-8 in Belgium. 
 
 
Materials and methods 
Cross-sectional serological data 
In Belgium, since the first episode of BTV-8 (second half of 2006), three cross-sectional 
serological surveys were undertaken in the same cattle herds during the winter periods 
(Winter Screenings (WSs) were performed during winter 2006-2007 (=WS1), during winter 
2007-2008 (=WS2) and during winter 2008-2009 (=WS3)) (Méroc et al., 2008). Table 1 
summarizes the characteristics of the WSs. The main difference between the three samplings 
relates to the age of the sampled cattle: in WS1, only adult cattle (>24 months of age) were 
sampled, whereas in WS2 and WS3 all cattle were considered. In WS3, the same number of 
animals was sampled in each age category (balanced sample), which was not the case in WS2 
(unbalanced sample). 
 
Table 1: Summary of the three winter screening (WS) samples 
 
 
 
The serum samples were analysed using the ‘ID Screen1 Bluetongue Competition’ assay (ID 
VET, Montpellier-FRANCE) according to the manufacturer’s instructions but with the cut-off 
 WS1 WS2 WS3 
Sampling period 
1st -31 January  
2007 
1st January- 
20 May 2008 
15 December 2008- 
7 February 2009 
Number of animals 25 846 21 498 7 175 
Number of herds 344 235 203 
Age characteristics adults (>2 years) 
unbalanced stratification,  
all ages 
balanced stratification, 
all ages 
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determined by Vandenbussche et al. (2008) (≤65 positive; >65 and ≤75 doubtful; >75 
negative). Results were expressed as percentage negativity (PN%= (Optical Density 
sample/Optical Density negative kit control)*100). Bad quality sampling results were deleted 
from the final datasets.  
The serological results from the WSs were evaluated by first estimating the three within-herd 
seroprevalences using logistic-normal regression models (SAS Inc, Version 9.2). In order to 
make these seroprevalences comparable from one to the other, the estimations were restricted 
to adult animals. The true prevalences, reflecting the real serological status of the animals, 
were derived by taking the sensitivity (87.8%) and the specificity (98.2%) of the c-elisa test 
into account (Rogan and Gladen, 1978; Vandenbussche et al., 2008).  
 
Virological data 
During WS3, uncoagulated blood samples (EDTA) were collected by the official farm 
veterinarians and were conditioned at the regional laboratories of ‘Dierengezondheidszorg 
Vlaanderen’ and the ‘Association Régionale de Santé et d'Identification Animales’. The 
EDTA samples were analysed with a RT-qPCR as described by Vandenbussche et al. (2008). 
Based on a cut-off which was set at a Ct-value of 40, results were defined as ‘positive’ (<40) 
or ‘negative’ (≥40). 
 
Vaccination data 
During the vaccination campaign, information on the vaccination progress of each livestock 
farm (date of primo- and booster-vaccination rounds and brand of vaccine used) was recorded 
by the Belgian Federal Agency for the Safety of the Food Chain (FASFC). These vaccination 
data concerning the herds sampled within the WSs were extracted and analyzed. 
 
Change in individual serological profiles between WS2 and WS3 
In order to evaluate the individual serological profiles between WS2 and WS3, the following 
variables were created first: 
- ‘QuantiWS2’ and ‘QuantiWS3’ were defined as the percentage of negativity obtained 
by subtracting the PN% values at WS2 and WS3 (continuous variables) from 100 in 
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order to display an increased antibody response when there is truly an increase of 
antibodies. 
-  ‘Change’ (%), a continuous variable obtained by subtracting QuantiWS2 from 
QuantiWS3, which indicates for a given animal the change in serology between WS2 
(before vaccination) and WS3 (during or after vaccination). 
- ‘StatusWS1’, a dichotomous variable indicating whether the animal came from a herd 
where within-herd seroprevalence in WS1 was above the mean prevalence of 27% or 
not (Méroc et al., 2008). 
-  ‘Time’, a continuous variable reflecting the number of months between the date of 
first injection at herd level and the sampling date of the individual animal. After 
consideration of the variable’s histogram which clearly showed a bimodal pattern, it 
was decided to create from it a dichotomous variable determining if ‘time’ was 
superior to 3 months or not. 
- ‘Two injections’, a dichotomous variable indicating whether the animal had received 
its second vaccination (=1) or not (=0) at moment of sampling. 
- ‘Age’ (months), a continuous variable indicating the age of the animal. This was 
extracted from SANITEL. 
  
The profiles of cattle, strictly seropositive at WS2 (n=2360) were compared to that of animals 
strictly seronegative at WS2 (n=199). For the latest, the effects of vaccination variables 
(‘Time’, ‘Two injections’ and ‘Brand’), ‘StatusWS1’ and ‘Age’ on the ’Change’ were 
analysed at animal level. First, univariable associations between the response ‘Change’ and 
the different categorical independent variables (‘Time’, ‘Two injections’, ‘Brand’ and ‘Status 
WS1’) were explored using one-way ANOVAs. The clustering within the herds was not taken 
into account in this part of the analysis. Residuals plots were used to ensure that the 
assumptions underlying the ANOVAs were met. Then, a linear mixed model which takes into 
account the correlation among animals from a same herd by adding a random herd effect, was 
used for multivariable modelling (Dohoo, 2003). All pairwise correlations among predictor 
variables were examined using Pearson and Spearman correlation coefficient in order to 
identify pairs of variables containing essentially the same information. If the correlation 
between two variables was above 0.7, only the variable with the smallest p-value at the 
univariable analysis was kept in the multivariable model. The initial model considering all 
independent variables and two-way interactions was adjusted by looking for the most 
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parsimonious model as well as comparing the Akaike Information Criteria (AIC) estimates of 
all possible fits. The smaller the AIC value, the better a particular model fits (Akaike, 1974). 
A probability value of less than 0.05 indicated a statistically significant result. To assess the 
validity of the model, standardised residuals were computed and graphical methods were 
used; the homoscedasticity assumption was verified by plotting the standardised residuals 
against the predicted means and a normal probability plot for the residuals was used to 
examine the normality. 
 
 
RT-PCR positives 
The univariable association between the RT-PCR status and the age of the animal was 
explored by means of a marginal model, the generalized estimating equations (GEE), which 
takes into account the clustering within herds (Liang and Zeger, 1986). A dichotomous 
variable ‘seroWS2’ was created where ‘seroWS2’=1 when on a herd at least one animal 
remained seronegative at WS2. The effects of the vaccination variables, status2007 and 
seroWS2 on the RT-PCR status of the herd were analysed using a multivariable logistic 
regression. The best model was looked for by comparing AIC estimates of all possible models 
with main effects and their two-way interactions. The Hosmer-Lemeshow goodness-of-fit test 
was used to assess the fit of the model (Dohoo, 2003). The results for the risk factors, from 
fitting the final model, were expressed as odds ratios along with their corresponding 95% 
confidence intervals and probability values. A probability value of less than 0.05 indicated a 
statistically significant result. 
 
 
Results 
Cross-sectional serological data 
The true within-herd seroprevalence in adult cattle increased from 23.8% (95%CI: 20.1%-
28.1%) at WS1, to 98.84% (95%CI: 97.63%-99.58%) at WS2 and, eventually, to 100% 
(95%CI: 99.5%-100%) at WS3. 
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Vaccination data 
The herds sampled during WS3 were all completely vaccinated (two injections) between 6 
May 2008 and 16 January 2009. The lag time between primo- and booster injection ranged 
between 11 and 161 days, with an average of 29 days and a standard deviation of 14. Figure 1 
shows the progress in time of the vaccination campaign. At the end of November 2008, 80% 
of the Belgian cattle herds had started vaccination. Eighty percent of the herds had completed 
the vaccination process at the end of December 2008. 
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Figure 1: Cumulative proportion of number of herds vaccinated according to date of a. first 
injection b. last injection 
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Change in individual serological profiles between WS2 and WS3 
The individual change in the ‘Quanti’ value between WS2 and WS3 is presented in figure 2. 
The serological patterns of animals strictly positive at WS2 (using a cut off level of 
quantiWS2>35%) is shown in figure 2a. Of those animals, it appears that 88% were already 
highly seropositive (quantiWS2>80%) at that time and stayed highly positive at WS3 (straight 
horizontal line). A portion of animals however, were highly positive at WS2 and became less 
positive at WS3 (quantiWS3<80%) (9% of animals) or even negative (quantiWS3<25%) ( 5% 
of animals). Figure 2b shows the same information for animals negative at WS2 (using a cut 
off level of quantiWS2<25%). 
 
 
Figure 2:  Individual quantitative serological response (quanti) at winterscreening 2008 (WS2) and 
winterscreening 2009 (WS3). a. animals BT-seropositive at WS2. b. animals BT-seronegative at WS2. 
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It is observable that quantiWS3 ranges from 0 to 100% with more values around 100%. The 
quantiWS3 distribution of animals seronegative at WS2 is presented in figure 3. Eighty 
percent of those animals became seropositive (quantiWS3>25%). 
 
Figure 3: Distribution of quantitative serological response (quantiWS3) of animals BTV-seronegative 
at winterscreening 2008 (WS2) 
 
 
From 199 animals we could extract data for which WS2 and WS3 serological responses were 
available and that were seronegative at quantiWS2 (using a cut off level of quantiWS2<25%). 
For those animals, quantiWS3 was significantly higher (mean=59; standard deviation=33.33) 
than quantiWS2 (mean=4.6; standard deviation=6.61) (p<0.0001). Out of these 199 animals, 
185 (93%) demonstrated an increase in their serological response between WS2 and WS3. 
Table 2 shows the distribution of the variable ‘Change’ among the different levels of the 
categorical independent variables considered in the multivariable model analysis. The animals 
with a longer duration between first vaccine injection and sampling (‘Time’=1) have a 
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superior ‘Change’ on average than the others. In the same way, subjects which had received 
two vaccine injections at sampling time (‘Two injections’=1) had a significantly higher 
‘Change’ than those that received only one vaccination. 
 
Table 2: Description of the increase in serology between winterscreening 2008 (WS2) and 
winterscreening 2009 (WS3) (‘Change’) among categories of discrete variables and results of one-way 
ANOVAs (p-value) 
 
Variable Type n %mean %sd p-value 
Time 0 72 45.54 36.96 0.03 
  1 127 58.29 31.62   
Two injections 0 74 38.74 34.3 <0.0001 
 1 125 63.67 30.26  
StatusWS1 0 148 53.27 32.27 0.42 
  1 51 57.69 38.6   
Brand both 52 54.75 30.96 0.83 
 brand1 89 55.64 35.27  
  brand2 58 52.18 34.93   
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The results of the multivariable model at the animal level are presented in table 3. It appears 
that after taking into account all independent covariates simultaneously and adjusting for herd 
effect, the only significant effect was the interaction between ‘Time’ and ‘Two injections’. 
 
Table 3: Results of the linear mixed model modelling the increase in serology between 
winterscreening 2008 (WS2) and winterscrening 2009 (WS3) (‘Change’) 
 
Variable Type Coefficient Standard Error P-value 
Age   0.34 0.31 0.27 
Time   27.69 10.01 <0.01 
Two injections   52.01 11.28 <.0001 
StatusWS1   8.05 6.42 0.21 
Brand both 17.11 11.4 0,33 
 brand1 25.67 9.11  
 brand2 15.04 10.17  
 Time*Two 
Injections   -32.69 12.31 0.02 
Injection*Age   -0.57 0.35 0.11 
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Table 4 describes the mean ‘Change’ for each of the patterns formed by combining ‘Time’ 
and ‘Two Injections’. The results show that by themselves ‘Time’ (48.64-31.2=17.44%) and 
‘Two injections’ (70.42-31.2=39.22%) make ‘Change’ increase. However, when those factors 
are both present, instead of adding the sum of the two main effects (17.44+39.22=57%) to the 
baseline level of mean ‘Change’, only 61.53-31.2=30.33% is added. Considering only animals 
with ‘Two injections=1’, time between this last injection and sampling was significantly 
shorter in the group with ‘Time=0’ (9.5 days) compared to the group with ‘Time=1’ (51.3 
days) (p-value<0.001). 
 
Table 4: Description of mean ‘Change’ (winterscreening 2008 (WS2) and winterscreening 2009 
(WS3)) among different patterns formed by ‘Two Injections’ and ‘Time’ 
  
                 Two injections=0 
 
                 Two injections=1 
 
           Total 
 
Time n 
%mean 
Change n 
%mean 
Change              n 
%mean     
Change 
0 42 31.2 30 70.42 72 47.54 
1 32 48.64 95 61.53 127 58.29 
Total 74 38.75 125 63.67 199 54.4 
 
 
RT-PCR positives 
Out of 5792 animals tested with RT-PCR, 146 (2.5%) turned out to be positive. In 56 out of 
211 herds (26.5%), at least one animal was positive. Mean WS2 seroprevalence in those PCR 
positive herds (mean of 0.99 (s.d.= 0.02)) was found to be statistically similar to that of the 
other herds (mean= 0.97(s.d=0.09)) (p=0.17). The results of the GEE model at the animal 
level indicated that the effect of the animal’s age on the RT-PCR response wasn’t statistically 
significant (OR=0.98; p-value=0.46). Table 5 presents the estimated odds ratios from the 
multiple logistic regression model at the herd level. The results showed that ‘StatusWS1’, 
‘Time’, ‘Two injections’  and ‘SeroWS2’ acted as protective factors on the risk of being RT-
PCR positive (OR<1). However, none of these effects were found to be statistically 
significant, except for ‘Time’ that was borderline significant. 
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Table 5: Results of the multivariable logistic regression modelling the risk of a herd having a positive 
rt-PCR result: estimated odds ratios for independent variables (and 95% confidence interval limits 
(CL)) and p-values (comparison to reference category for each variable) 
 
Variable Type OR 95%CI P-value 
Time  0.6 0.34-1.07 0.08 
Two injections  0.66 0.36-1.18 0.16 
StatusWS1  0.64 0.33-1.25 0.19 
SeroWS2  0.7 0.4-1.24 0.22 
Brand both vs brand1 1.32 0.82-2.18 0.25 
 brand2 vs brand1 0.83 0.53-1.29 0.41 
  both vs brand2 1.59 0.71-3.55 0.26 
 
 
 
                              Discussion 
The results of the three cross sectional studies showed that adult cattle population in Belgium 
had reached a seroprevalence level of nearly 100% since the end of the second episode of 
BTV-8 (WS2). Antibodies typically appear within one or two weeks after infection and this 
response may last for several years (Afshar et al., 1989; Walton and Osburn, 1992). Ward and 
Carpenter (1996) suggested a duration of immunity of 33 months compatible with prevalence 
observed in the field. Therefore, in Belgium, we were obviously dealing before the onset of 
vaccination with a situation where at least some of the host sub-populations had already 
obtained natural immunity towards BTV-8. However, because of all newborn animals, part of 
the cattle population will continuously remain susceptible. Another factor which influences 
the change in within-herd seroprevalence from one WS to the other is cattle movement. For 
example, importation of animals from a BTV-8 free area into a herd will contribute to make 
its global serology level decrease. 
The objective of vaccinating was four-fold: i) Reduce clinical disease, ii) Stop dissemination 
of BTV, iii) Facilitate live animal trade and iiii) lead to eradication in the future. An 
inactivated vaccine was used in Belgium against serotype 8. Compulsory vaccination of all 
domestic cattle and sheep began in May and had to be completed before 31 December 2008. 
Chapter V: Evaluation of the Bluetongue Vaccination Campaign 
 
 
113 | P a g e  
 
Cattle born later than 1 September 2008 and other species of ruminants could also take part to 
the campaign on a voluntary basis. It was decided to start vaccination before the summer 
period since the two previous episodes of BTV-8 started in August 2006 and July 2007 
(Méroc et al., 2009). The serological profiles of cattle still seronegative before the vaccination 
campaign was interesting since it turned out that 80% of these animals had seroconverted at 
WS3 (Figure 3). Considering that only a small number of infections seems to have occurred 
during 2008 (2.5% of samples positive at RT-PCR), this would bring us to say that the 
vaccination’s target of reaching 80% of coverage was correctly attained. However, pertaining 
to the first injection of cattle herds, only by end November was 80% coverage attained (figure 
1). The whole process was not completed until January 2009. This discrepancy between 
planning and reality is related to organisation and delays in reception of vaccine stocks linked 
to the emergency context. We may ask ourselves what is the purpose of legislation allowing 
vaccination after the high risk period has already largely started and until December 31. 
After a second episode of BTV-8 in 2007 devastating in terms of ruminant morbidity and 
mortality, the first reason for vaccinating massively (i.e. reduce the clinical impact) seems to 
be justified since only 50 outbreaks were reported in 2008. However, as aforementioned, 
cattle were obviously already largely immunized before the campaign was launched, so it is 
quite difficult to determine the role vaccination truly played here. 
This study showed that a majority of the cattle was already highly seropositive at WS2 and 
was still seropositive at WS3. However, in a certain proportion of animals, a decrease in the 
serologic response was observed between the two years. This could be linked to several 
factors. First of all, we have to keep in mind that the sensitivity of the c-elisa test is not perfect 
and so we therefore must be careful in interpreting the quantitative serologic response. A 
possible explanation could also be the age of the animals at WS2. Young animals, still having 
colostral antibodies at the time of WS2 have lost them since then. A decrease of the immunity 
response occurring naturally with time could also be plausible. In either case, an animal 
becoming truly seronegative at WS3 would probably mean that there was a problem at one 
point in the vaccination process: either the vaccination wasn’t done, or it was incorrectly 
done, or it didn’t work on this particular animal for one reason or another. 
Significant univariate associations were found between the individual change in serology on 
one hand and ‘Time’ and ‘Two Injections’ on the other hand. Indeed, the vaccine producers 
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indicated in their leaflet (European Medicines Agency, 2010) that the inactivated vaccines 
should be administrated in two separate doses and that the onset of immunity occurs more or 
less three weeks after administration of the booster injection. These findings pinpoint the 
importance of respecting the vaccination protocol in its entirety and of vaccinating in due 
time. Multivariable modelling showed a significant interaction between ‘Time’ and ‘Two 
Injections’. For those animals that had received the booster injection at sampling time, a 
longer time since first injection (‘Time’=1) was associated to a lower ‘Change’ (Table 4). 
This association seems to reflect the decrease of the serologic response after reaching a peak 
linked to the booster injection, since it was also shown that ‘Time’ was positively correlated 
to the time between second injection and sampling. The evaluation of vaccination could only 
be done on 199 animals as these animals were the only ones still seronegative just before 
vaccination, while all the others were already seropositive. Another drawback is that 
vaccination variables were solely available at herd level. Thus, individual variation within 
herds regarding the risk factors could not be accounted for in the analysis and this may have 
induced a bias. 
Only 2.5% of the samples in this study were PCR positive. First of all, we have to consider 
the limits of the RT-PCR test itself. Indeed, Vandenbussche et al (2008) found that the 
specificity of the test used in the present study was of 98.5% (95%CI: 97.1-100.0). It could 
thus be possible that as much as 1.5% (with a maximum of 2.9%) of the samples were false 
positives, leaving us with 1% of true positives. Considering the situation where animals were 
truly positive and knowing that cattle stays RT-PCR positive for a maximum period of more 
or less 200 days after it has been infected, this would probably mean that the positive animals 
in this study were infected during the second half of 2008 (during or even after the 
vaccination campaign). It is important to notice that we have absolutely no information on the 
status of the animals between WS2 and WS3, and it may well be that they were RT-PCR 
positive at one point between the two screenings and then became negative before WS3 was 
undertaken. Thus we have to keep in mind that the number of positives could be 
underestimated. The use of sentinel herds for instance instead of annual cross-sectional 
surveys would allow a better estimation of the annual incidence rate of infection.  
We could have expected a difference in age between cattle PCR positive and negative, with 
more animals being younger in the group of positives because less protected (lower 
seroprevalence and no vaccination in young calves). However, no age difference was detected 
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between the positive and negative group. The findings of the multivariable study showed that 
the vaccination and serology variables were protective factors but didn’t indicate significant 
effect of any of these, except for the time since first injection that was borderline significant. 
Unfortunately, because of a lack of positive cases (2.5% of animals sampled) and no 
vaccination data at animal level, all risk factors except for the age could not be studied at 
animal level. Other extrinsic factors such as conservation of the doses, the way administration 
was performed, or animal health at time of injection were not considered at all in the 
multivariable analysis and obviously are critical points which should be accounted for. 
 
 
Conclusion 
In conclusion, at first sight the vaccination objectives of reducing clinical symptoms and 
stopping the dissemination of BTV-8 seem to have been fulfilled as few outbreaks and 
positive RT-PCR results were detected after the campaign took place in 2008. However, the 
intrinsic effect of vaccination was difficult to evaluate as there was already a high 
seroprevalence in cattle at moment of vaccination. The target of 80% of vaccination coverage 
was well attained but late in the year. This study demonstrated the importance of respecting 
the vaccination protocol in its entirety and of vaccinating in due time.  
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Abstract 
Bluetongue virus serotype 8 (BTV-8) emerged in Central Western Europe in 2006 causing a 
large scale epidemic in 2007 that involved several European Union (EU) countries including 
Belgium. As in several other EU member states, vaccination against BTV-8 with inactivated 
vaccines was initiated in Belgium in spring 2008 and appeared to be successful. Since 2009, 
no clinical cases of Bluetongue (BT) have been reported in Belgium and BTV-8 circulation 
seemed to have completely disappeared by spring 2010. Therefore, a series of repeated cross-
sectional surveys, the BT sentinel surveillance program, based on virus detection in blood 
samples by means of real-time RT-PCR (RT-qPCR) were carried out in dairy cattle from the 
end of 2010 onwards with the aim to demonstrate the absence of BTV circulation in Belgium. 
This paper describes the results of the first two sampling rounds of this BT sentinel 
surveillance program carried out in October-November 2010 and January-February 2011. In 
addition, the level of BTV-specific maternal antibodies in young non-vaccinated animals was 
monitored and the level of herd immunity against BTV-8 after 3 consecutive years of 
compulsory BTV-8 vaccination was measured by ELISA.  
During the 1st sampling round of the BT sentinel surveillance program, 15 animals tested 
positive and 2 animals tested doubtful for BTV RNA by RT-qPCR. During the 2nd round, 17 
animals tested positive and 5 animals tested doubtful. The positive/doubtful animals in both 
rounds were re-sampled 2-4 weeks after the original sampling and then all tested negative by 
RT-qPCR. These results demonstrate the absence of BTV circulation in Belgium in 2010 at a 
minimum expected prevalence of 2% and 95% confidence level. The study of the maternal 
antibodies in non-vaccinated animals showed that by the age of 7 months maternal antibodies 
against BTV had disappeared in most animals. The BTV seroprevalence at herd level after 3 
years of compulsory BTV-8 vaccination was very high (97.4% [95% CI: 96.2-98.2]). The 
overall true within-herd BTV seroprevalence in 6-24 month old Belgian cattle in early 2011 
was estimated at 73.4% (95% CI: 71.3-75.4).  
 
Keywords: Bluetongue virus; Sentinel surveillance; RT-PCR; Seroprevalence; Vaccination; 
Immunity 
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Introduction   
Bluetongue (BT) is an infectious, non-contagious disease of ruminants caused by Bluetongue 
virus (BTV), an arbovirus of the genus Orbivirus within the Reoviridae family (Mertens et al., 
2004). The virus can only be transmitted by certain species of Culicoides biting midges 
(Mellor et al., 2000; Tabachnick, 2004). In the past, BTV infection was limited to tropical and 
subtropical regions around the world between latitudes of approximately 40-50ºN and 35ºS 
but during the epidemic caused by BTV serotype 8 (BTV-8) in Western Europe in 2006-2007, 
the virus spread far beyond the previously known northern boundaries for BTV (Toussaint et 
al., 2006). Up to date, 24 distinct BTV serotypes have been identified, a 25th has been 
suggested in goats in Switzerland (Hofmann et al., 2008), and a novel BTV isolate from 
Kuwait has been proposed as BTV-26 (Maan et al., 2011). BTV outbreaks can cause 
substantial economic losses due to clinical disease especially in sheep (Calistri et al., 2004; 
Elbers et al., 2008b; Elbers et al., 2009) and, more importantly, due to the restrictions on trade 
of animals and animal products between BTV infected and non-infected areas (MacLachlan 
and Osburn, 2006).  
In August 2006, BTV-8 unexpectedly emerged in Central Western Europe affecting Belgium, 
Luxembourg, the Netherlands, Germany and the North of France (Toussaint et al., 2007; 
Wilson et al., 2007; Elbers et al., 2008a; Méroc et al., 2008). The origin and the route of 
introduction of BTV-8 into Central Western Europe remain unknown (Mintiens et al., 2008). 
The virus survived the winter and a large-scale epidemic started in July 2007, this time also 
involving the United Kingdom, Switzerland, Denmark and the Czech Republic. Due to the 
size of the epidemic, a BTV-8 vaccination campaign using inactivated vaccines was 
implemented by the Belgian authorities in spring 2008 (FAFSC, 2008). A clear decline in the 
number of clinical cases and in virus circulation was observed in 2008, most likely as a result 
of natural immunity, vaccination and a number of climatic factors (Zientara et al., 2010).  
In Belgium, a cross-sectional survey of cattle, the BT winter screening, has been carried out 
once a year during winter since 2007 in order to assess the spread of BTV-8 infection after 
each period of vector activity and to assess the level of herd immunity induced either by 
natural infection, by vaccination, or by a combination of both (Méroc et al., 2008). In 
addition, spleen samples from aborted bovine foetuses have been tested by BTV real-time 
RT-PCR (BTV RT-qPCR) since the start of the vaccination campaign in 2008 in order to 
monitor the level of trans placental infections (Garigliany et al., 2011). All these results 
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suggested that a low level of virus circulation was still present in 2009. From spring 2010 
onwards there seemed to be a complete disappearance of BTV-8 infection (Garigliany et al., 
2011). Based on this, it was decided to initiate repeated cross-sectional surveys every 3 
months in non-vaccinated dairy cattle from the end of 2010 onwards with the aim to 
demonstrate the absence of BTV circulation in Belgium and, consequently, to re-gain 
Belgium’s BTV free status in accordance with European Commission (EC) Regulation No 
1266/2007 (CEC, 2007). For this purpose, a number of young non-vaccinated animals from 
selected herds are tested for the presence of BTV RNA by RT-qPCR performed on EDTA 
blood. The repeated cross-sectional studies can be considered as a sentinel system whereby 
the selected herds (and not the animals) function as sentinel units. This paper describes the 
results of the first two sampling rounds of the BT sentinel surveillance program carried out in 
October-November 2010 and January-February 2011 and the results of the BT winter 
screening 2011 to assess the serological status of animals and herds after 3 consecutive years 
of compulsory vaccination against BTV-8 in Belgium  
 
 
Materials and methods 
Repeated cross-sectional studies in non-vaccinated animals: Bluetongue (BT) sentinel 
surveillance program 
• Sampling design 
A total of 300 dairy herds, 30 herds in each Belgian province, were selected as sentinel herds 
for the BT sentinel surveillance program. These herds were randomly selected from the list of 
6,600 active Belgian dairy herds that were expected to have a minimum of 15 animals present 
between 4 and 12 months of age at the start of the sentinel program. The first two sampling 
rounds in the sentinel surveillance program were carried out in October-November 2010 and 
January-February 2011. During each sampling round, a target number of 15 non-vaccinated 
animals between 4 and 12 months of age were sampled in each sentinel herd.  
The number of animals to be sampled was calculated to detect an incidence of BTV infection 
of 2% with 95% confidence in each geographical unit of reference in accordance with EC 
Regulation No 1266/2007 (CEC, 2007). To facilitate the practical organisation of the 
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program, the surface area of each Belgian province was assumed to be equal to 2 geographical 
units of reference of 45 x 45 km or approximately 2,000 km2 each. The obtained sample size 
of 150 animals per geographical unit was then multiplied by 1.5 to ensure that enough 
samples would be obtained. As such the final target sample size was estimated at 4,500 
animals.  
 
• Diagnostic methods: RT-qPCR and ELISA 
EDTA blood samples were collected by the farm veterinarians and sent to the National 
Reference Laboratory (NRL) for BTV at the Veterinary and Agrochemical Research Centre 
(CODA-CERVA, Brussels, Belgium). There, samples were tested for the presence of BTV 
RNA by means of a non-serotype specific quantitative reverse-transcription PCR assay 
targeting BTV segment 5 (pan-BTV/S5 RT-qPCR) according to the method described by 
Vandenbussche et al. in 2010. Test results were classified as follows: Crossing Point values 
(Cp-values) <40.0 were classified as positive, Cp-values ≥40.0 but <45.0 were classified as 
doubtful, and Cp-values ≥45.0 were classified as negative. For the cut-off Cp-value of 40, the 
diagnostic sensitivity (DSe) and diagnostic specificity (DSp) of this RT-qPCR assay was 
estimated at 99.5% (95% Confidence Interval: 99.0-100.0) and 98.5% (95% CI: 97.1-100.0), 
respectively (Vandenbussche et al., 2008).  
All samples that tested positive or doubtful by pan-BTV/S5 RT-qPCR were also tested by 
serotype-specific RT-qPCR assays for BTV-8 (BTV-8/S2), BTV-1 (BTV-1/S2), BTV-6 
(BTV-6/S2) and BTV-11 (BTV-11/S2) since those were the serotypes that have been detected 
over the past years in Central Western Europe (De Clercq et al., 2009; Maan et al., 2010). The 
serotype-specific RT-qPCR assays were performed as described by Vandenbussche et al. in 
2009. Cut-off Cp-values were identical to the pan-BTV/S5 RT-qPCR.  
During both sampling rounds, with the exception of one animal, all animals that tested 
positive or doubtful by pan-BTV/S5 RT-qPCR were re-sampled 2-4 weeks (mean of 17 days) 
after the original sampling. These samples were also tested by pan-BTV/S5 RT-qPCR as 
described above.  
In order to monitor the level of maternal antibodies against BTV in young non-vaccinated 
animals, plasma samples from a random selection of 25% of all sentinel herds sampled during 
the 1st sampling round were tested for the presence of BTV-specific antibodies by means of a 
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commercially available competitive ELISA (c-ELISA) (ID Screen® Blue Tongue 
Competition, ID VET, Montpellier, France) performed according to the OIE Manual of 
Diagnostic Tests (OIE, 2011) and the instructions provided by the manufacturer. Results were 
expressed as a percentage negativity (PN) compared to the negative kit control and were 
classified into positive (PN ≤65), doubtful (PN >65 but ≤75) and negative (PN >75) results 
based on the optimal cut-off point for diagnostic purposes of 65 PN determined by 
Vandenbussche et al. (2008). All doubtful results were classified as positive in the data 
analysis. The DSe and DSp of the c-ELISA corresponding with this approach were 
determined by means of a Receiver Operating Characteristic (ROC) analysis as 92.0% (95% 
CI: 88.8-94.6) and 95.7% (95% CI: 92.7-97.7), respectively (Vandenbussche et al., 2008).  
 
• Statistical methods 
For the study of the decline of maternal antibodies, estimations of the within-herd antibody 
prevalence (with 95% CI) were made for 3 different age categories: below 6 months of age, 6-
8 months and 9-12 months of age. The estimation of the within-herd antibody prevalence was 
based on a Generalized Estimating Equation (GEE) using the GENMOD procedure in SAS® 
version 9.2 (SAS Institute Inc., Cary, NC, USA) taking into account the possible correlation 
among animals within the same herd. A logit link function and binomial distribution were 
assumed. An exchangeable working correlation was assumed. Apparent within-herd antibody 
prevalence estimates and their 95% CI’s were converted into true antibody prevalence 
estimates by means of the Rogan and Gladen estimator (1978) assuming a sensitivity of 
92.0% and a specificity of 95.7% for the c-ELISA.  
 
BT winter screening 2011: herd immunity after 3 years of compulsory vaccination 
• Sampling design 
A total of 1,100 cattle herds were selected for this cross-sectional serological survey carried 
out between January and March 2011. The selection consisted of the 300 dairy herds that 
were already selected for the BT sentinel surveillance program and an additional 800 dairy, 
beef or mixed cattle herds. The additional herds were randomly selected, stratified by 
province and proportional to the number of herds present in each province. The sampling 
frame was provided by the list of all 22,609 active Belgian cattle herds that remained after the 
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exclusion of veal holdings, herds with less than 10 animals present at the time of selection, 
and the already selected 300 BT sentinel herds. Within each of the 1,100 herds, blood samples 
were collected by the farm veterinarians from a target number of 10 animals between 6 and 12 
months of age and 10 animals between 12 and 24 months of age. In the BT sentinel herds, it 
was allowed to sample the same animals for the serological testing and for the virus detection 
by RT-qPCR.  
The sample size for the BT winter screening 2011 was based on the sample size that had been 
calculated for the winter screening the year before. The screening carried out during the 
winter of 2009-2010 was primarily designed to demonstrate the absence of BTV circulation in 
Belgium (minimum expected prevalence of 2%) by means of testing by RT-qPCR. Despite 
the fact that the objective of the BT winter screening 2011, due to the introduction of the BT 
sentinel surveillance program, changed to becoming a seroprevalence survey, it was felt 
appropriate to keep the same sample size. A sample size of 1,100 herds is more than sufficient 
to make reliable seroprevalence estimations.  
 
• Diagnostic methods 
Blood samples were collected by the farm veterinarians and conditioned to serum samples at 
the regional laboratories of “Dierengezondheidszorg Vlaanderen (DGZ)” and the 
“Association Régionale de Santé et d’Identification Animales (ARSIA)”. Serum samples were 
tested for the presence of BTV-specific antibodies using a commercially available competitive 
ELISA (c-ELISA) (ID Screen® Blue Tongue Competition, ID VET, Montpellier, France) 
performed according to the OIE Manual of Diagnostic Tests (OIE, 2011) and the instructions 
provided by the manufacturer.  
 
• Statistical methods 
The estimation of the within-herd seroprevalence was based on a GEE as described earlier. 
Estimations of the within-herd seroprevalence were made by Belgian province, by age 
category (6-12 months and 12-24 months) and by production type. For the latter, herds were 
classified as dairy herds if they were commercial milk suppliers as defined by their presence 
in the registers of the Belgian Milk Control Centers (MCC), and were classified as non-dairy 
herds if they were absent in those registers. Again, all obtained apparent within-herd 
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seroprevalence estimates were converted into true seroprevalence estimates by means of the 
Rogan and Gladen estimator (1978).  
The estimation of the herd seroprevalence was obtained using a logistic regression 
(GENMOD procedure, SAS® version 9.2). A herd was considered seropositive if at least one 
of the sampled animals had a positive or doubtful c-ELISA test result.  
Maps were produced using ArcMap® version 3.2.1 (ESRI, Redlands, CA, USA). An 
interpolation map showing the distribution of the true within-herd seroprevalence across 
Belgium was produced using the Inverse Distance Weighting (IDW) tool. This deterministic 
method determines cell values using a linear-weighted combination set of sampling points, in 
our case the 12 nearest herds. Assigned weights were an inverse function of the distance to 
these neighboring herds.  
 
 
Results 
BT sentinel surveillance program 
• Results of RT-qPCR 
During the 1st sampling round in October-November 2010, a total of 3,684 animals from 264 
BT sentinel herds were sampled. An average of 14 animals (range between 3 and 15) were 
sampled in each herd. During the 2nd sampling round in January-February 2011, a total of 
2,150 animals from 202 sentinel herds were sampled. An average of 11 animals (range 
between 1 and 15) were sampled per herd. Out of the total of 283 sentinel herds that have 
been sampled in the BT sentinel program up to now, 182 herds were sampled during both 
sampling rounds, 81 herds were sampled in October-November 2010 only and 20 herds were 
sampled in January-February 2011 only.  
During the 1st sampling round, 15 animals tested positive and 2 animals tested doubtful by 
pan-BTV RT-qPCR (Table 1). These 17 animals originated from 5 different herds (Figure 1a) 
located in 4 different Belgian provinces. All RT-qPCR positive/doubtful animals were born in 
the herd in which they were sampled and their age ranged between 3 and 11 months with a 
mean of 8 months. Out of the 15 pan-BTV positive samples, 10 tested positive, 3 tested 
doubtful and 2 tested negative by BTV-8 specific RT-qPCR. Both samples that tested 
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doubtful by pan-BTV RT-qPCR tested negative by BTV-8 specific RT-qPCR (Table 1). 
Results of the BTV-1, BTV-6 and BTV-11 specific RT-qPCR tests were all negative. The 
serological status of the 17 animals that tested positive/doubtful by pan-BTV RT-qPCR was 
verified by means of the c-ELISA performed on plasma. All animals were seronegative for 
BTV. When re-sampled 2-4 weeks after the original sample collection, all 17 animals tested 
negative by pan-BTV RT-qPCR.  
 
Table 1: Results of pan-BTV/S5 and BTV-8/S2 RT-qPCR during the 1st and 2nd sampling 
rounds of the BT sentinel surveillance program in Belgium (2010-2011) 
 
Pan-BTV/S5 RT-qPCR BTV-8/S2 RT-qPCR 
 
Number 
of 
animals 
tested 
Number of 
animals 
positive 
Number of 
animals 
doubtful 
Number of 
animals 
tested a 
Number of 
animals 
positive 
Number of 
animals 
doubtful 
1st sampling 
round 
(Oct-Nov 
2010) 
3,684 15 2 17 10 3 
2nd sampling 
round 
(Jan-Feb 
2011) 
2,150 17 5 22 13 2 
a
 Only samples that tested positive or doubtful by pan-BTV/S5 RT-qPCR were tested by BTV-8/S2 
RT-qPCR. 
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Figure 1: Cp-values for all animals that tested positive or doubtful by pan-BTV/S5 RT-qPCR, 
organised by herd, during the 1st round (Figure 1a) and 2nd round (Figure 1b) of the Bluetongue 
sentinel surveillance program in Belgium in 2010-2011. Different animals within the same herd are 
displayed in different colors 
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During the 2nd sampling round, 17 animals tested positive and 5 animals tested doubtful by 
pan-BTV RT-qPCR (Table 1). These 22 animals originated from 12 different herds (Figure 
1b) located in 7 different provinces. The 12 herds were different from the 5 herds with 
positive/doubtful results during the 1st round. During the 2nd round also all animals that tested 
positive or doubtful by pan-BTV RT-qPCR were born in the herd in which they were 
sampled. Their age ranged between 3 and 13 months with a mean of 7 months. Out of the 17 
pan-BTV RT-qPCR positive samples, 11 were confirmed to be BTV-8 positive, 1 tested 
doubtful and 5 tested negative by BTV-8 serotype specific RT-qPCR. Out of the 5 pan-BTV 
RT-qPCR doubtful samples, 2 tested positive, 1 tested doubtful and 2 tested negative by 
BTV-8 serotype specific RT-qPCR (Table 1). Results of the BTV-1, BTV-6 and BTV-11 
specific RT-qPCR assays were again all negative. A verification of the serological status was 
not possible for 8 out of the 22 animals with positive/doubtful pan-BTV RT-qPCR results as 
not enough plasma was left for performing the c-ELISA. One 4-month-old animal tested 
positive for antibodies against BTV. The remaining 13 animals were BTV seronegative. 
When re-sampled 2-4 weeks after the original sample collection, all animals, with the 
exception of 1 animal that was not re-sampled, tested negative by pan-BTV RT-qPCR. 
 
• Maternal antibodies in young animals 
In order to monitor the level of BTV-specific antibodies in young non-vaccinated animals 
during the sentinel program, a total of 1,008 plasma samples from 68 randomly selected herds 
in the 1st sampling round were tested by c-ELISA. True within-herd antibody prevalence 
estimates for animals below 6 months of age, 6-8 month old and 9-12 month old animals are 
shown in Table 2. Figure 2 shows the quantitative results of the c-ELISA in function of age. 
This figure clearly shows that by the age of 7 months maternal antibodies against BTV had 
disappeared in most animals.  
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Table 2: Bluetongue true within-herd antibody prevalence (%) in young non-vaccinated cattle during 
the 1st round of the Bluetongue sentinel surveillance program in Belgium in 2010 
 
Age category (median age) Number of animals 
tested 
Within-herd antibody 
prevalence (%) 
95% Confidence 
Interval 
< 6 months (5 months) 193 21.8 13.3-32.8 
6-8 months (7 months) 470 1.0 0.0-4.9 
9-12 months (10 months) 274 3.3 0.0-9.1 
 
 
 
 
 
Figure 2: Quantitative results of BTV antibody ELISA (c-ELISA) in function of age for a random 
selection of non-vaccinated animals during the 1st 526 round of the Bluetongue 
527 sentinel surveillance program in Belgium in 2010-2011 
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BT winter screening 2011: herd immunity after 3 years of compulsory vaccination 
A total of 16,616 animals from 1,030 herds (292 BT sentinel herds and 738 additional herds) 
were sampled for the yearly cross-sectional serological survey. An average of 16 animals 
(range between 1 and 25) were sampled per herd. Among all animals, 10,823 (65.1%) tested 
positive and 557 (3.4%) tested doubtful for antibodies against BTV. The overall true within-
herd seroprevalence in 6-24 month old Belgian cattle and within-herd seroprevalence 
estimates per production type are shown in Table 3. Figure 3 presents within-herd 
seroprevalence estimates for each Belgian province. Higher seroprevalence estimates were 
found in the north than in the south of the country. The within-herd seroprevalence was 
highest in the provinces of West Flanders, East Flanders and Antwerp. The spatial distribution 
of the true within-herd seroprevalence in Belgium is presented in Figure 4. The within-herd 
seroprevalence in the sampled herds ranged between 0 and 100%. Approximately half the 
herds sampled (54.5%) had a true within-herd seroprevalence equal to or above 80% (Figure 
5). The true within-herd seroprevalence was higher in the 12-24 month old animals (79.5%, 
95% CI: 77.4-81.4) than in the 6-12 month old animals (66.3%, 95% CI: 63.4-69.1).  
 
Table 3: Bluetongue overall true within-herd seroprevalence (%) and within-herd seroprevalence (%) 
per production type in 6-24 month old Belgian cattle during the winter screening 2011 
 
Type of herd Number of herds tested Within-herd seroprevalence 
(%) 
95% Confidence 
Interval 
Dairy 612 73.2 70.5-75.8 
Non-dairy 418 73.7 70.3-77.0 
Total 1,030 73.4 71.3-75.4 
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Figure 3: Bluetongue within-herd seroprevalence (%) and associated 95% Confidence 
Interval at the provincial level in Belgian cattle based on the winter screening 2011 
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Figure 4: Distribution of Bluetongue within-herd seroprevalence (%) in Belgian cattle 
based on the winter screening 2011 
 
Figure 5: Histogram of Bluetongue within-herd seroprevalence (%) in Belgian cattle based on the 
winter screening 2011 
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The overall BTV seroprevalence at herd level in Belgium was estimated at 97.4% (95% CI: 
96.2-98.2). The herd seroprevalence was very high in each province and ranged between 
94.6% (95% CI: 88.5-97.6) in Liege and 99.4% (95% CI: 96.1-99.9%) in West Flanders.  
 
 
Discussion 
This paper describes the results of the first two sampling rounds of a series of repeated cross-
sectional studies, the BT sentinel surveillance program, in Belgium carried out in October-
November 2010 and January-February 2011, and the results of a large cross-sectional 
serological survey for BTV, the BT winter screening, performed between January and March 
2011 in 6-24 month old Belgian cattle.  
EC Regulation No 1266/2007 (CEC, 2007) last amended in July 2011 prescribes that a BT 
sentinel monitoring program has to be implemented by all EU member states in BTV 
restricted zones. Rather than providing fixed guidelines, this regulation is oriented towards 
setting the minimum requirements for BT monitoring and surveillance, leaving a certain 
degree of flexibility with each member state to design its own monitoring and surveillance 
system in order to meet the objectives. In Belgium, repeated cross-sectional studies were 
initiated from the end of 2010 onwards with the aim to demonstrate the absence of BTV 
circulation in Belgium. Due to the wide spread of the BTV-8 infection in Belgium during the 
epidemic in 2007 (Méroc et al., 2009) and due to the introduction of compulsory vaccination 
of cattle and sheep against BTV-8 in 2008, a serological testing was of no longer use to 
monitor the level of BTV infection. As BTV-8 RNA can be detected by RT-PCR in the blood 
of infected cattle for several months after infection (MacLachlan, 2004; Di Gialleonardo et 
al., 2011), RT-PCR was believed to be a valid method for the monitoring of BTV circulation. 
Because of its high diagnostic sensitivity (99.5%) and specificity (98.5%) (Vandenbussche et 
al., 2008) the pan-BTV/S5 RT-qPCR assay was selected as the diagnostic test to be used. It 
has been shown that vaccination, even with inactivated vaccines, may interfere with the 
results of RT-qPCR performed on blood (Steinrigl et al., 2010). It was therefore decided to 
only sample young non-vaccinated animals between 4 and 12 months of age in selected dairy 
herds due to the all-year round availability of young calves in those herds and because of the 
easier sampling logistics compared to beef herds. Through these repeated cross-sectional 
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surveys, a practical and relatively cheap “sentinel” system for BTV was installed in Belgium 
to meet the objectives of regulation No 1266/2007. Belgian farmers and veterinarians 
appreciated this way of monitoring more than the “classical” sentinel system for which the 
same animals need to be sampled at each sampling occasion. The latter causes serious 
practical problems and hampers trade.  
During the 1st sampling round in October-November 2010, significantly more herds and 
animals (3,684 samples, 264 herds) were sampled than during the 2nd round in January-
February 2011 (2,150 samples, 202 herds). This can be explained by the fact that the 
compulsory BTV-8 vaccination is often carried out during the winter months November and 
December while the animals are housed, resulting in few unvaccinated young animals being 
left early in the year compared to the months October-November. Still, the sample size 
obtained in both sampling rounds was sufficiently large to draw reliable conclusions with 
respect to freedom of disease. Considering that BTV-8 RNA can be detected in the blood of 
calves for at least 150 days following infection (Di Gialleonardo et al., 2011) and the main 
activity of the vector was demonstrated to occur in Belgium between August and November 
(De Deken et al., 2008), the samplings performed in October-November 2010 and January-
February 2011 allow us to draw conclusions regarding the occurrence of any possible BTV 
circulation during the whole year 2010.  
During the 1st sampling round, 15 animals tested positive and 2 animals tested doubtful by 
pan-BTV/S5 RT-qPCR. During the 2nd sampling round, 17 animals tested positive and 5 
animals tested doubtful. It was remarkable that BTV RNA could not be detected anymore in 
any of these animals when they were re-sampled 2-4 weeks later. BTV RNA can be detected 
by RT-PCR in blood much beyond the period during which infectious virus can be isolated 
(MacLachlan, 2004; Di Gialleonardo et al., 2011). Therefore, we believe it is very unlikely 
that these animals would have been infected with BTV. Moreover, a verification of the 
serological status of several of the animals at the first sampling showed that they were BTV 
seronegative with the exception of one animal. Although it is possible for an infected animal 
to test seronegative if the animal is sampled shortly after infection before seroconversion has 
occurred, it is very unlikely that this would have been the case for all these animals. One 4-
month-old animal tested positive for BTV antibodies but seen the young age of this animal, 
these antibodies may well be of maternal origin. Indeed, our random selection of animals 
tested for antibodies during the 1st sampling round of the sentinel program included 80 calves 
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at the age of 4 months. Thirty-six (44%) of these calves tested BTV antibody positive (Fig. 2). 
By the age of 7 months maternal antibodies had disappeared in almost all animals. To 
facilitate the interpretation of the RT-qPCR results in the next sampling round, the age of the 
animals to be sampled will be increased to 8-14 months and an additional clotted blood 
sample for verification of the serological status by means of the c-ELISA performed on serum 
will be collected.  
When testing large numbers of negative animals (from an infection free population with or 
without a history of BTV infection) it is considering the characteristics of the used RT-qPCR 
assay completely acceptable to observe some positive test results. Therefore, it is 
recommended to re-sample these positive animals a few days or weeks later as we did in our 
study. A more strict recording and verification of the BTV-8 vaccination status at individual 
animal is also recommended and is crucial to allow a correct interpretation of the RT-qPCR 
results. Based on the results generated in the sentinel program so far, we conclude that there 
was no BTV circulation in Belgium in 2010 (minimum expected prevalence of 2%, 95% 
confidence level). This conclusion is further supported by the fact that no clinical cases of BT 
were found in 2010 and the fact that all spleen samples from aborted foetuses tested by RT-
qPCR after mid-April 2010 were negative (Garigliany et al., 2011). The BT sentinel program 
will continue in 2011 and 2012 to demonstrate the absence of BTV circulation in 2011 and to 
consequently re-gain Belgium’s BTV free status.  
The cross-sectional serological survey performed between January and March 2011 showed a 
true BTV within-herd seroprevalence of 73.4% (95% CI: 71.3-75.4) in 6-24 month old 
animals. This is below the 80% vaccination coverage target that was set at the start of the 
vaccination campaign (CEC, 2008). In fact, only half of the herds sampled reached this 80% 
target. It has to be kept in mind though that our survey was carried out in 6-24 month old 
animals and that some of the youngest animals may not have been vaccinated yet or may have 
been vaccinated in the face of maternal antibodies, resulting in the absence of a humoral 
immune response post-vaccination (Vitour et al., 2011). Moreover, no animals above 24 
months of age, which are all expected to be seropositive due to natural infection or the receipt 
of at least one booster vaccination, were included in our survey. Therefore, the true within-
herd seroprevalence of the entire Belgian cattle population is expected to be higher than the 
73.4% estimated in our study. It was noticed that the within-herd seroprevalence in 2011 
decreased compared to the winter screening in 2009-2010 (true within-herd prevalence of 
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82.4%, 95% CI: 80.4-84.3; unpublished data). This may indicate that the motivation of 
farmers or veterinarians to vaccinate against BTV-8 has somewhat decreased. Indeed, a 
questionnaire performed in 2010 showed that only 48% of the farmers would continue to 
vaccinate their cattle against BTV-8 if vaccination was no longer compulsory (unpublished 
data). From the 1st of January 2011, the compulsory vaccination against BTV-8 is 
discontinued in Belgium. A cross-sectional serological survey carried out in 2012 or 2013 
would be very useful to monitor the decline of the vaccine-induced population immunity 
against BTV-8.  
 
 
Conclusion 
The results of this study demonstrate the absence of BTV circulation in Belgium in 2010. The 
BTV seroprevalence at herd level after 3 years of compulsory BTV-8 vaccination was very 
high (97.4%). The overall true within-herd BTV seroprevalence in 6-24 month old cattle in 
Belgium in early 2011 was estimated at 73.4%. Maternal antibodies against BTV had 
disappeared by the age of 7 months.  
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Abstract 
A serological survey to detect Schmallenberg virus (SBV)-specific antibodies by ELISA was 
organised in the Belgian sheep population to study the seroprevalence at the end of the 
epidemic. One thousand eighty two sheep samples which were collected from 83 herds all 
over Belgium between November 2011 and April 2012 were tested. The overall within-herd 
seroprevalence and the intra-class correlation coefficient (ICC) were estimated at 84.31% 
(95%CI: 84.19-84.43) and 0.34, respectively. The overall between-herd seroprevalence was 
98.03% (95%CI: 97.86-98.18). A spatial cluster analysis identified a cluster of six farms with 
significantly lower within-herd seroprevalence in the south of Belgium compared to the rest 
of the population (p=0.04).  It was shown that seroprevalence was associated to flock density 
and that the latter explained the presence of the spatial cluster. Additionally, 142 goat samples 
from 8 different herds were tested for SBV-specific antibodies. The within-herd 
seroprevalence in goats was estimated at 40.68% (95%CI: 23.57-60.4%). The results of the 
current study provided evidence that almost every Belgian sheep herd has been in contact 
with SBV during 2011 and should be taken into consideration as part of comprehensive SBV 
surveillance and control strategies.  
 
Keywords 
Schmallenberg virus; Seroprevalence; Spatial cluster; ELISA; Sheep 
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Introduction  
At the end of summer 2011, an unidentified disease appeared in adult cattle in several farms 
located in Germany and the Netherlands (19 November 2011, Promed). The animals showed 
non-specific acute symptoms (milk drop, watery diarrhea and hyperthermia (>40°C)) and 
recovered after a few days. The Friedrich Loeffler Institute (FLI, Germany) conducted a 
metagenomic analysis in cattle blood samples and identified a new virus phylogenetically 
closely related to viruses of the Simbu serogroup of the genus Orthobunyavirus of the family 
Bunyaviridae (Hoffmann et al., 2012). This virus was shown to be responsible for the 
abovementioned symptoms and was named after the place in Germany it was first identified: 
the Schmallenberg virus (SBV) (Hoffmann et al., 2012; Muskens et al., 2012). Several viruses 
from the Simbu serogroup such as Shamonda, Akabane and Aino viruses are known to be 
teratogenic for ruminants when infected during a vulnerable period during gestation and may 
lead to abortion or congenital malformation (Yanase et al., 2012). In line with this, it was 
observed that starting from December 2011, cattle, sheep and goats in Germany and the 
Netherlands suffered from abortions and stillborn malformed offspring with signs including 
hydranencephaly and arthrogryposis. Real-time reverse transcription PCR (RT-qPCR) was 
made available by the FLI and was used to analyze SBV suspected animals (Hoffmann et al., 
2012). Thus far, most SBV cases have been confirmed in Belgium, France, Germany, the 
Netherlands and the United Kingdom, and more sporadic cases were confirmed in Italy, 
Luxembourg, Spain, Switzerland, Denmark and Sweden (EFSA, 2012). In Belgium, the first 
reports of malformation in newborn lambs occurred mid-December 2011 and were confirmed 
by RT-qPCR in a farm from the North of the country located near the Dutch border (23 
December 2011, Promed). At the end of August 2012, SBV had been detected by RT-qPCR 
in 407 cattle holdings, 167 sheep holdings and 2 goat holdings in Belgium.  
The viruses from the Simbu serogroup are all arthropod-borne viruses mainly transmitted 
between animals via Culicoides spp. and Culex mosquitoes (WHO, 1961; Takahashi et al., 
1968; Yanase et al., 2005). The detection of SBV in pools of heads of Culicoides obsoletus 
sensu stricto and Culicoides dewulfi captured in Belgium during the period September-
October 2011 (11 March 2012, Promed; De Regge et al., 2012) suggests a role of Culicoides 
in the transmission of SBV. So far, only transplacental and arthropod-borne transmissions 
have been described for SBV and there is no evidence that the virus could be transmitted 
horizontally (EFSA, 2012). Considering that SBV seems to be  spread by Culicoides, it can be 
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assumed that in Northern Europe it will be seasonally dependent and the important question at 
the moment is to know if a new wave of viral circulation could be expected in 2012 during the 
period of activity of Culicoides. Knowledge about the immunological anti-SBV status in the 
host population that has been acquired during the first circulation period in 2011 is needed to 
address this question since it could largely influence the outcome of a possible new 
appearance of the virus. Seroprevalence surveys in affected countries are therefore essential to 
estimate the real impact of SBV infection in 2011 and help to predict the potential further 
spread of the disease. In this context, a serological survey was conducted in the Belgian small 
ruminant population to investigate the situation at the end of the first wave of the SBV 
epidemics. 
 
 
Material and Methods 
 Sampling design 
The SBV sampling frame consisted of serum samples initially collected from sheep and goats 
in the context of the Maedi-Visna and Caprine Arthritis and Encephalitis programme for trade 
certification (Royal Decree 24-03-1993). This programme works on a voluntary basis. After 
applying for the accreditation scheme, two samplings are carried out in the flock at a time 
interval of six to twelve months. All animals older than one year are sampled. All samples 
collected between 4 November 2011 and 4 April 2012 were included in the current study.  
 
Diagnostic methods 
Blood samples were collected by farm veterinarians. Blood samples were conditioned and 
serum was collected at the regional laboratories in Belgium: ‘Dierengezondheidszorg 
Vlaanderen’ and the ‘Association Régionale de Santé et d'Identification Animales’. The 
serum samples were subsequently sent to the Veterinary and Agrochemical Research Centre 
(CODA-CERVA) where they were tested for the presence of SBV-specific antibodies using a 
commercially available ELISA kit (ID Screen® Schmallenberg virus Indirect ELISA kit, 
Montpellier, France). The validation of the test conducted by the manufacturer, using serum 
samples originating from France and Germany, demonstrated a relative sensitivity of 96.47% 
(95%CI: 93.43%-98.13%) and specificity of 99.75% (95%CI: 99.26%-99.92%) (IDVET, 
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2012). Results were expressed as S/P percentage using the optical densities (OD) from the 
ELISA reader (S/P % = ODsample/ODpositive control x 100). A cut-off prescribed by the 
manufacturer was used to assign the samples into a category (positive, negative, doubtful). 
Samples which presented an S/P lower or equal to 60%, between 60 and 70 per cent, and 
greater than 70 per cent were respectively considered as negative, doubtful and positive. In 
this study the doubtful results were considered as positive in the data analysis.  
 
Seroprevalence  
The sampling design of the study implied a hierarchical structure of the data, with animals 
typically clustered within flocks. Therefore, a marginal model, the generalized estimating 
equations (GEE) (Liang and Zeger, 1986), which takes into account the resulting correlation 
among animals, was used to estimate the within-herd seroprevalence with 95 per cent 
confidence intervals. In the current study, an exchangeable working correlation was assumed. 
The xtgee procedure in STATA® software version 10.0 was applied to fit the model. The 
within-herd seroprevalence estimates of the positive sheep flocks were plotted as a density-
scale histogram.  
A generalized linear mixed model with normally distributed random intercepts for each flock 
iu ~Normal ( 2,0 σ ) (Molenberghs and Verbeke, 2005) was then used to establish the 
correlation between the infection status of two animals within a flock. The gllamm procedure 
in STATA® was applied to estimate the Intraclass Correlation Coefficient (ICC): 
3/22
2
piσ
σ
+
=ICC
 
 
Between-herd seroprevalence (probability that a flock was infected) was estimated using a 
logistic regression model with the logit function in STATA®. For the purpose of this study, a 
flock was considered as positive if at least one of the animals sampled was positive, otherwise 
it was considered negative.  
Design-effect was taken into account by weighting each observation by the inverse of the 
sampling probability (number of flocks sampled per province/number of flocks per province 
and number of animals sampled per flock/number of animals per flock).  
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Spatial analyses 
In order to predict within-herd seroprevalence for unmeasured locations in Belgium, an 
interpolation from the data points was performed by the method of Inverse Distance 
Weighting based on the 6 nearest neighbours (Shepard, 1968; ESRI, 1996). A map showing 
the distribution of within-herd seroprevalence estimates was produced using ArcGIS, version 
9.3.1 (ESRI). 
A purely spatial weighted normal model was used to scan for clusters of sampled flocks with 
either high or low levels of within-herd seroprevalence. In short, this is done by using a 
variable circular window size and noting the number of observed and expected observations 
inside the window at each location. The model tests the null hypothesis that seroprevalence is 
homogeneously distributed among the flocks (no clusters of flocks with unusually high or low 
seroprevalence). The method uses a likelihood ratio test to identify clusters. To test the 
significance of this likelihood, 1000 Monte Carlo simulations were performed to obtain its 
distribution and clusters with p-value<0.05 were considered as statistically significant. Flock 
density by municipality was calculated using census data and farm X and Y coordinates 
extracted from the central identification and registration system of the Belgian Federal 
Agency for the Safety of the Food Chain (SANITEL). Subsequently we conducted the spatial 
analysis adjusting for flock density to investigate for the existence of clusters after taking into 
account this potentially explanatory variable. In order to do so, the residuals obtained after 
fitting a univariable linear regression model with flock density as covariate were used as 
observed values instead as the original within-herd prevalence estimates. In addition, the 
Spearman’s rank correlation coefficient was estimated in order to investigate the correlation 
between within-herd seroprevalence and flock density. All calculations were done using 
SaTScan 8.2.1. (Kulldorff, 1997) and STATA® software version 10.0.  
 
 
Results 
Seroprevalence  
A total of 1082 sheep from 83 flocks were sampled between 4 November 2011 and 4 April 
2012. The number of sampled animals per flock ranged from 2 to 110 (median=8). The 
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geographical localisation of the sampled flocks is shown in figure 1. The within-herd 
seroprevalence and the ICC in sheep were estimated at 84.31% (95%CI: 84.19-84.43) and 
0.34, respectively. In the seropositive flocks (at least one animal detected seropositive), the 
predicted value for within-herd seroprevalence ranged from 38.6% to 96.71% 
(median=89.28%) (figure 2). The between-herd seroprevalence in sheep was 98.03% (95%CI: 
97.86-98.18).  
In addition, 142 goats from 8 flocks were also sampled during the same period (figure 1). The 
within-herd seroprevalence was estimated at 40.68% (95%CI: 23.57-60.4%) for goats. 
 
 
Figure 1: Sheep and goat flocks sampled for Schmallenberg virus (SBV) in Belgium between 4 
November 2011 and 4 April 2012 and flock density (sheep and goat) at the municipality level 
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Figure 2: Density-scale histogram of within-herd seroprevalence estimates (%) in Belgian sheep 
flocks positive to Schmallenberg virus (SBV) 
 
 
 
 
Spatial analyses 
Figure 3 illustrates the geographical distribution of within-herd seroprevalence with 
interpolated predictions for unmeasured points. The prevalence is globally high (80-90%) and 
evenly distributed across the country.  The regions where seroprevalence was the highest were 
those located in the North-West of Belgium. The levels of within-herd seroprevalence were 
low in the South-Eastern part of the country and a significant spatial cluster of six farms was 
identified in that region. The mean seroprevalence in this cluster was 59.5% and outside the 
cluster 84.87% (p=0.04) (figure 3). Another spatial cluster of 32 farms in the Western part of 
Belgium had on the other hand a higher mean seroprevalence observed (87.94%) than 
expected (79.86%), but was not significant (p=0.08). Ovine flock density at the municipality 
level ranges from 0 to 8 flocks/km². The spatial cluster scanning was conducted again, taking 
flock density into account, and no significant cluster was detected. A statistically significant 
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Spearman’s rho of 0.25 (p=0.02) was obtained, indicating a moderate positive association 
between within-herd seroprevalence and flock density. 
 
 
Figure 3: Geographical distribution of Schmallenberg virus (SBV) within-herd seroprevalence in 
Belgian sheep flocks and spatial cluster for low within-herd seroprevalence 
 
 
 
Discussion 
The results of this survey demonstrated that the SBV seroprevalence in sheep was extremely 
high in winter 2011-2012. SBV seems to have circulated all over Belgium during the 2011 
vector season since the between-herd seroprevalence was almost 100%. The interpolation of 
within-herd seroprevalence estimates showed a high level of infection all over the territory. 
Within the positive flocks, seroprevalence ranged from 38.6% to 96.71%, but the great 
majority of the flocks (70%) had a seroprevalence above 80%. An ICC of 0.34 was found, 
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indicating that the correlation between two animals within a flock with respect to SBV result 
was high. The ICC of a livestock infectious disease is usually less than 0.2 and ranges from 
0.04 to 0.42 (Otte et Gumm, 1997). From a screening among Dutch dairy cattle by virus 
neutralization, a seroprevalence on animal level of 72.5% was found (Elbers et al., 2012). The 
first preliminary results of studies from other affected countries also showed a high 
seroprevalence with results from Germany and France at animal level ranging from 61 to 
100% in cattle (EFSA, 2012).  
            The regions where seroprevalence was the highest were those located in the North-East of 
Belgium corresponding to areas with high sheep density. Indeed, the results of this study 
demonstrated that the geographical pattern of seroprevalence was dependent on that factor. 
The existence of a spatial cluster with low seroprevalence seems to be linked to the fact that 
flock density in this part of the country is very low and may result in a smaller virus reservoir 
in the environment and consequently a weaker risk to disseminate the infectious disease by 
the vector, compared with high density regions.It should be noticed that the predicted 
seroprevalence in the South of Belgium result from an interpolation of sparser data compared 
to other areas, and this will eventually have an impact on the confidence intervals of the 
predictions. 
The sampling was done on a voluntary basis and the interested owners were those who 
practise trade. Therefore, the flocks which were sampled may have had some particular 
features in their management, size, etc. This type of sampling obviously presents opportunity 
risk of selection bias which must be accounted for when considering the results of the study. It 
seems also important to mention that sample size in the screening was limited to available 
samples and that a lack in number of observations will inevitably lead to less precise 
estimations. However, pertaining to sheep, the number of animals sampled per flock seems 
reasonable given that the median size of Belgian flocks is 4 and that a median number of 8 
animals were sampled. At the flock level, expecting a high between-herd seroprevalence (90-
95%), a sample size of 73-139 flocks would be required to reach a desired confidence level of 
95% and accepted error of 5%. Thus, the 1082 sheep from 83 flocks analysed in this study 
seem suitable to give reasonable estimates of seroprevalence in Belgium. Moreover, 
representativeness is obtained as the sampled flocks were well distributed within the 10 
Belgian provinces and the sampling probability of each animal and farm was taken into 
account in the analysis by weighting observed values. 
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The current screening was not able to give very precise estimates for the goat population, as 
pointed out by the considerably large confidence interval, but gives an indication that the 
infection level in this species might be lower than it is in sheep and cattle. This would mean 
that a considerable portion of the goat population remains susceptible and may be sufficient to 
maintain the infection in Belgium during the following transmission season.  
Our results show that there is a high discrepancy between the number of flocks in which the 
presence of SBV was confirmed by rRT-PCR (167 (0.6% of the total flock population in 
Belgium)) and the number of flocks that have been infected with the virus based on the 
serological results. The first factor to explain this difference could be underreporting. This can 
be expected when dealing with a new virus for which farmers and animal health professionals 
are completely unfamiliar. Moreover, SBV is not a notifiable disease in Belgium and there is 
no obligation to report infections to the authorities. The second factor is related to the absence 
of symptoms in adult sheep. Thus far, the disease has only been observed  in lambs after 
vertical transmission. Indeed, if the ewe was contaminated before or after the vulnerable 
period during gestation, the infection would have passed unnoticed. The exact vulnerable 
period in sheep is currently being investigated but in reference to other viruses of the Simbu 
serogroup, should last more or less three weeks (Hashinguchi et al., 1979; Steukers et al., 
2012). Finally, a third factor is the absence of virus in some lambs despite clinical suspicion 
indicating a possible clearance of the virus before birth. 
It is interesting to note that despite a shorter viremia (Hoffmann et al., 2012), SBV has spread 
much faster than Bluetongue virus serotype 8 (BTV-8) did after its emergence in the same 
region five years ago (Elbers et al., 2008; Méroc et al., 2008). Several possibilities can be 
suggested to try and explain this difference of dissemination between the two Culicoides-
transmitted viruses: 1. additional routes of transmission exist for SBV, 2. the host range of 
SBV is not limited to ruminants, 3. the infectious dose and the competence of Culicoides for 
transmitting the two viruses are not similar (Kirkland, 2012), 4. SBV was already present in 
Belgium prior to 2011 and 5. no legal measures such as live animal standstill were taken for 
SBV as it was the case for BTV-8. Although some of those hypotheses have already been 
investigated, more research is still necessary to elucidate clearly which of those should be 
retained.  
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In conclusion, the results of the current study provided evidence that almost every Belgian 
sheep herd has been at one point in contact with SBV. Thus, if we extrapolate from other 
viruses from the Simbu group like the Akabane virus which is the most well-known species of 
the serogroup, this means that the vast majority of sheep could by now have acquired natural 
protective immunity against SBV which may last for a few years (Anonymous, 2008; 
Steukers et al., 2012). Therefore, it seems probable that even if the virus overwinters, regions 
with high seroprevalence such as Belgium should not experience a similar epidemic in 2012-
2013 and that only animals located in areas that are still free of SBV could in turn become 
infected, just as lambs after the waning of maternally derived antibody. Regions neighbouring 
affected areasare probably the most at risk for virus circulation, especially since Culicoides 
from the Obsoletus group, the identified vectors of SBV, are present in most European 
countries except Northern parts of Norway and Sweden (EFSA, 2012). Nevertheless, even in 
highly immunised livestock, because of all new-born animals, part of the host population will 
continuously remain susceptible. For these different reasons, the cluster identified in the 
South of Belgium with lower seroprevalence than the rest of the country should be prioritized 
in the context of future surveillance actions. In Australia, Akabane disease is controlled by 
acting on herd management, for instance by moving susceptible animals into endemic areas in 
time to develop immunity before they are first bred (Kirkland, 2012). 
The findings presented in the current study should be taken into consideration as part of 
comprehensive SBV surveillance strategy.  It is important to underline the paramount need to 
answer specific questions such as the duration of post infection protective immunity and the 
exact host range. Especially since, the emergence of exotic and newly identified arthropod-
borne pathogens seems to happen more and more frequently in recent years. 
 
 
Acknowledgements 
The authors gratefully acknowledge Sylvie Malbrecq, the staff of ARSIA and DGZ for 
providing the samples and the administrative data, as well as the technical assistance of Laura 
Georges and  Muriel Verhoeven. The authors thank the veterinarians and all the persons who 
have contributed to the collection of data for their cooperation in this study. 
 
Chapter VII: Emergence of Schmallenberg virus in Belgium 
 
 
156 | P a g e  
 
References 
Anonymous, 2008. Bunyaviral diseases of animals. OIE Terrestrial Manual 2008, 1166-1163. 
De Regge, N., I. Deblauwe, R. De Deken, P. Vantieghem, M. Madder, D. Geysen, F. Smeets, B. 
Losson, T. van den Berg, and A.B. Cay, 2012. Detection of Schmallenberg virus in different 
Culicoides spp. by real time RT-PCR. Transbound. Emerg. Dis. 59, 471-5. 
EFSA, European Food Safety Authority, 2012.”Schmallenberg’ virus: Analysis of the 
epidemiological data and Impact Assessment. Available at: 
http://www.efsa.europa.eu/fr/efsajournal/pub/2768.htm (accessed 1 July 2012). 
Elbers, A.R., W.L. Loeffen, S. Quak, E. de Boer-Luijtze, A.N. van der Spek, R. Bouwstra, R. 
Maas, M.A. Spierenburg, E.P. de Kluijver, G. van Schaik, W.H. van der Poel, 2012. 
Seroprevalence of Schmallenberg Virus Antibodies among Dairy Cattle, the Netherlands, Winter 
2011-2012. Emerg Infect. Dis. 18, 1065-71. doi: 10.3201/eid1807.120323. 
Elbers, AR, J. Popma,  S. Oosterwolde,  P.A. van Rijn,  P. Vellema,  E.M.A. van Rooij,  2008. A 
cross-sectional study to determine the seroprevalence of bluetongue virus serotype 8 in sheep 
and goats in 2006 and 2007 in the Netherlands. BMC Vet Res.27;4:33. 
ESRI, 1996. Arc View Spatial Analyst. Arcview Spatial Analysis Using Raster and Vector Data. 
Environmental  Sysrtems Research Institute Inc., Redlands, CA, 81-11 
Hashinguchi, Y., K. Nanba, T. Kumagai, 1979. Congenital abnormalities in newborn lambs 
following Akabane virus infection in pregnant ewes. National Institute of Animal Health 
Quaterly  19, 1-11. 
Hoffmann, B., M. Scheuch , D. Höper , R. Jungblut , M. Holsteg , H. Schirrmeier , 2012. Novel 
orthobunyavirus in cattle, Europe, 2011. Emerg. Infect. Dis. 18:469–72. 
IDVET, 2012. Validation Report, ID Screen Schmallenberg virus Indirect. 06/04/2012. 
Kirkland, P.D., 2012. Akabane and Other Simbu Viruses: Epidemiology, Pathogenesis and 
Impact. Accessed on 3 July 2012. Available at: 
http://ec.europa.eu/food/animal/diseases/schmallenberg_virus/docs/akabane_other_sbv_en.pdf 
(accessed on 9 July 2012). 
Chapter VII: Emergence of Schmallenberg virus in Belgium 
 
 
157 | P a g e  
 
Liang, K.Y., S.L. Zeger, 1986. Longitudinal data analysis using generalized linear models. 
Biometrika 73, 13-22. 
Méroc E, C. Faes, C. Herr, C. Staubach, B. Verheyden, T. Vanbinst, F. Vandenbussche, J. 
Hooyberghs, M. Aerts, K. De Clercq, K. Mintiens, 2008. Establishing the spread of bluetongue 
virus at the end of the 2006 epidemic in Belgium. Vet. Microbiol. 131, 133-44. 
Molenberghs, G., G. Verbeke, 2005. Models for Discrete Longitudinal Data. Springer Series in 
Statistics. Springer, New York. 
Muskens, J., A.J. Smolenaars, W.H. van der Poel, M.H. Mars, L. van Wuijckhuise, M. 
Holzhauer, H. van Weering, P. Kock , 2012. Diarrhea and loss of production on Dutch dairy 
farms caused by the Schmallenberg virus. Tijdschr Diergeneeskd. 137, 112-5. 
Otte, M.J., I.D. Gumm, 1997. Intracluster correlation coeffcicient of 20 infections calculated 
from the results of cluster-sample surveys. Prev. Vet. Med. 31, 147-150. 
ProMED-Mail. Schmallenberg virus – Europe (07): (Belgium) congenital malformations, ovine. 
ProMED-mail 2011; 23 Dec: 20111223.3665. < http://www.promedmail.org> (accessed on  July 
2012). 
ProMED-Mail. Schmallenberg virus – Europe (26): (Belgium, Germany) vector, morphology. 
ProMED-mail 2011; 11 March: 20120311.1066949. <http://www.promedmail.org> (accessed on 
2 July 2012). 
ProMED-Mail. Undiagnosed illness, bovine-Germany, Netherlands (02): New virus suspected.  
ProMED-mail 2011; 19 Nov: 20111119.3404 <http://www.promedmail.org> (accessed on 10 
July 2012). 
Shepard, 1968. A two-dimensional interpolation function for irregularity-spaced data. In: 
Proceedings of the 23rd National Conference ACM. 517-524. 
Steukers, L., G. Bertels, A.B. Cay, H.J. Nauwynck, 2012. Schmalleberg virus: emergence of an 
Orthobunyavirus among ruminants in Western Europe. Vlaams Diergenesskundig Tijdschrift, 
81, 119-126. 
Chapter VII: Emergence of Schmallenberg virus in Belgium 
 
 
158 | P a g e  
 
Takahashi, K., A. Oya, T. Okazda, R. Matsuo, M. Kuma, 1968. Aino virus, a new member of 
simbu group of arbovirus from mosquitoes in Japan. Japanese journal of medical science & 
biology, 21, 95-101. 
WHO, World Health Organization, 1961. Arthropod-borne viruses, report of a study group; 
[Geneva, 5 - 10 September 1960]. World Health Organization Technical Report Series, 219, 68 
pp. 
Yanase, T., K. Maeda, T. Kato, S. Nyuta, H. Kamata, M. Yamakawa, 2005. The resurgence of 
Shamonda virus, an African Simbu group virus of the genus Orthobunyavirus, in Japan. Arch. 
virol., 150, 361-369. 
Yanase T, T. Kato, M. Aizawa, Y. Shuto , H. Shirafuji, M. Yamakawa, T. Tsuda, 2012. Genetic 
reassortment between Sathuperi and Shamonda viruses of the genus Orthobunyavirus in nature: 
implications for their genetic relationship to Schmallenberg virus. Arch. Virol. doi 
10.1007/s00705-012-1341-8 
 
Chapter VIII : General Discussion 
 
 
159 | P a g e  
 
 
 
CHAPTER VIII 
 
GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter VIII : General Discussion 
 
 
160 | P a g e  
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter VIII : General Discussion 
 
 
161 | P a g e  
 
     The surveillance activities which were organized in Belgium during the BTV-8 and SBV 
epidemics in order to meet the different objectives evolving along with the epidemiological 
stages are summarized in table 1. These activities were presented and analyzed in this thesis: 
• In Chapters III, IV and VII, the first introduction of BTV and SBV in Belgium was 
described, giving the opportunity to address several approaches to install early 
detection systems.  
• The design and results of a study to evaluate BTV-8 vaccination was presented and 
criticized in Chapter V. 
• Chapter VI summarized the results of the surveillance activities which were 
implemented in the cattle population for substantiating freedom of BTV disease. 
 
The protocols, implementations and objective fulfillments of the different surveillance 
activities are reviewed and discussed in this section. 
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Table 1: Summary of the different surveillance activities which were carried out in Belgium during 
and after the BTV-8 (2006-2012) and the SBV epidemics (winter 2011-2012) 
Surveillance stage  Strategy BTV-8 Strategy SBV 
1. Early (re)detection -Clinical reporting  
-Culicoides monitoring 
-Animal sentinel system in 
cattle based on c-ELISA 
(2007) 
-abortus protocol  
 
-Clinical reporting  
-Culicoides monitoring 
-abortus protocol 
2. Impact description -Cross-sectional surveys 
based on c-ELISA in cattle 
and sheep (winter 2006-2007  
and 2007-2008) 
-To further measure clinical 
impact: clinical reporting+ 
results of surveys in outbreak 
herds 
 
-Cross-sectional serological 
surveys (winter 2011-2012 and 
2012-2013) 
-To further measure clinical 
impact:  clinical reporting+ 
results of surveys in outbreak 
herds 
 
3. Control progress 
assessment 
-Annual cross-sectional 
survey in cattle based on c-
ELISA and RT-qPCR (winter 
2008-2009) 
-Control clinical reporting and 
results of abortus protocol 
 
/  
4. Proof of freedom 
from infection 
-Repeated cross-sectional 
surveys in cattle every 3 
months based on RT-qPCR 
(2010-2012) 
-Control clinical reporting and 
results of abortus protocol. 
/ 
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VIII.I. How well were we prepared in Belgium for the Bluetongue virus epidemic? 
VIII.I.1. Anticipation of the epidemic 
Anticipating EID will contribute to facilitate timely recognition of outbreaks and their control. 
To be ready to face an epidemic, several aspects have to be considered beforehand: 
• Laboratory preparedness 
As a consequence of the emergence of BTV in Southern Europe, several diagnostic assays 
had already been implemented before 2006 in CODA-CERVA. In collaboration with French 
researchers, Toussaint et al. (2007a) had developed and partially validated two RT-qPCR able 
to detect strains from the 24 BTV serotypes. Next to this, two c-ELISA, virus isolation and a 
virus neutralization test had also been implemented in CODA-CERVA before the emergence 
of the virus in 2006. All this enabled prompt and fast confirmation of the first clinical cases of 
BT (Toussaint et al., 2007b). Besides the diagnostic tools available at that moment, a 
Laboratory Contingency Plan (LCP CODA-CERVA) was foreseen, designating the different 
responsibilities, procedures and supplies needed in case of an outbreak. BTV was already 
included in the LCP in order to have a crisis scenario ready in case the virus was introduced in 
Belgium. Diagnostic tests which meet the OIE standards were thus already available in 
Belgium before the emergence, even though the immediately available stock and expertise 
were relatively limited.   
• Surveillance systems for early detection 
For a long time, the presence of the main vector species of BTV, Culicoides imicola, has been 
considered the main risk factor for an emergence of BTV in Europe. Because Culicoides 
imicola, had been discovered in the Southern European countries following the 1998-2005 
outbreaks, BTV surveillance such as sentinel networks was already implemented in most of 
these countries prior to 2006 (Guis et al., 2011). In contrast, Culicoides imicola was and still 
is absent in Northern Europe, and, for this reason, BT was not expected to occur in this 
region. In addition, since most introductions of BTV into Europe before 2006 occurred via 
Anatolian Turkey or the Maghreb, Southern Europe was thought at that time to be the most 
exposed area of the continent (Wilson and Mellor, 2009). In 2003, Elbers et al. (2003) had 
evaluated the risk of BTV introduction in Northern Europe. Mainly because of evolving 
climatic conditions and increased animal flux in the South-North direction in Europe, the 
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authors anticipated that Culicoides imicola might expand its range of distribution and, in 
consequence, that an introduction of BTV in Northern Europe was possible. As a 
consequence, the authors advocated an incremental response with regard to BTV by 
developing a crisis strategy for BTV control and deepening strongly knowledge on vector 
distribution and competence. None the less, in most northern European countries, with the 
exception of Switzerland and the Netherlands (Elbers et al., 2003; Racloz et al., 2006b; 
Takken et al., 2008), no surveillance activities for early detection were in place to try to detect 
an eventual incursion of BTV in this region. 
• Clinical disease recognition 
When BTV-8 emerged in 2006, veterinary practitioners in Belgium were at least 
‘theoretically’ prepared to recognize the presence of the virus in hosts, since the virological, 
clinical and epidemiological aspects of this former-exotic virus were already addressed during 
the veterinary studies curriculum at that time. However, because of the abovementioned 
reasons, disease awareness among most veterinarians and farmers was quite inexistent. 
Moreover, because BTV clinical signs are usually restricted to sheep, disease descriptions 
mainly applied to sheep (Elbers et al., 2008). As we have seen both in Chapters III and IV, in 
contrast to other strains of BTV, the European strain of BTV-8 had also the capacity to induce 
important clinical signs in cattle, possibly explaining the misdiagnosis at the beginning of the 
epidemic in 2006. However, it was clear that the clinical signs in cattle were observed and 
recognized during the second wave of the epidemic in 2007. This illustrates that epidemics 
can help to prepare the veterinarians to make their differential diagnosis, based on clinical 
signs, more accurate than before. 
• Vector surveillance 
Next to the possibility that BTV could emerge in Northern Europe via the range expansion of 
Culicoides imicola, another possibility for the virus to spread towards this region was 
suspected. Indeed, BTV had also been isolated from two other species groups, Culicoides 
obsoletus and Culicoides pulicaris during the 2000 to 2003 Italian epidemic. (Caracappa et 
al., 2003; Miranda et al., 2003; Savini et al., 2003 ; De Liberato et al., 2005). Even though the 
potential of Culicoides obsoletus as BTV vector was thought to be quite low, the group 
species was known at that time to be present and abundant, especially during spring and 
autumn, in Europe from Italy to Great Britain (Rawlings and Mellor, 1994). As a consequence 
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of the findings mentioned previously, this means that we already knew before the BTV-8 
epidemic that the presence of Culicoides imicola was not necessarily required to initiate a 
BTV epidemic in Europe. Funding for areas such as entomological surveillance was relatively 
neglected in Belgium before 2006. Expertise pertaining to Culicoides was virtually non-
existing at that time, and had therefore to be organized in an emergency context. An 
entomological monitoring program has been subsequently implemented in 2007 by the 
FASFC and coordinated by IMT. In 2006, a cross-sectional study was organized to improve 
knowledge of the genus Culicoides and to identify plausible vectors during the 2006-epidemic 
(De Deken, 2008). The following years and until 2012, Culicoides captured with traps located 
all over Belgium were counted on a regular basis in order to monitor the activity period of the 
vectors. 
• Identification and surveillance of introduction pathways 
There are several potential entry paths of BTV into a new area: 1.via infected animals, 2.via 
infected Culicoides (via wind, plants, airplanes, etc) and 3.via infected biological products 
(Mintiens et al., 2008). Even though the likelihood of BTV emergence depends on several 
additional factors, including the occurrence of favorable climatic conditions, attempts to 
identify critical geographical points and periods at particular high risk of BTV introduction 
could have been initiated earlier, in order to instigate surveillance in these ‘hotspots’. Indeed, 
detecting the newly introduced BTV-8 earlier by better surveillance could have reduced the 
impact of the epidemic.  
 
VIII.I.2. Follow-up of epidemic surveillance 
From the start of the BTV-8 epidemic, trans-boundary collaborations favored by European 
financing have enabled fast development of expertise, especially pertaining to the fields of 
entomology and epidemiology. A local epidemiology network was spontaneously created by 
epidemiologists from the first line countries (i.e., Belgium, Germany and the Netherlands) 
immediately after the emergence. Shortly after, EFSA was requested by the EC to form a 
network of experts from the different MS and from the Commission and to produce 
epidemiological reports. The final EFSA report described the results of analyses on factors 
associated with the introduction, establishment and spread of BTV-8 in North-Western 
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Europe (EFSA, 2007). Several other European projects have arisen from the epidemic (e.g. 
EPIZONE Internal Calls IC 6.6 BT-Epidemiology and IC 6.7, IC 6.9 BT-DYNVECT). In 
addition, Northern MS have beneficiated from the help of Southern European MS which 
shared actively their past experience in terms of BTV surveillance and control, in particular 
their expertise in the field of Culicoides identification.  Individual MS have greatly benefited 
from the different outputs produced by all these European collaborations, since it helped 
improve globally the quality of the surveillance system. Nevertheless, sharing and analysis 
data at the European scale turned out not to always be simple tasks. For instance, in the 
framework of EPIZONE Internal Call BT-DYNVECT, the use of vector data for the 
development of models at the European level was hampered by differences in trapping 
protocols between MS (Guis et al., 2011).  
The urgent need for an integrated approach and a harmonization of data from the different MS 
to be able to analyze correctly surveillance data became quickly obvious during the progress 
of the BTV-8 epidemic.  It was more than one year after the onset of the epidemic, in 
November 2007, that Commission Regulation (EC) 1266/2007 implementing rules for 
Council Directive 2000/75/EC entered into force. The Annex I to Regulation introduced 
minimum requirements to harmonize BTV surveillance across the different countries. In light 
of the experience gained during the BTV-8 epidemic, the regulation has been amended twelve 
times following its initial publication. Recently, the EC was in need of scientific advice on 
two epidemiological parameters which are included in Commission Regulation (EC) 
1266/2007: 1.design prevalence for different epidemiological circumstances and 2.the size of 
the geographic unit of reference. Based on the Scientific Opinion delivered by EFSA 
answering the EC’s request (EFSA, 2011), and because the epidemiological situations as 
regards to BT may vary considerably between MS, the minimum requirements in Annex I 
were simplified in May 2012 to allow for more flexibility to design national surveillance 
programs. 
Focusing now on Belgium, the particularity of this vector-born epidemic was well dealt with 
by establishing several multidisciplinary collaborations. For instance, a team of 
entomologists, virologists and epidemiologists worked together in the framework of a project 
conceived to optimize the surveillance of BT, by studying among others, the role of different 
Culicoides species as BTV vectors and the association between the spread of the virus and 
wind characteristics (Federal Governmental Services; RF-6187). 
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In brief, even though concerns concerning the possibility of BTV emergence had been 
expressed beforehand, only limited resources and expertise were available in Belgium prior to 
2006. In consequence, nothing was done to try to prevent BTV from being introduced and 
established, and the country was not truly prepared to face the problems posed by the vector-
borne epidemic.  
 
VIII.II. Did the BTV experience helped to be better prepared for the Schmallenberg 
virus epidemic?  
VIII.II.1. Anticipation of the epidemic 
BTV-8 and SBV emerged in the exact same region. This means that this area is probably a 
‘hot-spot’ for (re-)emergence (Beer et al., 2013).  After the emergence of BTV-8 in 2006, it 
could have been interesting to study the characteristics of this geographical region to try to 
identify the route of introduction. This would have maybe helped to anticipate more a second 
emergence of ABV at a five-year interval. In contrast to BTV which was an exotic emerging 
disease, SBV was a totally new virus when it emerged and, in consequence, its emergence 
was totally unpredictable. Because of this, initially no diagnostic tools were available to detect 
it. However, metagenomic analysis has proven to be an effective tool to detect such unknown 
viruses (Blomström, 2011; Hoffmann et al., 2012). And as a consequence, diagnostic tools 
became available very early after the identification of the virus. It highlights the need to 
optimize this technology and to ensure that it is available at least in some reference 
laboratories in order to allow early recognition of potential other newly emerging pathogens.  
For most Belgian farmers, the BTV-8 epidemic was still a relatively recent unpleasant 
memory at the time SBV emerged. We can therefore hypothesize that both farmers and 
veterinarians have gained experience from the BTV-8 crisis and that it must have helped in 
the recognition and reporting of clinical signs. On the other hand, as we have seen in Chapter 
VII, most SBV infections were asymptomatic, especially in adult animals. In this case, a good 
option to detect early enough the start of an epidemic, could have been to analyze beforehand 
different data sources such as fertility data in a structured syndromic surveillance system 
(Madouasse et al., 2011). Unfortunately, no such system was in place in a structured way in 
Belgium at that time.  
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VIII.II.2. Follow-up of epidemic surveillance 
Both at national and supranational levels, several scientific networks, resulting directly from 
the BTV-8 epidemic, were very helpful for managing efficiently this new ABV emergence. 
This has contributed to allow a fast mobilization of the different research teams and available 
resources. Exchanges between European laboratories of protocols and diagnostic reagents 
essential to organize the diagnosis of SBV in the different affected countries were greatly 
facilitated by this past common experience. 
Because SBV was a new virus, at the beginning of the epidemic, nothing much was known 
about its epidemiology and only extrapolations from related viruses such as Akabane virus 
could be made. The fact that these related viruses were known to be transmitted by 
mosquitoes and biting midges led to the hypothesis that SBV might be spread by the same 
vectors. At the onset of the SBV epidemic, fortunately, the entomological surveillance 
program implemented in the context of the BTV-8 epidemic was still in place in Belgium. 
Culicoides continued to be captured regularly with traps located all over the country until the 
end of 2012. These captures were used by scientists from CODA-CERVA to show that 
several Culicoides species, previously shown to be vectors of BTV, were most probably also 
involved in the transmission process of SBV (De Regge, 2012). In addition, the BTV-8 
emergence inadvertently contributed to improve knowledge and scientific expertise in the 
field of entomology, which has contributed to facilitate the management of the SBV crisis. 
Furthermore, because of the high similarities between the two diseases both in their clinical 
and transmission aspects, the transposition of surveillance activities such as the screenings 
(Chapter VII; Méroc et al., 2013) and the abortion protocol to SBV were straightforward. 
Thus, we may conclude that, even though the BTV-8 epidemic did not contribute to prevent 
SBV from emerging in the same region, it considerably contributed to aid in the follow-up of 
the crisis. 
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VIII.III. How to plan surveillance in the context of an emerging arboviral infection? 
VIII.III.1. Early detection  
The early detection of a new ABV in animal and/or vector populations is essential to provide 
prompt warning of the onset of an epidemic and to guaranty all control policies to be 
developed effectively. The detection of suspicious clinical cases (passive surveillance) is a 
critical component of the early recognition process and represents a very important source of 
information since it (theoretically) covers continuously in time the whole susceptible 
population as well as the whole range of potential emerging viruses. In Chapter III, by 
comparing the final dispersion of the BTV based on seroprevalence estimates to that of 
notified clinical cases, we demonstrated that the case detection system based on clinical 
suspicion provided an accurate indication of the spatial distribution of the virus. Because the 
first clinical signs appear as soon as five days after the animal is infected, whereas BTV 
antibodies can only be detected by c-ELISA from 7-10 days post-infection (OIE, 2009), this 
demonstrates the importance of the passive surveillance component for BTV early detection. 
Welby et al. (2013) showed indeed that in terms of early detection, this surveillance 
component was the most effective. However, the results of the first Belgian BTV serological 
survey demonstrated that the case detection system based on clinical suspicion underestimated 
greatly the impact of the epidemic (between-herd prevalence of 0.7% versus 83.3% based on 
the results from the cross-sectional serological study) (Chapter III). Exactly the same fact was 
observed for SBV (Chapter VII). Indeed, the main drawback of clinical surveillance is that it 
relies totally on a chain of events to occur first. As a start, clinical surveillance requires the 
infection to produce clinical signs, which is not always the case. During the BTV-8 epidemic 
in 2006, it has been demonstrated that a fair proportion of cattle within a herd could be 
infected (RT-qPCR/c-ELISA positive) without showing any clinical signs. This was also 
clearly the same situation during the SBV epidemic, since adult cattle rarely showed acute 
clinical signs of the infection and adult sheep did not present any acute sign of the disease at 
all. We have seen in Chapter III, that there was a difference in terms of disease occurrence 
between cattle and sheep; the BTV-8 between-herd prevalence after the first episode in 2006 
was estimated at 0.7 per cent (95%CI 0.7-0.8) for cattle herds and 1.3 per cent (95%CI 1.2-
1.4) for sheep flocks. We also saw in Chapter IV, that impact of BTV-8 on mortality was 
more important in small ruminant than in cattle population. In line with this, it seems 
advisable to reinforce furthermore clinical surveillance especially in groups of animals more 
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prone to manifest the disease if infected, such as sheep for the specific case of BT. 
Nevertheless, because of strain-specific characteristics with respect to the clinical expression 
of the infection (as it was the situation for BTV-8 with its capacity to induce important 
clinical signs in cattle), it is also fundamental to ensure a broad coverage of all susceptible 
domestic and wild animal populations. 
Passive surveillance then also obviously relies totally on the recognition of pathognomonic 
signs of the disease (‘awareness’) by the farmers and veterinarians (animal-health 
professionals). This is not always warranted, especially in the context of an infection with an 
exotic virus such as BTV-8 or a new virus like SBV. Because of this, implementing this type 
of surveillance necessitates high vigilance of all involved animal-health professionals from 
farm to lab, maintained through regular contact, such as meetings with animations and 
simulation exercises designed to enhance disease awareness and facilitate access to 
differential diagnosis for the principal threats previously identified through a risk assessment. 
In case of reduced resources, it might already help to increase vigilance in a ‘subpopulation’ 
of animal-health professionals (‘sentinel vets or sentinel group of veterinarians’). For most 
ABV, enhancing disease awareness is even more essential during the vector activity 
(approximately April-November in North-Western Europe) seasons. Indeed, past experience 
has shown that the first outbreaks of BTV epidemics are mostly diagnosed between mid-
August and October (Gomez-Tejedor, 2004; Toussaint et al., 2007b). It is also essential to 
formulate a proper clinical case definition in order to increase the sensitivity of the passive 
surveillance system as well as its specificity and avoid unnecessary losses (expensive and 
time consuming laboratory confirmation procedures, trade impact, etc). Both the examples of 
BTV-8 and SBV have proven that this was not always an obvious task. Indeed, the clinical 
signs of BT may vary a lot between the host species and are never pathognomonic of the 
disease. It is so, that Toussaint et al. (2006) reported that at the beginning of the BTV-8 
epidemic in Belgium, contagious echtyma was diagnosed for several sheep that showed BT 
signs. In addition, the range and severity of clinical signs can sometimes evolve over time and 
between different serotypes (Doherr and Audigé, 2001; Dungu et al.., 2004). This pinpoints 
the need to monitor the range of the clinical signs and to adapt the clinical case definition if 
necessary.   
In situations for which the risk of emergence has been clearly identified, additional 
surveillance activities will increase the probability of detecting an emerging disease. 
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Introducing an active component in the surveillance process will allow identifying additional 
cases of disease. Moreover, this will also globally contribute to enhance disease awareness 
and thus improve the passive surveillance component (Doherr and Audigé, 2001). In any case, 
the active system should be adequate for long run application, that is as long as the ABV is 
absent from the population. One approach commonly used is sentinel surveillance which 
consists in cohorts of unexposed animals managed at fixed locations and monitored regularly 
to detect the emergence of new infections (OIE, 2013a).  Sentinel systems designed to detect 
emergences of ABV have been developed in many countries (Giovannini et al., 2004; 
Melville et al., 2004; Biteau-Coreller, 2006; Racloz et al., 2006a). Saegerman et al. (2009) 
described the sentinel network which has been organized in Belgium during spring 2007 to 
detect the re-emergence of BTV-8 after the 2006-2007 VFP. Starting on 20 March 2007, a 
total of 4050 initially seronegative cattle (from 300 farms) were tested monthly by c-ELISA 
and confirmed by RT-qPCR in case of a positive result. The sampling design was prepared 
following guidelines for BTV surveillance proposed in Chapter 8.3 of the OIE Terrestrial 
Animal Health Code (OIE, 2013b). In line with these guidelines, cattle were selected as study 
population. Concerning Culicoides-borne viruses in general, the target animal species will 
often be cattle, since, there are known to be the preferred host species of the midges (Nevill, 
1978). We decided to focus on dairy cattle because they are easier to monitor compared to 
other cattle types. Sentinel herds were selected based on the results of the cross-sectional 
serosurvey described in Chapter III and all herds with at least 20 animals seronegative were 
included in the sampling frame.  
Sample size will depend on several criteria, among which the design prevalence. The latter 
may in some instances be defined by the legislation, as it is the case for BTV since November 
2007 (cf. Commission Regulation (EC) No 1266/2007), or should be derived from field data 
if nothing is foreseen for this. Sample size for the 2007 BT-sentinel system was calculated 
based on OIE guidelines to allow the detection of a design prevalence of 2% with 95% CI in 
each geographical unit of reference. The latter corresponded to a conservative estimation of 
the expected monthly rate of seroconversion in an infected zone. Because of the central role 
of Culicoides in the BTV transmission cycle and to the fact that midges are never confined to 
a specific holding, the unit of reference for BTV is a geographical area: the geographical unit 
of reference. The latter was and is still defined as a grid of 45 x 45 km (approx. 2000 km²). 
This size was chosen because it is a compromise between the 20 km zone around infected 
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holdings as foreseen in EU legislation and the size of the administrative unit as defined in 
Directive 64/432/EEC (EFSA, 2011). In Belgium, a province (district) represents more or less 
two times this geographical unit in terms of surface, simplifying the organization of the 
sentinel network. It was chosen here to monitor seroconversion, but virus presence, or clinical 
signs of the disease may also be monitored. As abovementioned, the former is not always 
adapted to early detection, since antibodies need time before they become detectable. On the 
other hand, instigating active clinical surveillance performed by expert veterinarians may be 
more appropriate to meet this objective. For BTV, given, the presence of the virus may be 
detected in cattle blood for 150 days post-infection (Bonneau et al., 2002; Di Gialleonardo et 
al., 2011), the regular testing (e.g., every 4 months) of sentinel animals with RT-qPCR should 
ensure adequate early detection of BTV, even in an immunized population. In contrast, given 
the very short viraemia linked to SBV infection (with duration of maximum 6 days 
(Hoffmann et al., 2012)), this option would not be feasible in practice for this virus. In the 
case of SBV, a sentinel system based on serology (testing sentinel animals with c-ELISA for 
instance) would be more appropriate. At last, OIE guidelines recommended maximizing the 
chance of detecting BTV activity by selecting sentinel sites more at risk of infection (risk-
based surveillance). This recommendation was not followed because no risk assessment had 
been performed at that time. Today, sampling designs could be enhanced by using outputs of 
analyses carried out since then, such as for example the results found by Faes et al. (2013) 
which identified, among others, land cover to be a risk factor for BT incidence. 
Even though the Belgian sentinel network made possible the detection of BTV-8 re-
emergence in July 2007, the first seroconversions were not detected before the first outbreaks 
occurred identified with clinical surveillance. Among the various key-parameters stated by the 
authors to help improve the quality of this type of system, is its earlier implementation during 
the year than the beginning of spring as it was done in 2007. Indeed, the exact starting point 
of the vector period is usually unknown. Moreover, it has been shown that Culicoides were 
able to overwinter inside cowsheds (Losson et al., 2007; Zimmer et al., 2010).  
Sentinel systems may also focus on the vectors instead of the hosts. Monitoring vector 
populations at fixed sampling points may be useful to detect an introduction or an increase of 
known vector populations. This is important in order to identify areas and periods at risk 
(vector-active periods) for ABV introduction. Another possibility is to use these repeated 
collections of vectors to monitor the presence of the virus, as this was recently done in Italy to 
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investigate whether SBV had spread in a given area (Goffredo et al., 2013). Even though 
difficult to implement and labor-intensive, this type of sentinel surveillance is important to 
consider and maybe the only one truly helpful in some situations, since it is known that ABVs 
are capable of developing transmission strategies such as vertical transmission or 
overwintering that can ensure their survival in a region even in the absence of disease in host 
animals (Gould et al., 2006).  
 
VIII.III.2. Impact description 
At the point of the epidemic where the vector activity and the number of new outbreaks have 
decelerated and reached a steady state, the main surveillance objective will be to assess the 
extent and the impact of the infection.  
During the first episode of the BTV-8 epidemic (2006), in the affected countries, a follow-up 
visit was executed by official veterinarians in the herds where a clinical suspicion had been 
reported and consisted of: 1. a clinical inspection of all animals in the herd, 2. sampling 
(EDTA blood and serum) of maximum three animals and testing with RT-qPCR and c-ELISA 
in case of a confirmed clinical suspicion, and 3. an epidemiological investigation using a 
standardized questionnaire. The questionnaire included questions concerning the date of first 
clinical suspicion, the number of animals that had clinical signs/died, as well as information 
on contact herds. In the context of the SBV epidemic, a similar epidemiological survey has 
been organized in a portion of selected Belgian outbreak herds and its analysis is currently in 
progress. This kind of clinical surveillance data provides the approximate timing of the 
infection. The presumed dates of infection occurrence can be used to build an epidemic curve. 
The information is of considerable value for modeling, for developing causal hypotheses and 
for predicting future spread of the infection (Martin et al. 1987). In addition, this gives 
indication on the origin of the epidemic (index case) and will help investigating on the route 
of introduction of the virus. Also, the numbers of animals that had clinical signs or died 
following the infection can be used to estimate key parameters such as the morbidity, 
mortality and case fatality rates (Elbers et al., 2008). This kind of clinical surveillance 
information provides valuable data to establish the impact of an epidemic. However, it has 
also several limitations mentioned previously like the fact that it will usually lead to an 
underestimation of the true picture. In addition, this type of surveillance principally works 
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only at the herd scale. In the case of BTV-8 and SBV in Belgium, a maximum of three 
animals were sampled in each suspicious herd to be tested with RT-qPCR and c-ELISA. This 
sample size is too small to estimate the proportion of animals infected (i.e, the within-herd 
prevalence); indeed, at the time sampling was done, we had no information on the expected 
prevalence, and, to estimate an unknown prevalence (50%) at a confidence level of 95% in a 
cattle herd of 90 animals (median size of Belgian cattle herds), a sample size of 73 is 
theoretically necessary and in a sheep flock of 4 animals (median size of Belgian sheep 
flocks), all sheep need to be sampled (Cannon and Roe, 1982). From the results presented in 
Chapter III we could now adjust slightly sample size; indeed, to estimate BTV-8 within-herd 
seroprevalence in an infected cattle herd after first transmission season, a sample size of 69 
would be sufficient (with expected seroprevalence of 23.8%).   
The results of passive surveillance may be used as a tool to determine between-herd 
prevalence (proportion of outbreaks in population). However, as shown in Chapter III and for 
the different reasons afore-mentioned, this kind of approach will often lead to an 
underestimation of the latter. 
Next to this, as described in Chapter IV, a high level of correlation was observed between 
ruminant mortality/abortion rate and BT incidence data. In the context of the SBV epidemic in 
Belgium, bovine abortion and birth records from 2010-2012 have been analyzed and have 
shown an increase in the number of abortion reported and a decrease in the number of cattle 
births between September 2011 and March 2012 (Van der Stede, 2012). This kind of 
population-level data can be used to gain more reliable information on the impact of an 
epidemic as it was done for example by Perrin et al. (2010) to estimate indirectly the excess 
mortality during to the BTV-8 epidemic. 
To have an unbiased estimation of the true impact of an epidemic, it will usually be essential 
to organize a screening of the population at risk. As described in Chapters III, V, VI and VII, 
cross-sectional surveys were organized in the Belgian domestic ruminant populations during 
the VFP following the different BTV-8 and SBV epidemics episodes. These surveys allowed 
estimating the geographical distribution of the infection, between-herd, within-herd 
seroprevalence and animal seroprevalence. Depending on the objective and the ABV, the 
samples can be tested either to identify the presence of the virus (virology) or of acquired 
specific antibodies (serology). A positive result in serology indicates that the tested animal 
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was at one point infected with the specific virus. As a whole (all sampled animals together), 
this gives an indication of the level of immunity of the population. Besides allowing a valid 
impact assessment to be made, the level of immunity is also an essential parameter to 
anticipate a potential overwintering of the ABV by defining on time the optimal national 
control strategy.  An insufficient level of immunity will be the justification for implementing 
a vaccination campaign within an animal population. Moreover, identifying differences with 
respect to the level of immunity between categories of animals (e.g. age class, geographical 
localization of the farm, etc), will allow prioritizing control measures if necessary. 
The results of the screening studies may also serve as basis for future surveillance; indeed, 
design prevalences to estimate sample sizes for future surveillance can be derived from 
observed prevalence estimates. However, EFSA performed a systematic literature review of 
prevalence data from MS and concluded that the plateau prevalence (after prevalence rise) of 
BTV-8 was markedly higher than that of other serotypes in Southern Europe (EFSA, 2011). 
This would be an important factor to take into account if a new serotype of BTV would 
emerge in the future.  
From the results of our cross-sectional surveys we also estimated ICC of 0.41 and 0.34, 
respectively for BTV-8 in the Belgian cattle population (Chapter III) and for SBV in the 
Belgian sheep population (Chapter VII).  This parameter indicates the level of correlation 
between two observations within a cluster (e.g., herd). Indeed, individuals within herds are 
often more similar than animals selected randomly from the target population. The ICC of a 
livestock infectious disease is usually less than 0.2 and ranges from 0.04 to 0.42 (Otte et 
Gumm, 1997; Dohoo et al., 2003). Sample size needs to be inflated to adjust for this 
clustering. The inflation will depend on both the ICC and the size of the clusters (Killip et al., 
2004). As an illustration, let’s calculate the effective sample size of the BTV-8 sentinel 
system described in previous section using the following formula: 
ESS= 			 	×	
1+(−1)

 
with ESS= effective sample size 
m= number of units in the cluster (15 animals sampled/herd in our example) 
k= number of clusters (=30 herds sampled/province in our example) 
ρ= ICC (0.41 in our example) 
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Hence, in our example ESS= 67. This means that, although 450 animals (30 herds with 15 
animals each) were sampled per province, from a statistical point of view, only 67 animals 
participated in the study (more or less 7 times less). Thus, to be able to detect seroconversion 
with 95% confidence, the sample should have been instead of 3033 animals (i.e. 202 herds 
with 15 animals each). 
The prevalence results will contribute to evaluate indirectly the level of under-reporting and 
this will allow defining the sensitivity of the passive surveillance system. It can be also useful 
to instigate awareness campaigns. This may contribute to improve the surveillance system 
globally. The survey outcomes can also be used for subsequent modeling: to predict future 
spread (knowing the amount of susceptible animals), to estimate the cost of the epidemic by 
linking them with productivity data, to identify risk factors for infection which is important to 
instigate a risk-based early detection system, and to study the role of the vector by identifying 
links between entomological and serological data. The resulting epidemiological information 
will be crucial to improve globally surveillance and control. 
The timing of the cross-sectional survey described in Chapter III, V and VI (January-March), 
initially selected for practical reasons in the context of the Brucellosis-Leucosis programme 
(WS), since the animals are in stables at that time of the year, fitted perfectly for a Culicoides-
borne disease such as BT (and later on SBV). It coincides indeed with the VFP and thus to the 
end of a transmission season. During winter months, the incidence is very low and the 
epidemic curve has reached a plateau. In consequence, it is the right moment to take stock of 
the situation. In contrast, as it was described in Chapter VII, planning a cross-sectional survey 
in domestic small ruminants was more problematic. The first difficulty was to find available 
samples collected following a structured sampling design. Blood samples originally collected 
in the context of the Maedi-Visna and Caprine Arthritis and Encephalitis program for trade 
certification (Royal Decree 24-03-1993) were used for this purpose. This program works on a 
voluntary basis; interested owners are those who practice trade. Therefore, the flocks which 
were sampled may have some particular features in their size (median flock size in the study 
was 8 versus 4 in a random flock), management, etc. This kind of sampling design presents 
opportunity risk for selection bias. Indeed, estimating the extent of an epidemic necessitates 
the sample to be as representative of the target population as possible. Provided the sampling 
units are randomly selected, a serological screening will yield unbiased seroprevalence 
estimates (Martin et al., 1987). Each individual unit within the target population should have 
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an equal chance of being sampled, but this is rarely the case in practice. In the different cross-
sectional studies described in this thesis, we saw indeed that the choice of the samples is often 
mainly dependent of practical and financial constraints (cf. dairy cattle older than 24 months 
in holdings with on-farm delivery of milk products in Chapter III). As a consequence, most 
samples are likely biased since they were seldom representative of all host species, breeds, 
herd types, ages, etc. This is also the reason why using data collected initially in the 
framework of surveillance for subsequent epidemiological research purposes should always 
be done with caution. Protocols designed for surveillance networks are not always adapted to 
study causal hypotheses (Dufour and Audigé, 1997). In order to ensure that adequate samples 
are always available to organize screenings, a collection of samples that can be kept in 
refrigerators (serum banks) representative of the different animal species is an interesting 
approach which has been developed in Belgian regional and national reference laboratories 
(ARSIA, DGZ and CODA-CERVA) since 2009. In addition, these samples constitute a 
sampling frame useful for potential retrospective monitoring, to date the introduction of a 
virus in a population (Martin et al., 1987). 
The quality of the at-risk population data is also a critical parameter to allow correct design 
and analysis of surveys. In Belgium, all herds of ruminants are supposed to be registered in 
SANITEL. In addition, cattle are ear-tagged individually and recorded in this database. The 
identification of sheep and goat flocks is not as complete and no recording of the 
identification at the animal level is organized. 
 
VIII.III.3. Control progress assessment 
Several indicators can be used to assess the impact of intervention strategies designed to 
jugulate the epidemic such as the vaccination against BTV-8 which started in 2008 in 
Belgium (Chapter V). 
A first line of approach can be to monitor the incidence of new outbreaks. As stated in 
Chapter V, only 50 outbreaks were reported in Belgium after the vaccination against BTV-8 
was implemented in the cattle and sheep population, compared to 6870 the year before the 
onset of the campaign. In addition to monitoring the incidence of new outbreaks, it can be 
valuable to follow up ruminant rendering plant data, as it had a positive correlation with BT 
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incidence (Chapter IV). It is important to keep in mind that it is possible that virus 
transmission continues to occur at low levels in a highly immunized population and that it is 
useful to carry out a survey to demonstrate in a structured manner changes in infection 
prevalence and/or in seroprevalence compared to a starting point. In the context of 
vaccination, a decrease of infection is whished for, whereas an increase in immunity is 
expected. We have seen in Chapter V that one of the requests of the FASFC was to evaluate if 
the targeted antibody coverage of 80% had been correctly reached after the first vaccination 
campaign against BTV-8 which began in May 2008. However, vaccination was carried out in 
a population in which a high proportion of animals had already been infected during the 
previous BTV episodes (2006-2008). Antibodies against BTV appear in infected animals 
typically within one or two weeks post-infection and last for several years (Afshar et al., 
1989; Walton and Osburn, 1992). Because of this and because no distinction between 
vaccinated and infected animals could be made based on serology (DIVA), the intrinsic effect 
of vaccination was hard to evaluate given the sampling design. Indeed, the survey (i.e., two 
cross-sectional serological surveys performed in the same cattle herds during consecutive 
VFP: one before and the other after the start of the vaccination) was initially designed to 
answer another objective (i.e, to describe seroprevalence after the consecutive transmission 
seasons, as described in previous section). The strategy for sampling and to avoid this issue 
consisted on focusing on individuals still seronegative before the vaccination’s onset and on 
estimating the level of seroconversion in this portion of the host population. However, based 
on the results of those surveys, we had no information about the status of the animals between 
the two surveys, and it may well be that some animals were infected at one point between the 
screenings and became seropositive because of natural infection, and not as a consequence of 
vaccination. These are the reasons why in this survey animals were also tested by RT-qPCR. 
Nevertheless, given that BTV-8 RNA can be detected in cattle for at 150 days following 
infection, it is possible that some animals were RT-qPCR positive at one point between the 
two screenings and then became negative before the second survey was carried out. In 
conclusion, the sampling design which was used at that time was not adapted to reach its main 
goal. An alternative approach could have been to select a representative sample of 
seronegative cattle and to test them with RT-qPCR more frequently throughout the year (e.g. 
every 4 months) to exclude infection and to prove that seroconversion was due to vaccination. 
This kind of repeated surveys organized in the same herds over the years is an adaptive form 
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of sentinel network surveillance and might be useful for different objectives in certain 
epidemiological circumstances (o.a. prove freedom of disease). 
  
VIII.III.4. Proof of freedom from infection 
When the epidemic has ceased following effective control actions and/or a natural fade-out, 
for OIE listed diseases such as BT, it is essential to actively substantiate freedom from 
infection in order to lift trade restrictions. Therefore, the purpose of the surveillance actions is 
now the same as before the emergence, hence, to detect the potential presence of infected 
individuals in host and/or vector populations.  
Guidelines to demonstrate freedom from infection after a BTV epidemic in the EU are 
informed in Commission Regulation (EC) No 1266/2007 and set conditions to prepare the 
sampling design of the surveillance survey. Cameron and Baldock (1998) proposed a method 
based on statistical formulae which may be used both to calculate sample size and to interpret 
accurately the results of freedom of infection surveys. This method takes into account the 
performance of the diagnostic test used (DSe and DSp) and provides the exact probability of 
observing the obtained results under the null hypothesis (that the disease is present in the 
population) and under the alternative hypothesis (that the population is free from the disease). 
Freedom of infection surveys imply that again a switch from a representative sampling design 
towards a more targeted sampling is done. The number of animals to be sampled was 
calculated to detect a minimal incidence of BTV infection of 2% with 95% confidence in each 
geographical unit of reference in accordance with EC Regulation No 1266/2007. This value 
has recently been reviewed in an EFSA Scientific Opinion and it was shown that it was 
slightly higher than the median observed value in an endemically infected area (EFSA, 2011). 
We have already seen so far that repeated cross-sectional surveys were useful in order to 
organize sentinel systems (early detection) and to estimate the spread of an epidemic. From 
the end of 2010, repeated cross-sectional surveys have also been organized every three 
months in the same cattle farms with the objective of proving the absence from BTV infection 
(Chapter VI). This particular type of sentinel network usually causes less practical constraints 
and is thus often more appreciated by farmers and veterinarians than the traditional system for 
which the same animals need to be sampled at each sampling round.  
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However, the system has been confronted to several issues during the analysis of its outputs, 
related to the recent infectious history of the target population. When implementing this type 
of sentinel network, it is essential to keep in mind that, at this stage, the host populations have 
considerably changed since the emergence. Consequently, this has an impact on the choice of 
the diagnostic test used and on the individuals that are to be sampled. Indeed, a serological 
testing was of no longer use to monitor the infection in the highly immunized population. In 
consequence, RT-qPCR was selected as the diagnostic test to be used.  However, because 
vaccination, which has been carried out compulsory during three consecutive year in Belgium 
(from 2008 to 2010), may interfere with RT-qPCR results (De Leeuw et al., 2013), the correct 
recording of the vaccination history of the animal sampled is a critical parameter to allow a 
correct interpretation of the results. Unfortunately, the vaccination data at animal level is not 
centralized in Belgium, leaving room for potential misrecordings and/or interpretation errors. 
Because the positive samples were to be confirmed using the c-ELISA, it was also essential to 
make sure that animals were free of maternal antibodies in order to avoid interference with the 
c-ELISA results. Therefore, after having evaluated the average age of maternal immunity 
decline, and having observed that by the age of 7 months maternal antibodies had disappeared 
in most animals, it was decided to focus on cattle between 8 and 14 months in non-vaccinated 
herds, keeping in mind that it is still possible for outliers to occur. Again, the interpretation of 
the results is totally dependent on the availability and validity of administrative data. 
Concerning SBV, the duration of maternal-derived antibodies against the virus is not yet 
known, but Tsutsui et al. (2009) studied the duration of maternal immunity against Akabane 
virus in calves and found that 4-5 months is the estimated age when the maternal antibodies 
decay with a 90% probability. In a recent study, Elbers et al. (2013) found an average duration 
of 6 months between birth and first appearance of a seronegative status in young calves (min: 
4 months; max: 8 months). If we were to organize a study to prove freedom from disease for 
SBV, we could thus also select young calves older than 8 months of age.   
After Belgium re-gained its BTV free status, the repeated surveys were replaced by annual 
cross-sectional surveys which took place once a year during winter (January-February) 2012 
and winter 2013 (unpublished data). As mentioned previously, if using only RT-qPCR to test 
the animals only once a year, it is possible to miss some animals infected during the previous 
year. Also, because of the aforementioned reasons, testing cattle only by c-ELISA, will not 
always constitute a sufficient proof of infection/non-infection either. In consequence, the best 
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option would be to use the two types of tests in parallel to gather enough information to 
decide on the real status of the samples. 
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     Along this thesis, it has been clear that for an ABV surveillance system to be effective, an 
integrated approach of the three components - clinic, serology/virology and entomology - is 
fundamental. To anticipate a potential new ABV emergence, it is therefore advisable to 
organize regular simulation exercises with all concerned animal-health professionals 
(farmers, veterinarians, entomologists, laboratories, epidemiologists and the veterinary 
authorities). This thesis also demonstrated the importance of tailoring surveillance activities 
specifically to the objectives evolving with the epidemic stage. In addition, the surveillance 
system should be adapted continuously to the state of epidemiological knowledge (e.g. using 
adapted ICC and design prevalence). Table 2 summarizes the specific recommendations 
which were made in this thesis for BTV-8 and SBV surveillance. 
To ensure early detection of an ABV epidemic, clinical surveillance is fundamental but 
depends highly on the level of morbidity of the disease and on disease awareness. To answer 
these two limitations it is therefore advisable to: 1) increase surveillance especially in animal 
categories more prone to show clinical signs and 2) increase globally disease awareness from 
farm to lab, for the principal threats identified, by defining and communicating (via 
education, internet, etc) updated case definitions to animal-health professionals facilitating 
access to differential diagnosis and communicating clearly information on reporting 
procedures. It is also essential (also for an unknown disease) to designate beforehand a 
Reference Laboratory responsible to follow the disease situation and its evolution across the 
world. 
Next to this, when a risk of emergence has been assessed, it is also essential to implement an 
active component such as sentinel surveillance and follow this. The latter ideally should be 
organized both in vector and animal populations. The sentinel program should ensure that the 
virus is absent from the vector population and provide regular updates on vector counts to 
define periods at risk for introduction.  The animal surveillance system should focus more 
specifically on: 1.host species more prone to be exposed to the virus and 2.risk zones/periods 
of introduction identified through risk assessment.  
In order to describe the impact of an ABV epidemic, it is useful to gather and analyze 
population-level data and conduct individual epidemiological surveys in outbreak herds to 
estimate mortality/morbidity rates, timing of infection, etc. 
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To describe the extent of an ABV epidemic and prepare future potential control and 
surveillance strategies, it will be important to organize at the end of vector-active seasons, 
cross-sectional surveys representative of the main host population(s). These surveys greatly 
depend on the availability of unbiased samples which can be ensured through the 
development and management of serum banks. The quality of information and registration 
systems of these samples and animals is also a critical parameter to conduct correctly these 
surveys. A continuous investment of time and money for improvement of data quality and 
electronic systems (Laboratory information management system) to manage the data is 
recommended. 
In order to assess the control progress, it is essential to design and carry out a survey tailored 
to answer the specific question (e.g. what is the vaccination coverage and its impact?) taking 
into account the characteristics of the infection and of the diagnostic test which will be used.  
In order to demonstrate freedom of infection after an ABV epidemic, it is essential to 
organize targeted sampling taking into account the fact that the population is not naïve 
anymore. The implementation of repeated cross-sectional surveys is a convenient approach. 
Bad quality administrative data such as vaccination history may jeopardize the effectiveness 
of the system and lead to unwanted misinterpretation issues. It will be important to study and 
define the age of maternal immunity fade out. 
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Table 2: My recommendations for the surveillance activities which could have been carried out in Belgium during the BTV-8 (2006-2012) and the SBV 
epidemics (winter 2011-2012) 
Surveillance stage  Strategy BTV-8 Strategy SBV 
1. Early detection -Improve disease awareness and reporting systems 
(especially for sheep population). 
-Risk-based cattle (dairy) sentinel system based on non-
specific RT-qPCR testing every 4 months, covering (at 
least) vector active season. 
-Culicoides monitoring prior to 2006-emergence to define 
vector active season and places at risk. 
-abortus protocol : testing for BTV with RT-qPCR 
 
-Improve reporting systems. 
-Culicoides monitoring prior to 2011 to define periods/places 
at risk of new Culicoides-ABV emergence. 
-Organize structured syndromic surveillance (e.g. using 
fertility data). 
-abortus protocol 
 
 
 
2. Impact 
description 
-Representative cross-sectional surveys at the end of vector 
active season based on c-ELISA in both cattle and sheep. 
-To further measure clinical impact: use clinical reporting+ 
results of surveys in outbreak herds+ mortality and abortus 
protocol data. 
 
-Representative cross-sectional surveys at the end of vector 
active season based on ELISA testing in both cattle and sheep. 
-To further measure clinical impact: use clinical reporting+ 
results of surveys in outbreak herds+ mortality and abortus 
protocol data. 
 
3. Control progress 
assessment 
-To estimate vaccination coverage: representative cross-
sectional survey based on c-ELISA + to prove that 
immunization is not due to infection: repeated cross-
sectional surveys every 4 months (from start to end of 
vaccination campaign) survey in  seronegative cattle  (non-
vaccinated and between 8-14 months) based on RT-qPCR  
-Control clinical reporting and results of abortus protocol 
 
-To estimate vaccination coverage: representative cross-
sectional survey based on ELISA + to prove that 
immunization is not due to infection: repeated cross-sectional 
survey every 4 months (from start to end of vaccination 
campaign) surveys in seronegative cattle (non-vaccinated and 
between 8-14 months) based on ELISA testing. 
-Control clinical reporting and results of abortus protocol 
 
4. Proof of freedom 
from infection 
-Risk-based repeated cross-sectional surveys in non-
vaccinated cattle (verify status) between 8 and 14 months of 
age (verify identification) based on RT-qPCR and c-ELISA 
in parallel every 4 months (confirmation as soon as possible 
in case of positive result). 
-Control clinical reporting and results of abortus protocol. 
-Risk-based sentinel system based on ELISA in seronegative 
cattle every 4 months (confirmation as soon as possible in 
case of positive result). 
-Control clinical reporting and results of abortus protocol. 
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Summary       
Arthropod-borne viruses or arboviruses (ABV) are viral pathogens transmitted among 
vertebrate hosts by hematophagous arthropod vectors. More than 150 ABV are known to 
cause human and/or animal diseases. Bluetongue virus (BTV) is a virus which belongs to the 
genus Orbivirus and is transmitted to ruminants by midges of the genus Culicoides. Its 
emergence in 2006 in North-Western Europe was a major and unexpected animal health 
event. Five years later, history seemed to be repeating itself with the emergence of another 
virus affecting also ruminants in the exact same geographical area; research teams identified a 
novel ABV, the Schmallenberg virus (SBV), closely related to viruses from the Simbu 
serogroup part of the Orthobunyavirus genus and shown to be also transmitted to ruminants 
by Culicoides. 
In light of the increased risk of ABV emergence in Europe linked to globalization and climate 
change, it has become imperative for animal-health professionals to proactively improve the 
surveillance process aimed at producing data designed to guide decision-making. The 
objectives of surveillance applied to an emerging ABV usually follow the evolution of the 
epidemic curve: 1.early detection, 2.impact description, 3.control progress assessment and 
4.proof of freedom from infection. An overview of ABV emergence and its surveillance was 
described in Chapter I. 
                       The main objective of this thesis (Chapter II) was to use the recent examples of BTV and 
SBV emergences to analyze the surveillance activities which have been implemented in 
Belgium in the context of the two epidemics in order to be able to identify key elements and 
provide recommendations to enhance ABV surveillance in the future. 
In Chapter III, the emergence of BTV in Belgium was described. At the onset of the 
epidemic, case-reporting by the Veterinary Authorities relied almost exclusively on the 
identification of herds with confirmed clinical infected ruminants. A cross-sectional 
serological survey targeting Belgian cattle was then carried out during the vector-free season. 
The first objective of this survey was to obtain unbiased estimates of BTV-seroprevalence 
after the first transmission period. The overall between-herd and true within-herd 
seroprevalences were estimated respectively at 83.3% (79.2-87.0) and 23.8% (20.1-28.1). 
Since under-reporting was suspected during the epidemic, a second objective was to compare 
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the final dispersion of the virus based on the seroprevalence estimates to that of the confirmed 
clinical cases which were notified, in order to estimate the accuracy of the case-detection 
based on clinical suspicion. The analysis showed there was a strong correlation between the 
outbreak data and the data from the survey. The case detection system based on clinical 
suspicion underestimated the true impact of the epidemic, but indicated an accurate spatial 
distribution of the virus at the end of the epidemic. 
In Chapter IV, the evolution and the clinical impact of the 2007 episode of Bluetongue (BT) 
in Belgium were analysed. Overall cumulative incidence based on confirmed clinical cases 
was estimated at 11.5% (11.2-11.8) and 7.5% (7.3-7.8) % respectively in the cattle and sheep 
populations and a negative association was found between within-herd seroprevalence in 2006 
and the risk of showing clinical signs of BT in 2007. A very high level of correlation was 
demonstrated between BT incidence and small ruminant mortality data when shifting the 
latter of 1 week backwards supporting the hypothesis that the high increase in small ruminant 
mortality observed in 2007 was the consequence of the presence of BT.  In contrast, for cattle, 
the correlation was not as high. An increase in cattle foetal mortality was also observed during 
the year 2007 and a fair correlation was found between BT incidence and foetal mortality. 
In Chapter V, a study designed to evaluate the effect of the first vaccination campaign 
against BTV was presented and criticized. The results showed that the target of 80% of 
vaccination coverage was reached. However, vaccination was carried out in a population in 
which a high proportion of animals had already been infected. Because of this, and because no 
distinction between vaccinated and infected animals could be made based on serology, the 
intrinsic effect of vaccination was hard to evaluate given the sampling design.  
In Chapter VI, the design and partial results of the repeated cross-sectional surveys carried 
out in cattle from the end of 2010 onwards with the aim to demonstrate the absence from BT 
in Belgium were described and discussed. The results demonstrated the absence of BTV 
circulation in 2010 at the design prevalence of 2% and 95% confidence level. In addition, the 
study of the maternal antibodies in non-vaccinated animals showed that, by the age of 7 
months, BTV-specific maternal antibodies had disappeared in most animals.  
In Chapter VII, we described the results of a cross-sectional serological survey organised in 
the sheep and goat population to study the SBV seroprevalence after the first transmission 
period of the virus in Belgium. The overall within-herd seroprevalence and the intra-class 
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correlation coefficient (ICC) were estimated at 84.31% (95%CI: 84.19-84.43) and 0.34, 
respectively. The overall between-herd seroprevalence was 98.03% (95%CI: 97.86-98.18).  It 
was shown that seroprevalence was associated to flock density and that the latter explained 
the presence of a spatial cluster with lower seroprevalence. These results provided evidence 
that almost every Belgian sheep herd has been in contact with SBV during 2011.  
In Chapters VIII and IX, we have discussed that although concerns concerning the 
possibility of BTV emergence had been expressed beforehand, only limited resources and 
expertise were available in Belgium before 2006. As a result, the country was not truly 
prepared to face the problems posed by the ABV epidemic. It was observed that even though 
the BTV experience did not contribute to prevent SBV from becoming established, it 
considerably facilitated the follow-up of the epidemic. In addition, the different surveillance 
activities carried out during the BTV and SBV epidemics were reviewed in details. In 
summary, this highlighted the need to integrate continuously the three surveillance 
components -clinic, serology/virology and entomology- and demonstrated the importance of 
tailoring surveillance activities specifically to the objectives evolving with the epidemic stage 
and the state of epidemiological knowledge. We proposed concrete recommendations for the 
different surveillance activities which could have been carried out in Belgium during the BTV 
and SBV epidemics. 
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Samenvatting 
Arbovirussen (ABV) zijn virale pathogene micro-organismen die door hematofage arthropode 
vectoren overgedragen worden onder gewervelde gastheren. Meer dan 150 ABV die humane 
en/of dierziekten veroorzaken werden beschreven. Het blauwtongvirus (BTV), een virus dat 
tot het genus Orbivirus behoort, wordt naar herkauwers overgedragen door knutten van het 
genus Culicoides. Het opduiken van dit virus in Europa in 2006 was een belangrijke en 
onverwachte gebeurtenis in de dierengezondheid. Vijf jaar later, leek de geschiedenis zich te 
herhalen met het opduiken van een ander virus dat eveneens runderen aantastte op precies 
dezelfde geografische locatie; onderzoeksgroepen identificeerde een nieuw ABV, het 
Schmallenberg virus (SBV), dat nauw verwant bleek tot virussen van de Simbu serogroep van 
het Orthobunyavirus genus, en dat ook overgedragen bleek te worden naar herkauwers door 
Culicoides. 
In het licht van het verhoogde risico tot opduiken van ABV in Europa, gelinkt aan de 
globalisatie en de klimaatsverandering, is het voor diergeneeskundige professionals 
noodzakelijk geworden om proactief het bewakingsproces, dat gegevens tracht te verzamelen 
om de besluitvorming te ondersteunen, te verbeteren. De objectieven van een 
bewakingsprogramma, toegepast op een opduikend ABV, volgen meestal de evolutie van een 
epidemische curve: 1. vroegtijdige detectie, 2. beschrijving van de impact, 3. beoordeling van 
de vooruitgang in de beheersing en 4. bewijs van vrijheid van infectie (hoofdstuk I). 
Het belangrijkste doel van dit doctoraat (hoofdstuk II) was de recente voorbeelden van de 
BTV en SBV uitbraken te gebruiken om de bewakingsactiviteiten, die in België werden 
geïmplementeerd in het kader van de twee epidemieën, te analyseren zodat sleutelelementen 
kunnen gedefinieerd worden en aanbevelingen kunnen gemaakt worden om de ABV 
bewaking in de toekomst te verbeteren. 
In hoofdstuk III werd het opduiken van BTV in België beschreven. Aan het begin van de 
epidemie steunde het rapporteren van casussen door de diergeneeskundige autoriteiten bijna 
enkel op de identificatie van beslagen met bevestigde klinisch geïnfecteerde herkauwers. Een 
cross-sectionele serologische studie, gericht op Belgisch rundvee, werd vervolgens gedurende 
het vector-vrije seizoen uitgevoerd. De voornaamste doelstelling van deze studie was 
onpartijdige schattingen van de BTV-seroprevalentie te verkrijgen na de eerste transmissie 
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periode. De algemene bedrijfsseroprevalentie en de ware binnen-bedrijfsseroprevalentie 
werden respectievelijk geschat op 83.3% (79.2-87.0) en 23.8% (20.1-28.1). Aangezien tijdens 
de epidemie onder-rapportering verwacht werd, werd bijkomend beoogd de accuraatheid in te 
schatten van de op klinische verdenking gebaseerde casus-detectie. Hiervoor werd de 
uiteindelijke spreiding van het virus gebaseerd op de seroprevalentie schattingen vergeleken 
met de uiteindelijke spreiding van de gemelde bevestigde klinische casussen. De analyse 
toonde een sterke correlatie aan tussen de uitbraakgegevens en de data van de cross-sectionele 
studie. De casus-detectie, gebaseerd op klinische verdenking, onderschatte de ware impact 
van de epidemie maar gaf echter wel een accurate spatiale distributie van het virus aan het 
einde van de epidemie aan. 
In hoofdstuk IV werd de evolutie en de klinische impact van de ‘2007 episode’ van BTV in 
België geanalyseerd. De algemene cumulatieve incidentie werd in de rundvee -en 
schapenpopulatie respectievelijk geschat op 11.5% (11.2-11.8) en 7.5% (7.3-7.8) %. Een 
negatieve associatie werd aangetoond tussen de binnen-bedrijfsseroprevalentie in 2006 en het 
risico tot vertonen van klinische symptomen van BTV in 2007. Een sterke correlatie werd 
aangetoond tussen de BTV incidentie en mortaliteitsgegevens van kleine herkauwers wanneer 
laatstgenoemde 1 week vroeger werd verplaatst, de hypothese ondersteunend dat de sterke 
mortaliteitsstijging bij kleine herkauwers die werd waargenomen in 2007 het gevolg was van 
de aanwezigheid van BTV. In tegenstelling tot de schapenpopulatie was deze correlatie bij het 
rundvee niet zo uitgesproken. Een stijging in de foetale rundvee-sterfte werd eveneens 
waargenomen tijdens het jaar 2007 en een matige correlatie werd beschreven tussen BTV 
incidentie en foetale sterfte. 
In hoofdstuk V werd een studie, ontworpen om het effect van de eerste vaccinatiecampagne 
tegen BTV te evalueren, kritisch bekeken. De resultaten toonden dat het doel van 80% 
vaccinatiedekking werd gehaald.  De vaccinatie werd echter uitgevoerd in een populatie 
waarin een groot deel van de dieren reeds geïnfecteerd was. Hierdoor, en omdat er voorlopig 
geen serologisch onderscheid gemaakt kan worden tussen gevaccineerde en geïnfecteerde 
dieren, was het intrinsieke effect van de vaccinatie moeilijk te evalueren in deze 
steekproefopstelling.  
In hoofdstuk VI werden het ontwerp en de resultaten besproken van de herhaalde cross- 
sectionele studies, uitgevoerd in rundvee vanaf het eind van 2010 om de afwezigheid van 
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BTV in België te staven. De resultaten toonden de afwezigheid van BTV circulatie in 2010, 
aan een verwachte prevalentie van 2% en een 95% betrouwbaarheidsniveau. De bijkomende 
studie naar maternale antistoffen in niet-gevaccineerde dieren toonde aan dat, aan de leeftijd 
van 7 maanden, BTV-specifieke maternale antistoffen bij de meeste dieren verdwenen waren.  
In hoofdstuk VII werden de resultaten beschreven van een cross-sectionele serologische 
studie die werd georganiseerd in de schapen en geitenpopulatie om de seroprevalentie van 
SBV na de eerste transmissieperiode van het virus in België te bestuderen. De algemene 
binnen-bedrijfsseroprevalentie en de ICC (Intra-class correlation coefficient) werden geschat 
op respectievelijk 84.31% (95%CI: 84.19-84.43) en 0.34. De algemene 
bedrijfsseroprevalentie was 98.03% (95%CI: 97.86-98.18). De seroprevalentie bleek 
geassocieerd te zijn met de kuddedensiteit, wat de aanwezigheid van een spatiale cluster met 
significant lagere binnen-bedrijfsseroprevalentie verklaarde. Deze resultaten leverden het 
bewijs dat bijna elk Belgische schapenbeslag in contact was gekomen met SBV in 2011.  
In hoofdstukken VIII en IX werd aangehaald dat, ondanks dat de bezorgdheid omtrent het 
mogelijk opduiken van BTV op voorhand werd gedeeld, slechts beperkte middelen en 
expertise beschikbaar waren in België voor 2006. Hierdoor was het land niet echt voorbereid 
om de problemen betreffende een door vectoren overgedragen epidemie aan te pakken. 
Ondanks dat de expertise van de BTV epidemie het neerstrijken van SBV niet heeft kunnen 
voorkomen, vergemakkelijkte ze de opvolging van de SBV epidemie aanzienlijk.  
Bijkomend werden de verschillende bewakingsactiviteiten, uitgevoerd tijdens de BTV en 
SBV epidemieën, bekeken. Dit onderstreepte de noodzaak om continu de drie surveillance 
componenten - klinische presentatie, serologie/virologie en entomologie - te integreren en 
toonde het belang aan van het aanpassen van bewakingsactiviteiten volgens de objectieven, 
evoluerend met de epidemiologische fase en het niveau van epidemiologische kennis. 
Concrete aanbevelingen werden voorgesteld voor de verschillende bewakingsactiviteiten die 
in België uitgevoerd hadden kunnen worden tijdens de BTV en SBV epidemieën. 
 
 
                     
